<SEC-DOCUMENT>0001193125-17-308380.txt : 20171012
<SEC-HEADER>0001193125-17-308380.hdr.sgml : 20171012
<ACCEPTANCE-DATETIME>20171012070757
ACCESSION NUMBER:		0001193125-17-308380
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		9
CONFORMED PERIOD OF REPORT:	20171130
FILED AS OF DATE:		20171012
DATE AS OF CHANGE:		20171012
EFFECTIVENESS DATE:		20171012

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MYRIAD GENETICS INC
		CENTRAL INDEX KEY:			0000899923
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				870494517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26642
		FILM NUMBER:		171133762

	BUSINESS ADDRESS:	
		STREET 1:		320 WAKARA WAY
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84108
		BUSINESS PHONE:		801-584-3600

	MAIL ADDRESS:	
		STREET 1:		320 WAKARA WAY
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84108
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>d462900ddef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML><HEAD>
<TITLE>DEF 14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section 14(a) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Amendment No. &nbsp;&nbsp;&nbsp;&nbsp;) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the
Registrant&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Filed by a Party other than the
Registrant&nbsp;&nbsp;&#9744;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Preliminary Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Additional Materials</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Soliciting Material Under Rule 14a-12</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>Myriad Genetics, Inc.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">No fee required.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title of each class of securities to which transaction applies:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aggregate number of securities to which transaction applies:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing
fee is calculated and state how it was determined):</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proposed maximum aggregate value of transaction:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">5)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total fee paid:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee paid previously with preliminary materials.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amount previously paid:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form, Schedule or Registration Statement No:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filing party:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date Filed:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MYRIAD GENETICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">October&nbsp;12, 2017 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Stockholders, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You are cordially invited to attend the 2017 Annual Meeting of Stockholders of Myriad Genetics, Inc. (the &#147;Annual Meeting&#148;) to be
held at 9:00 a.m. MST on Thursday, November&nbsp;30, 2017, at our offices at 320 Wakara Way, Salt Lake City, Utah. Details regarding the meeting, the business to be conducted, and information about Myriad Genetics, Inc. that you should consider when
you vote your shares are described in this proxy statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Annual Meeting, three persons will be elected to our Board of
Directors. We also will seek stockholder approval (i)&nbsp;of our proposed 2017 Employee, Director and Consultant Equity Incentive Plan; (ii)&nbsp;to re-approve our 2013 Executive Incentive Plan, as amended (IRC section 162(m) plan); and
(iii)&nbsp;to ask stockholders to ratify the selection of Ernst&nbsp;&amp; Young LLP as our independent registered public accounting firm for the fiscal year ending June&nbsp;30, 2018. In addition, we will seek stockholder approval, on an advisory
basis, of the compensation of our named executive officers, as disclosed in this proxy statement, and on the frequency of holding an advisory vote on the compensation of our named executive officers. The Board of Directors recommends the approval of
all of these proposals, and a vote for a frequency of holding an annual advisory vote on the compensation of our named executive officers every year. Other business will be transacted that may be properly addressed during the Annual Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Securities and Exchange Commission rules that allow companies to furnish proxy materials to stockholders over the Internet, we have
elected to deliver our proxy materials to the majority of our stockholders in this manner. We believe this process will facilitate the accelerated delivery of proxy materials, save costs and reduce the environmental impact of our Annual Meeting. On
or about October&nbsp;12, 2017, we began sending our stockholders a Notice of Internet Availability of Proxy Materials containing instructions on how to access the proxy statement for our 2017 Annual Meeting of Stockholders and our 2017 annual
report on Form 10-K to stockholders. The Notice also provides instructions on how to vote online or by telephone and how to receive a paper copy of the proxy materials by mail. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hope you will be able to attend the Annual Meeting. Whether you plan to attend the meeting or not, it is important that you cast your vote.
You may vote over the Internet as well as by telephone. In addition, if you requested printed proxy materials, you may vote by completing, signing, dating and returning your proxy card by mail. You are urged to vote promptly in accordance with the
instructions provided in the Notice of Internet Availability of Proxy Materials or on your proxy card. We encourage you to vote by proxy so that your shares will be represented and voted at the meeting, whether or not you attend. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g462900g30n56.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B></B>Mark C. Capone<B></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Your vote is important. Please vote as soon as possible by using the Internet or by telephone or, if you received a
paper copy of the proxy card by mail, by completing, signing, dating, and returning the enclosed proxy card. Instructions for your voting options are described on the Notice of Internet Availability of Proxy Materials or proxy card. </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MYRIAD GENETICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>320 Wakara Way </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Salt Lake
City, Utah 84108 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF 2017 ANNUAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TIME: 9:00 a.m. MST </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DATE: Thursday, November&nbsp;30, 2017
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PLACE: The offices of Myriad Genetics, Inc., 320 Wakara Way, Salt Lake City, Utah 84108 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PURPOSES: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">To elect three Class III directors to the Board of Directors to serve three-year terms expiring in 2020; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">To approve the proposed 2017 Employee, Director and Consultant Equity Incentive Plan; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">To re-approve our 2013 Executive Incentive Plan, as amended; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">To ratify the selection of Ernst&nbsp;&amp; Young LLP as our independent registered public accounting firm for the fiscal year ending June&nbsp;30, 2018; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in this proxy statement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">To approve, on an advisory basis, the frequency of holding an advisory vote on the compensation of our named executive officers; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top">To transact such other business that is properly presented at the Annual Meeting and any adjournments or postponements thereof. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WHO MAY VOTE: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may vote if you were an owner of record of
Myriad Genetics, Inc. common stock at the close of business on October&nbsp;4, 2017. A list of stockholders of record will be available at the Annual Meeting and, during the 10 days prior to the meeting, at the office of the Secretary at the above
address. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All stockholders are cordially invited to attend the Annual Meeting. Whether you plan to attend the meeting or not, please vote by following the
instructions on the Notice of Internet Availability of Proxy Materials that you have previously received, which we refer to as the Notice, or in the section of this proxy statement entitled &#147;Important Information About the Annual Meeting and
Voting&nbsp;&#151;&nbsp;How Do I Vote?&#148; or, if you requested printed proxy materials, your proxy card. You may change or revoke your proxy at any time before it is voted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On or about October&nbsp;12, 2017, we began sending the Notice of Internet Availability of Proxy Materials to all stockholders entitled to vote at the annual
meeting. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">BY ORDER OF THE BOARD OF DIRECTORS</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g462900g42x55.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Richard M. Marsh</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Secretary</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October&nbsp;12, 2017 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCKHOLDER MEETING TO BE HELD ON NOVEMBER 30, 2017 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>This proxy statement and our annual report on Form 10-K to stockholders for the fiscal year ended June&nbsp;30, 2017 are available for
viewing, printing, and downloading at </B><B><I>www.proxyvote.com</I></B><B>. To view these materials, please have available your 12-digit control number(s) that appears on your Notice or proxy card. On this website, you can also elect to receive
future distributions of our proxy statements and annual reports to stockholders by electronic delivery. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Additionally, you may find
a copy of our annual report on Form 10-K, which includes our financial statements for the fiscal year ended June&nbsp;30, 2017, on the website of the Securities and Exchange Commission at </B><B><I>www.sec.gov</I></B><B>, or in the &#147;Financial
Reporting/SEC Filings&#148; section of the &#147;Investors&#148; section of our website at </B><B><I>www.myriad.com.</I></B><B> You also may obtain a printed copy of our annual report on Form 10-K, as amended, including our financial statements from
us, free of charge, by sending a written request to: Secretary, Myriad Genetics, Inc., 320 Wakara Way, Salt Lake City, Utah 84108. Exhibits will be provided upon written request and payment of an appropriate processing fee. </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MYRIAD GENETICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>320 WAKARA WAY </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SALT LAKE
CITY, UTAH 84108 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(801) 584-3600 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROXY
STATEMENT FOR THE MYRIAD GENETICS, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2017 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON NOVEMBER 30, 2017 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proxy statement, along with the accompanying Notice of 2017 Annual Meeting of Stockholders, contains information about the 2017 Annual
Meeting of Stockholders of Myriad Genetics, Inc., including any adjournments or postponements of the annual meeting, which we refer to as the Annual Meeting. In this proxy statement, we refer to Myriad Genetics, Inc. as &#147;Myriad,&#148; &#147;the
Company,&#148; &#147;we&#148; and &#147;us.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proxy statement relates to the solicitation of proxies by our Board of Directors
for use at the Annual Meeting. On or about October&nbsp;12, 2017, we began sending the Notice of Internet Availability of Proxy Materials, which we refer to throughout this proxy statement as the Notice, to all stockholders entitled to vote at the
Annual Meeting. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING AND VOTING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Why is the Company Soliciting My Proxy? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors of Myriad Genetics, Inc. is soliciting your proxy to vote at the Annual Meeting to be held at our offices, 320 Wakara
Way, Salt Lake City, Utah, on Thursday, November&nbsp;30, 2017, at 9:00 a.m. MST and any adjournments of the Annual Meeting. The proxy statement, along with the accompanying Notice of 2017 Annual Meeting of Stockholders, summarizes the purposes of
the Annual Meeting and the information you need to know to vote at the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have sent you the Notice and made this proxy
statement, the Notice of 2017 Annual Meeting of Stockholders, and our annual report on Form 10-K to stockholders for the fiscal year ended June&nbsp;30, 2017 available to you on the Internet because you owned shares of Myriad Genetics, Inc. common
stock on the record date. We also have delivered printed versions of these materials to certain stockholders by mail. The Company commenced distribution of the Notice and the proxy materials to stockholders on or about October&nbsp;12, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Why Did I Receive a Notice in the Mail Regarding the Internet Availability of Proxy Materials Instead of a Full Set of Proxy Materials? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As permitted by the rules of the U.S. Securities and Exchange Commission, or the SEC, we may furnish our proxy materials to our stockholders
by providing access to such documents on the Internet, rather than mailing printed copies of these materials to each stockholder. Most stockholders will not receive printed copies of the proxy materials unless they request them. We believe that this
process should expedite stockholders&#146; receipt of proxy materials, lower the costs of the Annual Meeting and help to conserve natural resources. If you received a Notice by mail or electronically, you will not receive a printed or email copy of
the proxy materials, unless you request one by following the instructions included in the Notice. Instead, the Notice will provide instructions on how you may access and review </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
all of the proxy materials and submit your proxy on the Internet or by telephone. If you requested a paper copy of the proxy materials, you may authorize the voting of your shares by following
the instructions on the enclosed proxy card, in addition to the other methods of voting described in this proxy statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Who Can Vote? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only stockholders who owned Myriad Genetics, Inc. common stock at the close of business on October&nbsp;4, 2017 are entitled to vote at the
Annual Meeting. On this record date, there were 69,206,848 shares of our common stock outstanding and entitled to vote. Common stock is our only class of voting stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You do not need to attend the Annual Meeting to vote your shares. Shares represented by valid proxies, received in time for the Annual Meeting
and not revoked prior to the meeting, will be voted at the meeting. For instructions on how to change or revoke your proxy, see &#147;May I Change or Revoke My Proxy?&#148; below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How Many Votes Do I Have? </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of
Myriad Genetics, Inc. common stock that you owned at the close of business on the record date, October&nbsp;4, 2017, entitles you to one vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How Do
I Vote? </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether you plan to attend the Annual Meeting or not, we urge you to vote by proxy. All shares represented by valid proxies
that we receive through this solicitation, and that are not revoked, will be voted in accordance with your instructions on the proxy card or as instructed via Internet or telephone. You may specify whether your shares should be voted for or withheld
for each nominee for director, and whether your shares should be voted for, against or abstain with respect to each of the other proposals. If you properly submit a proxy without giving specific voting instructions, your shares will be voted in
accordance with the board&#146;s recommendations as noted below. Voting by proxy will not affect your right to attend the Annual Meeting. If your shares are registered directly in your name through our stock transfer agent, American Stock Transfer
and Trust Company, or you have stock certificates registered in your name, you may vote: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>By Internet or by telephone.</B> Follow the instructions included in the Notice or, if you received printed materials, in the proxy card, to vote by Internet or telephone. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>By mail.</B> If you received your proxy materials by mail, you can vote by completing, signing, dating and returning the proxy card as instructed on the card. If you sign the proxy card but do not specify how you
want your shares voted, they will be voted in accordance with the board&#146;s recommendations as noted below. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>In person at the meeting.</B> If you attend the Annual Meeting, you may deliver a completed proxy card in person or you may vote by completing a ballot that will be available at the Annual Meeting. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Telephone and Internet voting facilities for stockholders of record will be available 24-hours-a-day and will close at 11:59 p.m. EST on
November&nbsp;29, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If your shares are held in &#147;street name&#148; (held in the name of a bank, broker or other holder of
record), you will receive instructions from the holder of record. You must follow the instructions of the holder of record in order for your shares to be voted. Telephone and Internet voting also will be offered to stockholders owning shares through
certain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
banks and brokers. If your shares are not registered in your own name and you plan to vote your shares in person at the Annual Meeting, you should contact your broker or agent to obtain a legal
proxy or broker&#146;s proxy card and bring it to the meeting in order to vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How Does the Board of Directors Recommend That I Vote on the
Proposals? </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors recommends that you vote as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;<B>FOR&#148;</B> the election of the three Class III directors for director; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;<B>FOR</B>&#148; the approval of our 2017 Employee, Director and Consultant Equity Incentive Plan; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>&#147;FOR&#148;</B> the re-approval of our 2013 Executive Incentive Plan, as amended; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;<B>FOR</B>&#148; the ratification of the selection of Ernst&nbsp;&amp; Young LLP as our independent registered public accounting firm for our fiscal year ending June&nbsp;30, 2018; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>&#147;FOR&#148;</B> the compensation of our named executive officers, as disclosed in this proxy statement; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>&#147;FOR&#148;</B> holding an advisory vote on the compensation of our named executive officers every year. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any other matter is presented, your proxy provides that your shares will be voted by the proxy holder listed in the proxy in accordance
with his or her best judgment. At the time this proxy statement was first made available, we knew of no matters that needed to be acted on at the Annual Meeting, other than those described in this proxy statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>May I Change or Revoke My Proxy? </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you
give us your proxy, you may change or revoke it at any time before the Annual Meeting. You may change or revoke your proxy in any of the following ways: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">By re-voting by Internet or by telephone as instructed above; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If you received printed proxy materials, by signing a new proxy card with a date later than your previously delivered proxy and submitting it as instructed above; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">By notifying our Secretary in writing before the Annual Meeting that you have revoked your proxy; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">By attending the Annual Meeting and voting in person. Attending the Annual Meeting in person will not in and of itself revoke a previously submitted proxy unless you specifically request it. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Your most current vote, whether by telephone, Internet or proxy card, is the one that will be counted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What if I Receive More Than One Notice or Proxy Card? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may receive more than one Notice or proxy card if you hold shares of our common stock in more than one account, which may be in registered
form or held in street name. Please vote in the manner described under &#147;How Do I Vote?&#148; for each account to ensure that all of your shares are voted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Will My Shares Be Voted if I Do Not Vote? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If your shares are registered in your name, they will not be voted if you do not vote as described above under &#147;How Do I Vote?&#148; If
your shares are held in street name and you do not provide voting instructions to the bank, broker or other holder of record of your shares as described above, the holder of record has the authority to vote your unvoted shares only on Proposal 4 if
it does not receive instructions from you and does not have the ability to vote your uninstructed shares on any other proposal. Therefore, we encourage you to provide voting instructions. This ensures that your shares will be voted at the Annual
Meeting and in the manner you desire. When your broker cannot vote your shares on a particular matter because it has not received instructions from you and does not have discretionary voting authority or because your broker chooses not to vote on a
matter for which it does have discretionary voting authority, it is referred to as a &#147;broker non-vote.&#148; Thus, if you hold your shares in a street name and do not instruct your bank, broker or other nominee how to vote, no votes will be
cast on any proposal on your behalf other than the ratification of the selection of the public accounting firm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What Vote is Required to Approve Each
Proposal and How are Votes Counted? </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><B>Proposal&nbsp;1:&nbsp;Elect&nbsp;Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The nominees for director who receive the most votes (also known as a &#147;plurality&#148; of the votes) will be elected. Abstentions are not counted for purposes of electing directors. You may vote either FOR all of the
nominees, WITHHOLD your vote from all of the nominees or WITHHOLD your vote from any one or more of the nominees. Votes that are withheld will not be included in the vote tally for the election of directors. Brokerage firms do not have the authority
to vote customers&#146; unvoted shares held by the firms in a street name on this proposal; therefore, any shares not voted by a customer will be treated as a broker non-vote. Such broker non-votes will have no effect on the results of this
vote.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><B>Proposal&nbsp;2:&nbsp;Approve&nbsp;the&nbsp;Myriad Genetics, Inc. 2017 Employee, Director and Consultant Equity
Incentive Plan</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The affirmative vote of a majority of the shares voted affirmatively or negatively for this proposal is required to approve the Myriad Genetics, Inc. 2017 Employee, Director and Consultant Equity Incentive Plan. Abstentions will
have no effect on the results of this vote. Brokerage firms do not have authority to vote customers&#146; unvoted shares held by the firms in street name on this proposal; therefore, any shares not voted by a customer will be treated as a broker
non-vote. Such broker non-votes will have no effect on the results of this vote.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><B>Proposal 3: Re-approve the 2013 Executive Incentive Plan, as amended</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The affirmative vote of a majority of the shares voted affirmatively or negatively for this proposal is required to re-approve, as amended, the Myriad Genetics, Inc. 2013 Executive Incentive Plan. Abstentions will have no effect
on the results of this vote. Brokerage firms do not have authority to vote customers&#146; unvoted shares held by the firms in street name on this proposal; therefore, any shares not voted by a customer will be treated as a broker non-vote. Such
broker non-votes will have no effect on the results of this vote.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><B>Proposal&nbsp;4:&nbsp;Ratify&nbsp;the&nbsp;Selection&nbsp;of our Registered Independent Public Accounting
Firm</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The affirmative vote of a majority of the shares voted affirmatively or negatively for this proposal is required to ratify the selection of Ernst &amp; Young LLP as our independent registered public accounting firm. Abstentions
will have no effect on the results of this vote. Brokerage firms have authority to vote customers&#146; unvoted shares held by the firms in a street name on this proposal. If a broker does not exercise this authority, such broker non-votes will have
no effect on the results of this vote. We are not required to obtain the approval of our stockholders to select our independent registered public accounting firm. However, if our stockholders do not ratify the selection of Ernst &amp; Young LLP as
our independent registered public accounting firm for the fiscal year ending June&nbsp;30, 2018, our Audit Committee of our Board of Directors will reconsider its selection.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><B>Proposal 5: Approve, on an Advisory Basis, the Compensation of Our Named Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The affirmative vote of a majority of the shares voted affirmatively or negatively for this proposal is required to approve, on an advisory basis, the compensation of our named executive officers, as disclosed in this proxy
statement. Abstentions will have no effect on the result of this vote. Brokerage firms do not have authority to vote customers&#146; unvoted shares held by such firms in street name on this proposal. As a result, any shares not voted by a customer
will be treated as a broker non-vote. Such broker non-votes will have no effect on the results of this vote. Although the advisory vote is non-binding, the Compensation Committee and the Board of Directors will review the voting results and take
them into consideration when making future decisions regarding the compensation of our named executive officers.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><B>Proposal 6: Approve on an Advisory Basis the Frequency of Holding an Advisory Vote on the Compensation of our Named
Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">This proposal provides for a choice among three frequency periods &#151; every year, every two years or every three years. The choice that receives the highest number of votes will be deemed the frequency approved, on an advisory
basis, by our stockholders. However, because the vote on the frequency of holding an advisory vote on the compensation of our named executive officers is not binding, the Compensation Committee and the Board of Directors will review the voting
results and take them into consideration when making a decision regarding the frequency of holding future advisory votes on the compensation of our named executive officers. Abstentions will have no effect on the result of this vote. Brokerage firms
do not have authority to vote customers&#146; unvoted shares held by the firms in street name on this proposal. As a result, any shares not voted by a customer will be treated as a broker non-vote. Such broker non-votes will have no effect on the
results of this vote</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Is Voting Confidential? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will keep all the proxies, ballots and voting tabulations private. We only let our Inspector of Elections and our transfer agent, American
Stock Transfer and Trust, examine these documents. Management, other than the Inspector of Elections Richard Marsh, General Counsel and Secretary, will not know how you voted on a specific proposal unless it is necessary to meet legal requirements.
We will, however, forward to management any written comments you make on the proxy card or elsewhere. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Where Can I Find the Voting Results of the
Annual Meeting? </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preliminary voting results will be announced at the Annual Meeting, and we will publish preliminary, or final
results if available, in a Current Report on Form 8-K within four business days of the Annual Meeting. If final results are unavailable at the time the Form 8-K is filed, we will file an amended report on Form 8-K to disclose the final voting
results within four business days after the final results are known. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What Are the Costs of Soliciting these Proxies? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay all of the costs of soliciting these proxies. Our directors and employees may solicit proxies in person or by telephone, fax or
email. We will pay these employees and directors no additional compensation for these services. We will ask banks, brokers and other institutions, nominees and fiduciaries to forward these proxy materials to their principals and to obtain authority
to deliver proxies. We will then reimburse them for their expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What Constitutes a Quorum for the Annual Meeting? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The presence, in person or by proxy, of the holders of a majority of the voting power of the outstanding shares of our common stock is
necessary to constitute a quorum at the Annual Meeting. Votes of stockholders of record who are present at the meeting in person or by proxy, abstentions, and broker non-votes are counted for purposes of determining whether a quorum exists. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Attending the Annual Meeting </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Annual
Meeting will be held at 9:00 a.m. MST on Thursday, November&nbsp;30, 2017 at the offices of Myriad Genetics, Inc., 320 Wakara Way, Salt Lake City, Utah 84108. When you arrive at our offices, our personnel will direct you to the appropriate meeting
room. You need not attend the Annual Meeting to vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Householding of Annual Disclosure Documents </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SEC rules concerning the delivery of annual disclosure documents allow us or your broker to send a single Notice or, if applicable, a single
set of our proxy materials to any household at which two or more of our stockholders reside, if we or your broker believe that the stockholders are members of the same family. This practice, referred to as &#147;householding,&#148; benefits both you
and us. It reduces the volume of duplicate information received at your household and helps to reduce our expenses. The rule applies to our Notices, annual reports, proxy statements and information statements. Once you receive notice from your
broker or from us that communications to your address will be &#147;householded,&#148; the practice will continue until you are otherwise notified or until you revoke your consent to the practice. Stockholders who participate in householding will
continue to have access to and utilize separate proxy voting instructions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If your household received a single Notice or, if applicable, set of proxy materials this year,
but you would prefer to receive your own copy, please contact Broadridge by calling their toll free number 1-800-542-1061. If you do not wish to participate in &#147;householding&#148; and would like to receive your own Notice or, if applicable, a
set of proxy materials in future years, follow the instructions described below. Conversely, if you share an address with another Myriad Genetics, Inc. stockholder and together both of you would like to receive only a single Notice or, if
applicable, set of proxy materials, follow these instructions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If your Myriad Genetics, Inc. shares are registered in your own name, please contact Broadridge and inform them of your request by calling them at 1-866-540-7095 or writing them at Broadridge Householding Department, 51
Mercedes Way, Edgewood, NY 11717. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If a broker or other nominee holds your Myriad Genetics, Inc. shares, please contact the broker or other nominee directly and inform them of your request. Be sure to include your name, the name of your brokerage firm
and your account number. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Delivery of Company Stockholder Communications </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Most stockholders can elect to receive notices of the availability of future proxy materials by email instead of receiving a paper copy in the
mail. You can choose this option and save the cost of producing and mailing these documents by following the instructions provided on your Notice or proxy card or following the instructions provided when you vote over the Internet at
<I>www.proxyvote.com</I>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information with respect to the beneficial ownership of our common stock as of September&nbsp;1, 2017
for (a)&nbsp;each stockholder that we know to be the beneficial owner of more than 5% of our common stock, (b)&nbsp;each of our executive officers named in the Summary Compensation Table of this proxy statement (the &#147;Named Executive
Officers&#148; or &#147;NEOs&#148;), (c)&nbsp;each of our directors and director nominees, and (d)&nbsp;all of our current directors and executive officers as a group. Beneficial ownership is determined in accordance with the rules of the SEC and
includes voting or investment power with respect to the securities. We deem shares of common stock that may be acquired by an individual or group within 60 days of September&nbsp;1, 2017 pursuant to the exercise of options and the vesting of
restricted stock unit awards to be outstanding for the purpose of computing the percentage ownership of an individual or group, but are not deemed to be outstanding for the purpose of computing the percentage ownership of any other person shown in
the table. Except as indicated in footnotes, we believe that the stockholders named in this table have sole voting and investment power with respect to all shares of common stock shown to be beneficially owned by them based on information provided
to us by these stockholders. Percentage of ownership is based on 68,666,713 shares of common stock outstanding on September&nbsp;1, 2017. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Shares&nbsp;Beneficially&nbsp;Owned</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:68.85pt; font-size:8pt; font-family:Times New Roman">Name&nbsp;and&nbsp;Address**</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Percent</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% or More Stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Baillie Gifford&nbsp;&amp; Co. (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,159,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Calton Square &#151; 1 Greenside Row</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edinburgh, Scotland EH13AN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BlackRock, Inc (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,391,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">55 East 52nd Street</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New York, NY 10055</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Vanguard Group (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,353,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">100 Vanguard Blvd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Malvern, PA 19355</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Camber Capital Management LLC (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,060,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">101 Huntington Avenue, Suite 2101</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boston, MA 02199</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State Street Corporation (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,589,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">One Lincoln Street</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boston, MA 02111</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">D.E. Shaw&nbsp;&amp; Co, L.P. (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,411,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1166 Avenue of the Americas, 9th Floor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New York, NY 10036</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Named Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark C. Capone (7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,333,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R. Bryan Riggsbee (8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alexander Ford (9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jerry S. Lanchbury, Ph.D. (10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">804,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard M. Marsh (11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">988,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors and Director Nominees</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John T. Henderson, M.D. (12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Walter Gilbert, Ph.D. (13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lawrence C. Best (14)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Heiner Dreismann, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dennis H. Langer, M.D., J.D. (15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S. Louise Phanstiel (16)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current executive officers and directors as a group (15 persons) (17)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,858,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Represents beneficial ownership of less than 1% of our outstanding shares of common stock. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top">Unless otherwise indicated, the address for each beneficial owner is c/o Myriad Genetics, Inc., 320 Wakara Way, Salt Lake City, Utah 84108. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">This information is based on a Schedule 13G/A filed with the SEC on February&nbsp;6, 2017 with respect to Myriad Genetics common stock. Baillie Gifford and Co beneficially owns 10,159,758 shares and has sole dispositive
power for these shares and has sole voting power for 9,042,883 shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">This information is based on a Schedule 13G filed with the SEC on March&nbsp;9, 2017 with respect to Myriad Genetics common stock. BlackRock, Inc. beneficially owns these shares and has sole dispositive power for
9,391,168 of these shares and sole voting power for 9,203,164 of these shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">This information is based on a Schedule 13G/A filed with the SEC on February&nbsp;10, 2017 with respect to Myriad Genetics common stock. The Vanguard Group beneficially owns 5,353,743 shares and has sole dispositive
power for 5,214,309 of these shares and sole voting power for 139,434 of these shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">This information is based on a Schedule 13G filed with the SEC on February&nbsp;14, 2017 with respect to Myriad Genetics common stock. Camber Capital Management LLC beneficially owns these shares and has sole
dispositive power and sole voting power for 0 of these shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">This information is based on a Schedule 13G filed with the SEC on February&nbsp;8, 2017 with respect to Myriad Genetics common stock. State Street Corporation beneficially owns 3,589,079 shares and has sole dispositive
power and sole voting power for 0 of these shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">This information is based on a Schedule 13G filed with the SEC on March&nbsp;6, 2017 with respect to Myriad Genetics common stock. D.E. Shaw&nbsp;&amp; Co, L.P. beneficially owns 3,411,217 shares and has sole
dispositive power and sole voting power for 0 of these shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Includes 1,275,035 shares of common stock subject to currently exercisable options and options exercisable and restricted stock unit awards which vest within 60 days of September&nbsp;1, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">Includes 34,425 shares of common stock subject to restricted stock unit awards which vest within 60 days of September&nbsp;1, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top">Includes 131,801 shares of common stock subject to restricted stock unit awards which vest within 60 days of September&nbsp;1, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top">Includes 779,487 shares of common stock subject to currently exercisable options and options exercisable and restricted stock unit awards which vest within 60 days of September&nbsp;1, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top">Includes 962,745 shares of common stock subject to currently exercisable options and options exercisable and restricted stock unit awards which vest within 60 days of September&nbsp;1, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top">Includes shares held directly by Dr.&nbsp;Henderson and his wife, as well as 180,000 shares of common stock subject to currently exercisable options as of September&nbsp;1, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top">Includes 90,000 shares of common stock subject to currently exercisable options as of September&nbsp;1, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top">Includes 150,000 shares of common stock subject to currently exercisable options as of September&nbsp;1, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top">Includes 150,000 shares of common stock subject to currently exercisable options as of September&nbsp;1, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top">Includes 150,000 shares of common stock subject to currently exercisable options as of September&nbsp;1, 2017. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(17)</TD>
<TD ALIGN="left" VALIGN="top">See Notes 7-16 above. Also includes 557,459 shares of common stock subject to currently exercisable options and options exercisable and restricted stock unit awards which vest within 60 days of September&nbsp;1, 2017
held by other current executive officers. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MANAGEMENT AND CORPORATE GOVERNANCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Board of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Restated
Certificate of Incorporation, as amended, and Restated By-Laws provide that our business is to be managed by or under the direction of our Board of Directors. Our Board of Directors is divided into three classes for purposes of election. One class
is elected at each annual meeting of stockholders to serve for a three-year term. The Board of Directors currently consists of seven members, classified into three classes as follows: John T. Henderson, M.D. and S. Louise Phanstiel constitute a
class with a term ending at the 2018 Annual Meeting (the &#147;Class I Directors&#148;); Mark C. Capone and Heiner Dreismann, Ph.D. constitute a class with a term ending at the 2019 Annual Meeting (the &#147;Class II Directors&#148;); and Walter
Gilbert, Ph.D., Dennis H. Langer, M.D., J.D., and Lawrence C. Best constitute a class with a term ending at the 2017 Annual Meeting (the &#147;Class III Directors&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;14, 2017, our Board of Directors accepted the recommendation of the Nominating and Governance Committee and voted to
nominate Walter Gilbert, Ph.D., Dennis H. Langer, M.D., J.D., and Lawrence C. Best for election at the Annual Meeting for a term of three years until the 2020 Annual Meeting of stockholders, and until their respective successors have been elected
and qualified, or until their earlier death, resignation, retirement or removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth below are the names of the persons nominated
as directors and directors whose terms do not expire this year, their ages as of September&nbsp;1, 2017, their offices in the Company, if any, their principal occupations or employment for at least the past five years, the length of their tenure as
directors and the names of other public companies in which such persons currently hold directorships or have held directorships in the past five years. Additionally, information about the specific experience, qualifications, attributes or skills
that led to the Board&#146;s conclusion at the time of the filing of this proxy statement that each person listed below should serve as a director is set forth below for each individual director. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:24.50pt; font-size:8pt; font-family:Times New Roman"><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:99.60pt; font-size:8pt; font-family:Times New Roman"><B>POSITION WITH MYRIAD</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John&nbsp;T.&nbsp;Henderson,&nbsp;M.D.&nbsp;(2)&nbsp;(3)&nbsp;(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chairman of the Board of Directors</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Walter Gilbert, Ph.D. (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vice Chairman of the Board of Directors</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark C. Capone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Executive Officer, Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lawrence C. Best (1)&nbsp;(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Heiner Dreismann, Ph.D. (2)&nbsp;(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dennis&nbsp;H.&nbsp;Langer,&nbsp;M.D.,&nbsp;J.D.&nbsp;(1)&nbsp;(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S. Louise Phanstiel (1)&nbsp;(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Member of the Audit Committee. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Member of the Compensation Committee. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Member of the Nominating and Governance Committee. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Member of the Strategic Committee </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a brief summary of the background and
business experience of each of our directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>John T. Henderson, M.D.</B>, Chairman of the Board of Directors, has been a director of
Myriad since May 2004 and Chairman of the Board since April 2005. Since December 2000, Dr.&nbsp;Henderson has served as a consultant to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pharmaceutical industry as President of Futurepharm LLC. Dr.&nbsp;Henderson currently serves on the Board of Directors of Cytokinetics, Inc. and during the past five years has served on the Board
of Directors of Myrexis, Inc. Until his retirement in December 2000, he was with Pfizer for over 25 years, most recently as a Vice President in the Pfizer Pharmaceuticals Group. Dr.&nbsp;Henderson previously held vice presidential level positions
with Pfizer in Research and Development in Europe and later in Japan. He also was Vice President, Medical for the Europe, U.S. and International Pharmaceuticals groups at Pfizer. He earned his bachelor&#146;s and medical degrees from the University
of Edinburgh and is a Fellow of the Royal College of Physicians (Ed.). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors has determined that Dr.&nbsp;Henderson
should serve on the Board for the following reasons: His medical background provides the Board with expertise in developing predictive, personalized and prognostic testing services. Dr.&nbsp;Henderson provides the Board with business and management
expertise from his senior positions at Pfizer for over 25 years, including expertise in research and development, which is critical to our development of molecular diagnostic testing services. He brings to the Board international experience as the
Company implements strategies for international expansion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Walter Gilbert, Ph.D.</B>, Vice Chairman of the Board of Directors, joined
Myriad as a founding scientist and director in March 1992. Dr.&nbsp;Gilbert won the Nobel Prize in Chemistry in 1980 for his contributions to the development of DNA sequencing technology.&nbsp;He was a founder of Biogen, Inc. and its Chairman of the
Board and Chief Executive Officer from 1981 to 1985.&nbsp;Dr.&nbsp;Gilbert has held professorships at Harvard University in the departments of Physics, Biophysics, Biology, Biochemistry and Molecular Biology, and Molecular and Cellular
Biology.&nbsp;He is a Carl M. Loeb University Professor Emeritus at Harvard University.&nbsp;Dr.&nbsp;Gilbert founded and served on the Board of Directors of both Memory Pharmaceuticals Corp. and Paratek Pharmaceuticals, Inc. He also currently
serves on the board of Amylyx Pharmaceuticals and is a General Partner of BioVentures Investors, an investment fund. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of
Directors has determined that Dr.&nbsp;Gilbert should serve on the Board for the following reasons:&nbsp;He provides the Board with a unique and extensive scientific background and expertise important to us in developing and commercializing
molecular diagnostic products, and understanding technological developments in the industry.&nbsp;Dr.&nbsp;Gilbert provides the Board with business, managerial and financial expertise based on having founded, managed, and directed several companies
in the healthcare industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Mark C. Capone</B>, was appointed as the President and Chief Executive Officer, or CEO, of Myriad
Genetics, Inc., and a member of the Board of Directors, effective July&nbsp;1, 2015. Previously, he served as the President of Myriad Genetic Laboratories, Inc., a wholly owned subsidiary of Myriad. Mr.&nbsp;Capone joined the Company in October
2002, initially as Vice President of Sales until being named Chief Operating Officer in February 2006, a position he held until his promotion to President of Myriad Genetic Laboratories, Inc. in March 2010. Prior to joining Myriad, he served 17
years with Eli Lilly and Company, where he held positions as Product Development Manager, Manufacturing Plant Manager, and Area Sales Director. Mr.&nbsp;Capone received his B.S. degree in Chemical Engineering from Penn State University, graduating
with highest distinction, his M.S. degree in Chemical Engineering from the Massachusetts Institute of Technology, and his M.S. in Management from the Massachusetts Institute of Technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors has determined that Mr.&nbsp;Capone should serve on the Board for the following reasons: He provides the Board with
business and management expertise at a molecular diagnostic company from his 14 years of service as President, Chief Operating Officer and Vice President of Sales at Myriad Genetic Laboratories. Mr.&nbsp;Capone brings to the Board additional
experience in operations management, product development, finance, sales, and other operational areas from his experience at Eli Lilly and Company. He also provides us with important expertise in investor relations based on his past interactions
with our investor base. Additionally, Mr.&nbsp;Capone&#146;s scientific, engineering and business management background and education provide important insights for the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Lawrence C. Best</B>, a director of Myriad since September 2009, is the Chairman and Founder of OXO Capital LLC, an investment firm focused
on life sciences and therapeutic medical device companies, since 2007.&nbsp;He joined Boston Scientific Corporation in 1992 and served for 15 years as the Executive Vice President-Finance&nbsp;&amp; Administration and Chief Financial
Officer.&nbsp;Prior to joining Boston Scientific, Mr.&nbsp;Best was a partner in the accounting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
firm of Ernst&nbsp;&amp; Young, where he specialized in serving multinational companies in the high technology and life sciences fields.&nbsp;He served a two-year fellowship at the SEC from 1979
to 1981 and a one-year term as a White House-appointed Presidential Exchange Executive in Washington, D.C.&nbsp;He is a founding director of the President&#146;s Council at Massachusetts General Hospital.&nbsp;Within the past five years
Mr.&nbsp;Best also has served on the Board of Directors of Haemonetics Corp, Biogen, Inc. and as Executive Chairman of Valtech Cardio Ltd., a privately held medical device company based in Tel Aviv, Israel.&nbsp;He received a B.B.A. degree from Kent
State University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors has determined that Mr.&nbsp;Best should serve on the Board for the following reasons:&nbsp;He
provides the Board with broad financial accounting and reporting expertise in the technology and life sciences fields.&nbsp;Mr.&nbsp;Best provides extensive financial, business, management and investment expertise from his 15 years of service as the
Chief Financial Officer at Boston Scientific.&nbsp;He also provides the Board with substantial experience in the event of potential mergers, acquisitions and licensing opportunities.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Heiner Dreismann, Ph.D.</B>, a director of Myriad since June 2010, had a successful career at the Roche Group from 1985 to 2006 where he
held several senior positions, including President and CEO of Roche Molecular Systems, Head of Global Business Development for Roche Diagnostics and member of Roche&#146;s Global Diagnostic Executive Committee.&nbsp;From 2006 to 2009,
Dr.&nbsp;Dreismann served as the CEO of Vectrant Technologies, Inc., and until 2013 was the Interim CEO for GeneNews Limited.&nbsp;He currently serves on the Board of Directors of Ignyta, Inc.&nbsp;During the past five years, Dr.&nbsp;Dreismann
served on the Board of Directors of Shrink Nanotechnologies, Med BioGene, Inc., Genenews Limited, and Interpace Diagnostics.&nbsp;He earned a M.S. degree in biology and his Ph.D. in microbiology/molecular biology (summa cum laude) from Westfaelische
Wilhelms University (The University of M&uuml;nster) in Germany.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors has determined that Dr.&nbsp;Dreismann should
serve on the Board for the following reasons:&nbsp;He provides the Board with important business and managerial expertise from his more than 20 years at Roche, including specific expertise in developing and commercially launching diagnostic
products.&nbsp;Furthermore, Dr.&nbsp;Dreismann has extensive experience in international markets, specifically in Europe, which is important as we seek to expand internationally.&nbsp;His scientific background and expertise also enable him to
provide the Board with technical advice on product research and development.&nbsp;Dr.&nbsp;Dreismann has a diversified background in managing and serving as a director of several companies in the healthcare industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Dennis H. Langer, M.D., J.D.,</B> has been a director of Myriad since May 2004. From January 2013 to July 2014 he served as Chairman and
Chief Executive Officer of AdvanDx, Inc. From August 2005 to May 2010, Dr. Langer served as Managing Partner of Phoenix IP Ventures, LLC. From January 2004 to July 2005, he was President, North America for Dr.&nbsp;Reddy&#146;s Laboratories, Inc.
From September 1994 until January 2004, Dr.&nbsp;Langer held several high-level positions at GlaxoSmithKline, and its predecessor, SmithKline Beecham, including most recently as a Senior Vice President of Research and Development. He has a broad
base of experience in innovative R&amp;D companies such as Eli Lilly, Abbott and Searle. He is also a clinical professor at the Department of Psychiatry, Georgetown University School of Medicine. Dr.&nbsp;Langer received a J.D. (cum laude) from
Harvard Law School, an M.D. from Georgetown University School of Medicine, and a B.A. in Biology from Columbia University. He currently serves on the Board of Directors of Dicerna Pharmaceuticals, Inc. and Pernix Therapeutics Holdings, Inc. During
the past five years, Dr.&nbsp;Langer served on the Boards of Delcath Systems, Inc. and Myrexis, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors has
determined that Dr.&nbsp;Langer should serve on the Board for the following reasons:&nbsp;His medical background provides the Board with expertise on developing predictive, personalized, and prognostic testing products.&nbsp;Dr.&nbsp;Langer provides
the Board with business and management expertise from senior positions at several major pharmaceutical companies, including expertise in research and development, which is critical to our development of molecular diagnostic testing services.&nbsp;He
brings international experience as we implement strategies for global expansion.&nbsp;Dr.&nbsp;Langer has a diversified background in managing and serving as a director of several companies in the healthcare industry.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>S. Louise Phanstiel</B>, a director of Myriad since September 2009, held several important
positions at WellPoint, Inc. from 1996 to 2007, including as President, Specialty Products (2003 to 2007), Senior Vice President, Chief of Staff and Corporate Planning in the Office of the Chairman (2000 to 2003), and Senior Vice President, Chief
Accounting Officer, Controller, and Chief Financial Officer for all WellPoint, Inc. subsidiaries, including Blue Cross of California (1996 to 2000). Previously, Ms.&nbsp;Phanstiel was a partner at the international services firm of
Coopers&nbsp;&amp; Lybrand where she served clients in life and property/casualty insurance, high technology, and higher education. She currently serves on the Board of Directors of Verastem, Inc. and the Stony Brook Foundation. Ms.&nbsp;Phanstiel
received a B.A. degree in Accounting from Golden Gate University and is a Certified Public Accountant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors has
determined that Ms.&nbsp;Phanstiel should serve on the Board for the following reasons: She provides the Board with important expertise on the medical insurance industry based on her extensive experience in several senior positions at WellPoint and
Blue Cross of California. This expertise is critical as we rely on third-party reimbursement for our molecular diagnostic services. Ms.&nbsp;Phanstiel also provides the Board with financial accounting and reporting expertise from her work at
Coopers&nbsp;&amp; Lybrand and as a Certified Public Accountant. In addition, she provides the Board with financial and investment expertise, as well as management expertise, resulting from managing and serving as a director of publicly-traded
companies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board of Directors has reviewed the materiality of any relationship that each of our directors has with Myriad, either directly or
indirectly. Based on this review, the Board has determined that the following members of the Board are &#147;independent directors&#148; as defined by The NASDAQ Stock Market LLC: Mr.&nbsp;Best, Dr.&nbsp;Dreismann, Dr.&nbsp;Gilbert,
Dr.&nbsp;Henderson, Dr.&nbsp;Langer, and Ms.&nbsp;Phanstiel. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Leadership Structure of the Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board does not have a policy regarding the separation of the roles of Chairman of the Board and Chief Executive Officer because the Board
believes that it is in our best interests to make that determination based on the position and direction of the Company and the membership of the Board. However, at this time, and since our inception, the Board has determined that having an
independent director serve as Chairman of the Board is in the best interests of our stockholders. Thus, the roles of Chairman of the Board and Chief Executive Officer are separated. This structure ensures a greater role for the independent directors
in the oversight of the Company and their active participation in setting agendas and establishing Board policies, priorities and procedures. This structure also allows the Chief Executive Officer to focus on the management of our day-to-day
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board&#146;s Role in the Oversight of Risk Management </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board has an active role, directly and through its committees, in the oversight of our risk management efforts. The Board carries out this
oversight role through several levels of review. It regularly reviews and discusses with members of management information regarding the management of risks inherent in the operations of our businesses and the implementation of our strategic plan,
including our risk mitigation efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the Board&#146;s committees also oversees the management of risks that are under each
committee&#146;s areas of responsibility. For example, the Audit Committee oversees management of accounting, auditing, external reporting, internal controls and cash investment risks. The Nominating and Governance Committee oversees our compliance
policies, Code of Conduct, conflicts of interest, director independence and corporate governance policies. The Compensation Committee oversees risks arising from compensation practices and policies. While each committee has specific responsibilities
for oversight of risk, the Board is regularly informed by each committee about such risks. In this manner the Board is able to coordinate its risk oversight. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board&#146;s Consideration of Diversity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board and Nominating and Governance Committee do not have a formal policy with respect to the consideration of diversity in identifying
nominees for director positions. However, the Board and Nominating and Governance Committee strive to nominate individuals with a variety of diverse backgrounds, skills, qualifications, attributes and experience such that the Board, as a group, will
possess the appropriate expertise, talent and skills to fulfill its responsibilities to manage the Company in the long-term interests of the stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board&#146;s Disclosure of Third Party Director and Nominee Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No member of the Board of Directors has any agreement or arrangement with any person or entity other than the Company relating to compensation
or other payment in connection with the Director&#146;s service as a Director of the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of the Board of Directors and Meetings
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Meeting Attendance.</I> During the fiscal year ended June&nbsp;30, 2017, or fiscal 2017, there were six meetings of the Board of
Directors, and the various committees of the Board met a total of 11 times. No director attended fewer than 75 percent of the total number of meetings and of committees of the Board on which he or she served during fiscal 2017. The Board has adopted
a policy under which each member is encouraged, but not required to attend each Annual Meeting of Stockholders. At the time of our 2016 Annual Meeting, all members of the Board of Directors were in attendance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Audit Committee.</I> Our Audit Committee met five times during fiscal 2017. This committee currently has three members: Ms.&nbsp;Phanstiel
(chair), Mr.&nbsp;Best, and Dr.&nbsp;Langer. The Audit Committee&#146;s roles and responsibilities are set forth in its written charter and include the authority to retain and terminate the services of our independent registered public accounting
firm. In addition, the Audit Committee reviews annual financial statements; considers matters relating to accounting policy and internal controls; reviews the scope of annual audits; and monitors our processes for complying with laws, regulations
and our Code of Conduct. Our Board of Directors has determined that all members of the Audit Committee satisfy the current independence standards promulgated by the SEC and by The NASDAQ Stock Market LLC, as such standards apply specifically to
members of audit committees. The Board has determined that Ms.&nbsp;Phanstiel is an &#147;audit committee financial expert,&#148; as the SEC has defined that term in Item&nbsp;407 of Regulation S-K under the Securities Act of 1933, as amended, or
the Securities Act. A copy of the Audit Committee&#146;s written charter is publicly available on the Investor Information &#150; Understanding Myriad/Corporate Governance section of our website at <I>www.myriad.com</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please also see the report of the Audit Committee set forth elsewhere in this proxy statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Compensation Committee.</I> Our Compensation Committee met two times during fiscal 2017. This committee currently has three members:
Dr.&nbsp;Dreismann (chair), Dr.&nbsp;Gilbert, and Dr.&nbsp;Henderson. The Compensation Committee&#146;s role and responsibilities are set forth in its written charter and include reviewing, approving and making recommendations regarding our
compensation policies, practices and procedures to ensure that legal and fiduciary responsibilities of the Board of Directors are carried out and that such policies, practices and procedures contribute to our success. The Compensation Committee also
is responsible for evaluating and determining the compensation of our President and Chief Executive Officer, and conducts its decision making process with respect to that issue without the President and Chief Executive Officer present. The Board has
determined that all members of the Compensation Committee qualify as independent under the definition promulgated by The NASDAQ Stock Market LLC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee is charged with establishing a compensation policy for our executives and directors that is designed to attract and
retain qualified executive talent, to motivate them to achieve corporate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
objectives, and reward them for superior performance. Our Compensation Committee is also responsible for establishing and administering our executive compensation policies and equity compensation
plans. The Compensation Committee meets at least two times per year and more often as necessary to review and make decisions with regard to executive compensation matters. As part of its review of these matters, the Compensation Committee may
delegate any of the powers given to it to a subcommittee. A copy of the Compensation Committee&#146;s written charter is publicly available on the Investor Information &#151; Understanding Myriad/Corporate Governance section of our website at
<I>www.myriad.com</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further discussion of the process and procedures for considering and determining executive compensation, including
the role that our executive officers play in determining compensation for other executive officers is included below in the section entitled &#147;Executive Compensation &#151; Compensation Discussion and Analysis.&#148; The Compensation Committee
has the authority to directly retain the services of independent consultants and other experts to assist in fulfilling its duties. For purposes of our fiscal year 2017 executive compensation determinations, the Compensation Committee retained Mercer
(US), Inc. (&#147;Mercer&#148;) to update our peer group of companies and provide competitive market data on the salaries and short-term and long-term incentive compensation of executive officers at comparable companies within our industry. Mercer
also was engaged to provide the Compensation Committee an analysis of, and recommendations for, annual salary compensation, short-term incentive compensation, and long-term incentive compensation for the President and CEO and other executive
officers. Mercer performs services solely on behalf of the Compensation Committee and has no relationship with Myriad or its management except as may relate to performing such services. The Compensation Committee has assessed the independence of
Mercer pursuant to SEC rules and the corporate governance rules of The NASDAQ Stock Market LLC and concluded that no conflict of interest exists that would prevent Mercer from independently representing the Compensation Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please also see the report of the Compensation Committee set forth elsewhere in this proxy statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Nominating and Governance Committee. </I>Our Nominating and Governance Committee met two times during fiscal 2017. This committee currently
has three members: Dr.&nbsp;Langer (chair), Dr.&nbsp;Henderson, and Ms.&nbsp;Phanstiel. This committee&#146;s role and responsibilities are set forth in the Nominating and Governance Committee&#146;s written charter and include evaluating and making
recommendations to the full Board as to the size and composition of the Board and its committees, identifying and evaluating potential candidates and recommending the director nominees for election, developing and recommending corporate governance
guidelines applicable to us, and reviewing and approving potential or actual conflicts of interest between our executive officers or members of the Board. The committee also oversees the annual Board performance evaluations, which may be submitted
anonymously at the discretion of the director concerned, as well as our policy on plurality voting for director elections, which is described in &#147;Proposal 1 &#151; Election of Directors&#148; of this proxy statement. The Board of Directors has
determined that all members of the Nominating and Governance Committee qualify as independent under the definition promulgated by The NASDAQ Stock Market LLC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a stockholder wishes to nominate a candidate for director who is not included in our proxy statement, the stockholder must follow the
procedures described in our Restated By-Laws and in &#147;Stockholder Proposals and Nominations for Director&#148; at the end of this proxy statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under our current corporate governance policies, the Nominating and Governance Committee may consider candidates recommended by
stockholders as well as from other sources such as other directors or officers, third-party search firms or other appropriate sources. For all potential candidates, the Nominating and Governance Committee may consider all factors it deems relevant,
such as a candidate&#146;s personal integrity and sound judgment; business and professional skills and experience; independence, knowledge of the industry in which we operate, possible conflicts of interest, the extent to which the candidate would
fill a present need on the Board; and concern for the long-term interests of the stockholders. In general, persons recommended by stockholders will be considered on the same basis as candidates from other sources. If a stockholder wishes to propose
a candidate for consideration by the Nominating and Governance Committee under our corporate governance policies, for each annual meeting, the Committee will consider only one recommended nominee from any stockholder or group of affiliated
stockholders, and such recommending stockholder or group must have held at least 5 percent of common stock for at least one year. All </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholder recommendations for proposed director nominees must be made in writing to the Nominating and Governance Committee, care of Myriad&#146;s Secretary at 320 Wakara Way, Salt Lake City,
Utah 84108, and must be received no later than 120 days prior to the first anniversary of the date of the proxy statement for the previous year&#146;s Annual Meeting. The recommendation must be accompanied by the following information concerning the
recommending stockholder: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The name, address and telephone number of the recommending stockholder; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The number of shares of our common stock owned by the recommending stockholder and the time period for which such shares have been held; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If the recommending stockholder is not a stockholder of record, a statement from the record holder verifying the holdings of the recommending stockholder and a statement from the recommending stockholder of the length
of time such shares have been held (alternatively, the recommending stockholder may furnish a current Schedule 13D, Schedule 13G, Form 3, Form 4 or Form 5 filed with the SEC, together with a statement of the length of time that the shares have been
held); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A statement from the recommending stockholder as to the good faith intention to continue to hold such shares through the date of the next annual meeting. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The recommendation must also be accompanied by the following information concerning the proposed nominee: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The information required by Items 401, 403 and 404 of Regulation S-K under the Securities Act; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A description of all relationships between the proposed nominee and the recommending stockholder, including any agreements or understandings regarding the nomination; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A description of all relationships between the proposed nominee and any of our competitors, customers, suppliers, labor unions or other persons with special interests regarding the Company; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The contact information for the proposed nominee. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The recommending stockholder must also
furnish a statement supporting a view that the proposed nominee possesses the minimum qualifications as set forth below for director nominees and describing the contributions that the proposed nominee would be expected to make to the Board and to
the governance of Myriad and must state whether, in the stockholder&#146;s view, the proposed nominee, if elected, would represent all stockholders and not serve for the purpose of advancing or favoring any particular stockholder or other
constituency of Myriad. The recommendation must also be accompanied by the written consent of the proposed nominee (i)&nbsp;to be considered by the Nominating and Governance Committee and interviewed if the Nominating and Governance Committee
chooses to do so in its discretion, and (ii)&nbsp;if nominated and elected, to serve as a director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For all potential candidates, the
Nominating and Governance Committee may consider all factors it deems relevant, including the following threshold criteria: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Candidates should possess the highest personal and professional standards of integrity and ethical values; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Candidates must be committed to promoting and enhancing the long-term value of Myriad for its stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Candidates must be able to represent fairly and equally all stockholders without favoring or advancing any particular stockholder or other constituency of Myriad; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Candidates must have demonstrated achievements in one or more fields of business, professional, governmental, community, scientific or educational endeavor, and possess mature and objective business judgment and
expertise; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Candidates are expected to have sound judgment, derived from management or policy making experience that demonstrates an ability to function effectively in an oversight role; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Candidates must have a general appreciation regarding major issues facing public companies of a size and operational scope similar to Myriad, including governance concerns, regulatory obligations, strategic business
planning, competition and basic concepts of accounting and finance; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Candidates must have, and be prepared to devote, adequate time to the Board of Directors and its committees. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Nominating and Governance Committee will take into account the extent to which the candidate would fill a present need on the
Board, including the extent to which a candidate meets the independence and experience standards promulgated by the SEC and by The NASDAQ Stock Market LLC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of the Nominating and Governance Committee&#146;s written charter is publicly available on the Investor Information&nbsp;&#151;
Understanding Myriad/Corporate Governance section of our website at <I>www.myriad.com</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The descriptions of our corporate governance
policies contained in this proxy statement are qualified in their entirety and subject to the terms of such policies as modified by the Board of Directors from time to time. The following corporate governance documents are publicly available on the
Investor Information &#151; Understanding Myriad/Corporate Governance section of our website at <I>www.myriad.com</I>: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Policy on Annual Shareholder Meeting Attendance by Directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Policy on Security Holder Communications with Directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Policy on Security Holder Recommendation of Candidates for Election as Directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Procedures for Security Holders Submitting Nominating Recommendations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Policy Regarding Qualifications of Directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Policy For Handling Complaints Regarding Accounting and Auditing Matters and Code of Conduct Matters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Policy on Plurality Vote for Director Elections; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Policy on Limiting Service on Public Company Boards; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Policy on New Director Orientation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Policy on Continuing Education for the Board; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Policy on Related Person Transactions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Director and Executive Officer Stock Ownership Guidelines; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Equity Award Holding Requirements for Named Executive Officers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Corporate Governance Principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Corporate Code of Conduct and Ethics and Whistleblower Policy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Policy on Incentive Compensation Repayment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Nominating and Governance Committee Charter; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Audit Committee Charter; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Compensation Committee Charter; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Strategic Committee Charter. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Strategic Committee. </I>Our Strategic Committee met two
times during fiscal 2017. This committee currently has three members: Dr.&nbsp;Henderson (chair), Mr.&nbsp;Best and Dr.&nbsp;Dreismann. The committee&#146;s roles and responsibilities are set forth in the Strategic Committee&#146;s written charter
and include advising and consulting with senior management on a broad range of strategic initiatives and making recommendations to the Board regarding such opportunities. A copy of the Strategic Committee&#146;s written charter is publicly available
on the Investor Information &#151; Understanding Myriad/Corporate Governance section of our website at <I>www.myriad.com</I>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Compensation Committee Interlocks and Insider Participation</I>. Our Compensation Committee
currently has three members: Dr.&nbsp;Dreismann (Chair), Dr.&nbsp;Gilbert, and Dr.&nbsp;Henderson. No member of our Compensation Committee has at any time been an employee of the Company. None of our executive officers is a member of the
Compensation Committee, nor do any of our executive officers serve as a member of the Board of Directors or Compensation Committee of any entity that has one or more executive officers serving as a member of our Board of directors or Compensation
Committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stockholder Communications to the Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, stockholders who have questions or concerns should contact our Investor Relations department at (801)&nbsp;584-1143. However, any
stockholder who wishes to address questions regarding our business directly with the Board of Directors, or any individual director, should send his or her questions in writing to the Chairman of the Board or a designated member of the Board at 320
Wakara Way, Salt Lake City, Utah 84108. Communications will be distributed to the Board, to the Nominating and Governance Committee, or to any individual director or directors as appropriate, depending on the facts and circumstances outlined in the
communications. Items that are unrelated to the duties and responsibilities of the Board may be excluded, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Junk mail and mass mailings; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Resumes and other forms of job inquiry; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Surveys; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Solicitations or advertisements. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, any material that is unduly hostile,
threatening, or illegal in nature may be excluded, provided that any communication that is excluded will be made available to any outside director upon request. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table
sets forth the name, age (as of September&nbsp;1, 2017) and position of each of our current executive officers: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:19.10pt; font-size:8pt; font-family:Times New Roman">Name</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Age</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:26.15pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Position</P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark C. Capone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alexander Ford</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Myriad Genetic Laboratories, Inc.</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gary A. King</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President, International Operations</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jerry S. Lanchbury, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Scientific Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard M. Marsh, Esq.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President, General Counsel and Secretary</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ralph L. McDade, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Myriad RBM, Inc.</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R. Bryan Riggsbee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer and Treasurer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bernard F. Tobin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Crescendo Bioscience, Inc.</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Verratti</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Assurex Health, Inc.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Mark C. Capone</B>. Please see biography above under &#147;Management and Corporate Governance
&#151; The Board of Directors.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Alexander Ford</B>, President of Myriad Genetic Laboratories, Inc. (&#147;MGL&#148;), a wholly
owned subsidiary of Myriad, has served in his current role since July&nbsp;1, 2015. Mr.&nbsp;Ford joined Myriad in June 2010. Before being named to his current position, he served as the Chief Commercial Officer of MGL. Prior to joining Myriad,
Mr.&nbsp;Ford held leadership positions at Novartis, Sanofi-Aventis, Nektar Therapeutics and Pfizer in the areas of Marketing Research, Product Marketing, Managed Care, Sales and Business Development. He has more than 25 years of experience in the
pharmaceutical and biotechnology industries. Mr.&nbsp;Ford received his B.A. degree in Communications from the University of North Carolina, Wilmington and his M.A. degree from New York University.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Gary A. King</B>, Executive Vice President, International Operations, joined us in July 2010. Mr.&nbsp;King has been employed in the life
sciences industry for more than 25 years. From June 2008 to June 2010, he was the Chief Executive Officer of AverDx Incorporated, an international biotechnology company that develops novel biomarker diagnostics for critical diseases. From June 2002
to February 2008, he served as Vice President, International Operations at Biosite Incorporated, a developer of diagnostic products and antibody development technologies where he spent six years building and leading all of the company&#146;s
commercial activities outside the United States. Mr.&nbsp;King received his B.A. degree in Zoology from Pomona College and a M.B.A. degree from Stanford University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Jerry S. Lanchbury, Ph.D.,</B> Chief Scientific Officer, joined the Company in September 2002 as Senior Vice President of Research. In July
2005 he was appointed Executive Vice President of Research, a position he held until he was named to his current position in February 2010. Dr.&nbsp;Lanchbury came to us from GKT School of Medicine, King&#146;s College where he had served as Reader
in Molecular Immunogenetics and Head of Molecular Immunogenetics Unit since 1997. Dr.&nbsp;Lanchbury earned his Ph.D. from the University of Newcastle upon Tyne and 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> Class Honours, B.Sc.
&#147;Biology of Man&nbsp;&amp; his Environment&#148; degree from the University of Aston. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Richard M. Marsh, Esq., </B>Executive Vice
President, General Counsel and Secretary, joined Myriad in November 2002. He previously served as Director of Intellectual Property (2001-2002), Acting General Counsel and Secretary (2000-2001), and Director of Commercial Legal Affairs (1998-2000)
for Iomega Corporation. Mr.&nbsp;Marsh served as a partner with the law firm of Parsons, Behle&nbsp;&amp; Latimer in Salt Lake City from 1989 to 1998. He received an LL.M. degree in Taxation from Georgetown University Law Center, a J.D. degree,
magna cum laude, from Thomas M. Cooley Law School, and a B.S. degree in accounting from Brigham Young University, and was formerly a Certified Public Accountant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Ralph L. McDade, Ph.D.</B>, President of Myriad RBM, Inc., a wholly owned subsidiary of Myriad, has served in his current role since
January 2014. Previously, he served as Chief Operating Officer of Myriad RBM. Dr.&nbsp;McDade was formerly Strategic Development Officer for Myriad RBM and was in that position since the company&#146;s inception in 2002. Prior to joining Myriad RBM,
he was Chief Scientific Officer for Luminex Corporation from 1996 to 2002, where he was closely involved with the development of xMAP technology. Dr.&nbsp;McDade received his Ph.D. in Microbiology from the University of Texas Southwestern Medical
School in 1980. Following postdoctoral training at The University of Connecticut Medical Center in Farmington, he held faculty positions at the Rockefeller University in New York and at Louisiana State University School of Medicine in New Orleans.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>R. Bryan Riggsbee</B>, Chief Financial Officer and Treasurer, joined us in October 2014. He previously served 10 years with Laboratory
Corporation of America (LabCorp) where his most recent position was as Senior Vice President of Corporate Finance with responsibility for the financial planning and analysis and treasury functions. Prior to LabCorp, Mr.&nbsp;Riggsbee served in
various finance roles with General Electric and began his career in the audit division of KPMG. He received a B.A. in Accounting from North Carolina State University, a B.A. in political science from the University of North Carolina at Chapel Hill
and an M.B.A. from Northwestern University. Mr.&nbsp;Riggsbee is a Certified Public Accountant licensed in the State of North Carolina. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Bernard F. Tobin</B>, President of Crescendo Bioscience, Inc., has served in that role since
January 2015. He previously held several senior positions at Amgen over the course of 8 years, including Executive Director of National Accounts, General Manager of both the Netherlands and Brazil, and Global Head of Commercial Excellence. In
addition, he led the global integration of business development acquisition in more than 100 countries. Prior to that, Mr.&nbsp;Tobin held a variety of leadership roles in the commercial organization at Eli Lilly and Co. over the course of 16 years.
He received his B.S. degree in public service and administration from Iowa State University and his M.B.A from the Fuqua School of Business, Duke University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Mark Verratti, </B>President Assurex Health, Inc., a wholly owned subsidiary of Myriad, has served in his current role since August&nbsp;1,
2017. He previously served as SVP, Chief Sales and Business Development officer at Assurex since January 2016. Mr.&nbsp;Verratti also held senior leadership positions with Cyberonics (now known as LivaNova) from 2005-2016, and earlier with Forest
Pharmaceuticals where he led commercial teams with revenues approaching $500 million dollars. He received a B.S. in Life Sciences with a minor in Physiology from The Pennsylvania State University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have employment agreements with all of our executive officers. The employment agreements for each of our named executive officers are
described elsewhere in the proxy statement under the caption &#147;Executive Compensation&nbsp;&#151; Narrative Disclosure to Summary Compensation Table and 2017 Fiscal Year Grants of Plan-Based Awards Table.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Compensation Discussion and Analysis </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Executive Summary </U></I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Overview
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a leading molecular diagnostic company, with the goal of providing physicians and their patients with critical information to
guide healthcare management. Our goal is to manage our business to maximize the value we provide through our services, making the Company more successful and valuable, and hence maximizing our long-term stockholder value. Our compensation programs
are designed to support these goals, with the primary objectives of attracting and retaining executive talent, motivating our executive officers through pay-for-performance metrics to enhance our growth and profitability, and increasing long-term
stockholder value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The four principal components of our compensation program for executive officers are: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Annual salary; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Short-term incentive compensation in the form of an annual cash incentive bonus; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Long-term incentive compensation in the form of a three-year cash incentive bonus; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Long-term incentive compensation in the form of restricted stock units or RSUs, subject to time-based vesting, with a performance-based factor applicable to our NEOs. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that these compensation components provide the appropriate balance of short-term and long-term compensation and incentives to our
executives to drive our performance, success and long-term growth. As indicated in the charts below, our pay mix largely follows that of our peers, with the majority of our compensation in the form of long-term incentive compensation. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g462900g24p45.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Peer Pay Mix data is a composite of our peer group data and published survey data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our compensation program seeks to align compensation with Company performance, and hence reward our executive officers for their contribution
to our growth, profitability and increased stockholder value through the recognition of individual leadership, initiatives, achievements and other contributions. Each year our Compensation Committee approves Management Business Objectives
(&#147;MBOs&#148;) for each executive officer that consist of (i)&nbsp;pre-established financial performance targets for the Company such as revenue and adjusted operating income (&#147;Company Financial MBOs&#148;), and (ii)&nbsp;individual
objectives tailored to each executive (&#147;Individual MBOs&#148;). The Compensation Committee reviews the achievement of these MBOs in determining compensation to be paid to our executive officers. The Compensation Committee believes that the MBOs
are based on an appropriate mix of financial performance targets and individual objectives that provide appropriate pay-for-performance metrics to incentivize executive officers to increase our profitability, success and long-term stockholder value.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Fiscal Year 2017 Performance </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For fiscal year 2017 our revenues were up two percent year-over-year to $771 million, GAAP earnings per share of $0.32 and pro forma earnings
per share of $1.05. During fiscal year 2017, we believe we accomplished many of our strategic objectives that positions the Company for long-term growth. We made substantial progress on our five strategic critical success factors to: i) stabilize
hereditary cancer revenue, ii) grow new product volume, iii) expand reimbursement coverage for new products, iv) increase RNA kit revenue internationally, and v) improve profitability with our Elevate 2020 Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We continued generating strong cash flows from operations and in fiscal year 2017 we generated over $100 million in GAAP free cash flow. We
ended the year with $199 million in cash, cash equivalents, and marketable investment securities and plan to continue to exercise a balanced approach to capital deployment, including investing for future growth, paying down debt associated with
recent acquisitions, business development activities and share repurchases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An explanation of the adjustments to our GAAP financial
measures used in this proxy and a reconciliation of the adjusted financial measures to the comparable GAAP financial measures are included in Appendix A to this proxy statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During fiscal year 2017 we reduced the level of our share repurchases to 1.6&nbsp;million shares as we focused on reducing the balance on our
credit facility associated with the Assurex acquisition. Since fiscal year 2010, we have purchased over 49&nbsp;million shares of our common stock under our stock repurchase program for $1.239 billion at a weighted average price of $25.18 per share.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g462900g35h68.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Focusing on our longer-term growth, over the past five years, we have accomplished a 5 percent compound
annual growth rate (&#147;CAGR&#148;) for revenues. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g462900g05h24.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Over the past five years, we experienced a 2 percent annual stockholder return on our stock price versus a
16 percent return for the NASDAQ composite index reflecting the increased competition we faced after the early patent expiration of key hereditary cancer patents covering greater than ninety percent of our revenue in fiscal year 2014. Additionally,
we ended the first quarter of our fiscal year 2018 with a stock price of $36.18, which represents a 40% increase in our stock price over our fiscal year 2017 year-end price. Taking into account our first quarter of fiscal year 2018, we experienced a
76% return on our stock price over the past twelve months for the quarter ending September&nbsp;30, 2017 versus 22% for the NASDAQ composite index over the same period. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g462900g08i11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our financial results during fiscal year 2017, we also achieved the following progress on
our five critical success factors: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Stabilize Hereditary Cancer Revenue</U> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Achieved fiscal year 2017 hereditary cancer revenue of $569 million which was nearly identical to the revenue in fiscal year 2013, the year before the U.S. Supreme Court BRCA patent decision. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Returned hereditary cancer business to year-over-year volume growth, with the fiscal fourth quarter at a 6 percent year-over-year growth rate. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Signed long term contracts with payers representing 86 percent of revenue for our hereditary cancer business. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Signed preferred provider agreements with U.S. Oncology and the Integrated Oncology Network (ION). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Launched customizable gene panel option increasing market penetration with academic and genetic customers. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Grow new product volume</U> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Grew new product volumes by 20 percent in aggregate when normalized for full-year 2016 volumes. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Completed the largest acquisition in our history and successfully integrated the Assurex business with revenues exceeding expectations and having achieved profitability in less than nine months. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">GeneSight test volume grew 45 percent when normalized for a full year, and is now our highest volume test at a run rate of over a quarter of a million tests per year, and would represent revenue of $500 million per year
if fully reimbursed. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Completed the acquisition and integration of Sividon which brought EndoPredict to Myriad, a second generation test to guide treatment decisions for breast cancer patients that markedly outperformed the first generation
test. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">EndoPredict volume grew 67 percent in fiscal year 2017 and was launched in the US market in the third quarter. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Vectra DA returned to sequential volume growth in the last two quarters of the year and demonstrated that it was the most predictive disease activity measure for rheumatoid arthritis with more than three times the
predictive power of standard of care measures. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Prolaris maintained its market leadership position as a prostate cancer prognostic with volumes increasing 26 percent. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Completed validations for myPath Melanoma which demonstrated that the test is the most accurate diagnostic for differentiating benign lesions from melanoma, with an extensive dossier submitted for reimbursement to
Medicare and private payers. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Validated that myChoice HRD can identify patients with enhanced response to PARP inhibitors, and validated BRACAnalysis CDx as a companion diagnostic with AstraZeneca&#146;s Olaparib in a new 60,000 patient per year
metastatic breast cancer market. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Expand reimbursement coverage for new products</U> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Increased reimbursement for Prolaris from 35 to 50 percent of the total addressable market as the first test to receive a Medicare LCD expansion for favorable intermediate patients. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Increased coverage for EndoPredict by over 120&nbsp;million commercial covered-lives and received a favorable Medicare draft LCD, which if approved, will attain reimbursement for greater than 75 percent of the total
addressable market. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Completed enrollment in our landmark 1,200 patient clinical utility study for GeneSight with results expected by the end of calendar year 2017. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Published health economic studies for GeneSight demonstrating first year savings of $2,500 and completed a number of payer demonstration projects with large national payers including United Healthcare, Humana and
Anthem. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Advanced reimbursement with Vectra DA by increasing enrollment in the prospective clinical utility study, initiating a number of payer demonstration projects, and providing strong evidence for inclusion in ACR
guidelines this fall. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Added additional management capabilities during the year and implemented a number of innovative new approaches to accelerate reimbursement, including the portfolio approaches used in many of our new long-term contracts.
</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Increase RNA kit revenue internationally</U> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Grew EndoPredict revenue by 69 percent year-over-year. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Received reimbursement approval in France, Quebec, and an expanded number of German sites and laid the groundwork for favorable decisions in the United Kingdom, additional Canadian provinces, and further expansion in
German reimbursement sites in fiscal year 2018. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Advanced our kit based initiatives for Prolaris and myPath Melanoma in fiscal year 2017 and plan to complete the validation of these products in fiscal year 2018. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Improve profitability with Elevate 2020</U> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In the fourth-quarter of fiscal year 2017 we introduced a new program called Elevate 2020 with a goal of increasing fiscal year 2020 operating profit by $50 million through cost reduction initiatives and strategic
projects to grow revenue. Several programs were initiated in the fiscal fourth quarter which we anticipate will drive a $17 million improvement in operating profit in fiscal year 2018. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Performance Pay for Fiscal Year 2017 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To reflect our pay for performance philosophy, based on the Company&#146;s performance for fiscal year 2017, our Compensation Committee: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced the respective fiscal year 2017 annual cash incentive bonuses awarded to our NEOs by 10 to 18 percent of target based on each NEO&#146;s individual MBO score to reflect the degree to which annual targets were
achieved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">awarded no compensation under our fiscal year 2015-2017 three-year, long term cash incentive plan because target thresholds were not achieved; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in connection with our Elevate 2020 Program and our efforts to increase our annual operating profitability, accepted the recommendation of our executive officers to freeze the annual base salary of our executive
officers for fiscal year 2018. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the Compensation Committee determined to freeze the level of RSUs awarded to
our executive officers at the levels awarded in fiscal year 2016 aligning total compensation to our goal of between the 50<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> to 75<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> percentile
of our compensation benchmarks. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Say-on-Pay Results </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At our last annual meeting of stockholders in December 2016, we held a stockholder advisory vote on the fiscal year 2016 compensation of our
NEOs. This is generally referred to as a &#147;Say-on-Pay&#148; vote. ISS and Glass Lewis recommended for the approval of our Say-on-Pay vote and our stockholders approved the compensation of our NEOs with 95 percent of stockholder votes cast in
favor of our Say-on-Pay resolution for fiscal year 2016. Notwithstanding this high approval percentage, we continued our outreach to our stockholders to identify and understand feedback that they may have about our executive compensation with the
goal of sustaining a high level of approval. Our stockholders consistently made the following comments: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Continued support for switching from granting stock options to restricted stock units and the stated goal to target compensation at the 50<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> to 75<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> percentile of our compensation benchmarks; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Support for CEO and CFO total compensation to be within the 50<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> to 75<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> percentile of our compensation
benchmarks; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Recommendation to continue the alignment of performance metrics for our three-year long term cash incentive plan to our disclosed strategic goals. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we considered concerns raised by ISS and Glass Lewis with respect to our executive compensation program regarding (i)&nbsp;our
Board of Directors&#146; discretion to accelerate vesting on equity incentive awards, (ii)&nbsp;the lack of a one year minimum vesting requirement for all equity awards, and (iii)&nbsp;that the Company&#146;s Claw Back Policy does not provide for
the recoupment of equity incentive compensation. We have addressed these items as discussed below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Changes To Our Pay Practices and Philosophy </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In response to the feedback expressed by our stockholders, ISS and Glass Lewis, we are making the following changes, or continuing prior
responsive practices, to our executive compensation program: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have amended our Claw Back Policy to now require an executive officer to repay to us the amount of any cash <U>and</U> equity incentive compensation that an executive officer receives to the extent that:
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amount of such payment was based on the achievement of certain financial results that were subsequently the subject of a restatement that occurred within 12 months of such payment; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the executive officer had engaged in theft, dishonesty or intentional falsification of documents or records that resulted in the obligation to restate our financial results; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a lower cash or equity incentive compensation payment would have been made to the executive officer based upon the restated financial results. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have approved, subject to shareholder approval at our 2017 Annual Meeting of Stockholders, our new 2017 Employee, Director and Consultant Equity Incentive Plan (the &#147;2017 Plan&#148;) to address comments of our
shareholders, ISS and Glass Lewis. Specifically our 2017 Plan, provides: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to continue our efforts to reduce the dilutive impact of equity compensation awards on our shareholders, any stock right awarded under the 2017 Plan must be in the form of a restricted stock unit or a restricted stock
grant; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">incentive stock options and non-qualified options will not be permitted under the 2017 Plan; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all stock rights awarded must have a minimum vesting period of at least one year (we have historically provided for a four year vesting period for our equity incentive awards, and intend to continue that practice);
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the vesting of any stock right awarded under the 2017 Plan cannot be accelerated from the original grant vesting schedule except in connection with death, disability or a change in control; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the 2017 Plan does not permit the payment of any dividend on any stock right which is not fully vested. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g462900g82f46.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Based on the 2017 Mercer Executive Compensation Review for fiscal year 2017, total compensation for our President and CEO was below the 50<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> percentile of our
compensation data, and the total compensation for our other executive officers was within, or below, the 50<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> and 75<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> percentiles of our
compensation data; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The performance target metrics for our 3 year cash incentive plan for fiscal years 2018- 2020 have performance metrics which align with our strategic goals based on revenue growth, adjusted operating margin, and
diversification from non-hereditary cancer revenue. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Pay Practices </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Previously, we adopted other practices that reflect the high standards our Compensation Committee seeks to attain for our compensation
philosophy and pay practices, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The period required for full vesting of restricted stock units shall be greater than four years; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All restricted stock units awarded to our NEOs are granted subject to a predetermined, objective, formula-based, financial performance metric; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Stock ownership guidelines for our directors (three times annual cash retainer) and executive officers subject to Section&nbsp;16 reporting (for President and CEO, three times annual base salary, and for other executive
officers, two times annual base salary); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Annual cash bonus an executive officer may receive is capped at a percent of his or her target bonus percentage amount; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Prohibiting any tax gross-up payments by the Company with respect to compensation paid to any employees or directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Prohibiting hedging the economic risk of holding our stock, including trading in our stock on a short-term basis, short sales of our stock and similar transactions, for which waivers are not granted; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Prohibiting the pledge or use of our stock to secure a margin or other loan, for which waivers are not granted; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Prohibiting the Company&#146;s repurchase of underwater stock options under our 2010 Employee, Director and Consultant Equity Incentive Plan, as amended, (the &#147;2010 Plan&#148;); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Prohibiting the repricing of stock options and other awards under our 2010 Plan without stockholder approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Prohibiting the grant of in-the-money stock options under our 2010 Plan; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Employing each executive officer on an &#147;at will&#148; basis without any guarantee as to employment term, salary, or bonus. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the annual review of our executive compensation program and compensation pay components, we will continue our general
approach of establishing Company Financial MBOs and Individual MBOs for our executive officers. These MBOs assist the Compensation Committee in evaluating the performance of our executive officers and to then reward them through short- and long-term
incentive compensation for the value they deliver to our stockholders as demonstrated by the enhanced growth and profitability of the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Fiscal Year 2017 Named Executive Officer Compensation </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Elements of our Compensation Program </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation program for our executive officers consists principally of a base salary, an annual cash incentive bonus, long-term
compensation in the form of a three-year cash incentive bonus award and equity incentive compensation in the form of restricted stock units with a performance-based factor applicable to our NEOs. We believe that these elements of our compensation
strike an appropriate balance to incentivize and reward our executive officers for ongoing, short- and long-term performance. An annual base salary provides the foundation of our compensation program and ensures that the executive officer is being
paid ongoing compensation, which allows us to attract and retain high-quality talent. The annual cash incentive bonus forms an important part of our compensation strategy by providing an incentive to reward short-term performance as measured by
Company performance and accomplishment of individual MBOs. The long-term cash incentive bonus awards and equity incentive compensation also form an important part of our compensation strategy. These incentive bonus awards and equity grants reward
our executive officers for the long-term performance of Myriad, and help to ensure that our executive officers have a stake in our long-term success by providing an incentive to improve our overall growth and value. For example, under our long-term
cash incentive awards, performance metrics are measured by achieving three-year financial performance targets reflecting growth of revenue, diversifying revenues and improving operating margins. These performance metrics align with our strategic
goals and objectives and thus aligns the executive officers&#146; interests with stockholders&#146; long-term interests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee, in collaboration with management, attempts to develop an overall
compensation program that incentivizes the executive officers to achieve their objectives without encouraging them to take excessive risks to the business. We believe that this is accomplished through the balance of the various elements of our
compensation program, including the establishment of annual MBOs for each of the executive officers to appropriately guide their performance objectives, establishment of preset annual and three-year growth financial performance targets, and preset
limits on cash incentive compensation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Formulating and Setting Executive Compensation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee is responsible for formulating, evaluating and approving the compensation, including the award of equity
compensation, for our executive officers, including our President and CEO. The Compensation Committee also assists the full board in establishing appropriate incentive compensation and equity-based plans generally for all employees and is
responsible for administering these plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For fiscal year 2017, the Compensation Committee retained Mercer (US) Inc.
(&#147;Mercer&#148;) for the purpose of updating our peer group of companies and to provide competitive market data on the salary, short-term incentive compensation and long-term incentive compensation of executive officers at comparable companies
within our industry. The Compensation Committee uses this competitive market data on compensation in determining annual salary compensation, short-term (annual) incentive compensation and long-term incentive compensation (both cash and equity
incentive compensation) for the President and CEO and other executive officers of the Company (the &#147;2017 Mercer Executive Compensation Review&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a basis for the source market data for the 2017 Mercer Executive Compensation Review, Mercer utilized compensation data from the following
group of 15 peer companies, which is our peer group from last fiscal year. We believe the selected peer group of companies reflects our industry and aligns with the ISS Glass Lewis selected peer group for Myriad. Presently, 10 of the 15 companies in
our peer group are companies which were selected by ISS as part of ISS&#146;s compensation pay review from last year, and 9 of the 15 companies in our peer group of companies are companies selected by Glass Lewis as part of Glass Lewis&#146;
compensation pay review from last year. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Acorda Therapeutics, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Alexion Pharmaceuticals, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Alkermes plc</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Biomarin Pharmaceutical, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cepheid</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hologic, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">IDEXX Laboratories, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Illumina, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Insys Therapeutics, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Medivation, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Quidel Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Regeneron&nbsp;Pharmaceuticals,&nbsp;Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ResMed, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">United&nbsp;Therapeutics&nbsp;Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Vertex Pharmaceuticals, Inc.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Mercer gathered competitive market data from published survey data in the biotech industry for
similarly sized entities as reflected in the 2016 Mercer US Global Premium Executive Remuneration Suite and the 2017 Radford Global Life Sciences Survey. To determine competitive market compensation, where possible, composite survey data were
equally blended with the proxy data from our peer group set forth above. Compensation data for the peer group were collected from available proxy-disclosed data. This information was gathered and analyzed for the 25th, 50th and 75th percentiles for
annual salary, short-term incentive pay elements and long-term incentive pay elements. Where possible, our executive officers were matched to appropriate proxy and survey positions based on job content and level of responsibility. Proxy-based and
survey-based salaries were aged to 2017 at an annual rate of 3 percent, the average 2016/2017 salary increase for executives in the U.S. Restricted stock units were valued at fair market value (the closing price of our common stock) on the date of
grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the compensation information obtained from the 2017 Mercer Executive Compensation Review provides us appropriate
compensation data and benchmarks, because it is derived from companies that are in our industry, share similar corporate structures, and have similar factors such as number of employees, market value, revenues, net income, product pipeline and gross
margins. Through Mercer, we have selected those companies that we believe represent the various factors of our business as outlined above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Utilizing the composite peer group data provided to us in the 2017 Mercer Executive Compensation Review, the Compensation Committee analyzed,
among other criteria, the average salary, short-term incentive bonus compensation and long-term incentive bonus compensation (both cash and equity compensation) for each of our executive officers at the
25<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>, 50<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> and 75<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> percentile ranges. In addition, for long-term incentive equity
compensation, the Compensation Committee analyzed, among other criteria, the average equity compensation for each of our executive officers at the 25<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>, 50<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> and 75<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> percentile range from the Mercer composite compensation data. The Compensation Committee also analyzed our equity burn rate, issued
equity overhang, total equity overhang and stockholder value transfer. Finally, the Compensation Committee considered the number of restricted stock units awarded to executive officers as a group, as compared to all restricted stock units awarded.
In so doing, the Compensation Committee noted that it anticipates that this ratio will continue to be weighted toward the executive officer group as we transition away from our historical practice of granting equity incentive compensation to all
employees. For example, new employees below the director level are now compensated under our profit sharing plan, rather through equity compensation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee has approved a pay-for-performance philosophy for the compensation of
our executive officers that is intended, in general, to provide base salary, bonus and total compensation within the 50<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> to 75<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> percentile of
comparable companies in our industry. However, we may award compensation above the 75<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> percentile when deemed appropriate to further promote and achieve the primary objectives of our compensation
programs. The comparable group of companies on which we rely to corroborate our determinations are those represented by the peer groups utilized in the Mercer Executive Compensation Review and those that participated in the industry survey reports
used by Mercer. Within the scope of this pay-for-performance philosophy, we have determined the various components of each executive&#146;s compensation package based on various factors, including: the executive&#146;s particular background,
training and relevant work experience; the executive&#146;s role and responsibilities and the compensation paid to similar persons in comparable companies represented in the compensation data that we utilized; the demand for individuals with the
executive&#146;s specific talents and expertise and our ability to attract and retain comparable talent; Company Financial MBOs and Individual MBOs; the other expectations of the executive for the position; and the comparison to other executives
within our Company having similar skills and experience levels and responsibilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Base Salary </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each year we evaluate base salaries as part of our management performance program, and establish each executive&#146;s base salary for the
ensuing year. In establishing base salaries, we assess the executive officer&#146;s performance in each of the areas in which MBOs were established, the financial performance of the Company in the areas of responsibility of the executive officer,
the overall financial performance of the Company, the experience of the executive, the executive&#146;s role and responsibilities and particular background, and other significant accomplishments and contributions of the executive officer. An
executive&#146;s base salary is also evaluated together with other components of the executive&#146;s compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of our
Elevate 2020 Plan and our goal of increasing our operating profitability, our executive officers recommended, which the Compensation Committee accepted, to not receive a cost-of-living adjustment or other increase to their base salaries for fiscal
year 2018. Accordingly, for fiscal year 2018, the base salary of our President and CEO and CFO and Treasurer are both below the 50th percentile of base salaries for our peer group as provided in the 2017 Mercer Executive Compensation Report. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:64.40pt; font-size:8pt; font-family:Times New Roman"><B>Name and Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal&nbsp;2018</B><br><B>Base&nbsp;Salary&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal&nbsp;2017</B><br><B>Base&nbsp;Salary&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%<BR>Increase</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark C. Capone<BR>President and Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">852,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">852,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alexander Ford<BR>President, Myriad Genetic Laboratories, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">499,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">499,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R. Bryan Riggsbee<BR>Chief Financial Officer and Treasurer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">432,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">432,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jerry S. Lanchbury, Ph.D.<BR>Chief Scientific Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">493,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">493,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard M. Marsh<BR>Executive Vice President, General Counsel and Secretary</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">493,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">493,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that maintaining all of our executive officers&#146; base salary at FY 2017 levels reflects the
commitment and contribution of the executive officers to our goal of increasing our operating profitability, while being set at a level that appropriately attracts and retains key talent necessary to support the continued growth of the Company. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Annual Cash Incentive Bonus </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The annual cash incentive bonus amount is determined as part of our management performance program. As a part of this review, we assess the
executive officer&#146;s performance in each of the areas in which MBOs were established, our financial performance in the areas of responsibility of the executive officer, our overall financial performance and other significant accomplishments and
contributions of the executive officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For fiscal year 2017, for purposes of determining the annual cash incentive bonuses paid to our
NEOs and executive officers, other than our President and CEO, the Compensation Committee used a formulaic approach, based on a target incentive bonus as a percentage of base salary determined in early fiscal year 2017, Company performance, and the
achievement of MBOs. The target incentive bonus as a percentage of base salary for each executive officer ranged from 45 to 60 percent, depending on the responsibilities and experience of the executive officer, and was based on the target incentive
bonus percentage from our peer group for each of the individual executive officers. The annual cash incentive bonus amount for each executive officer was then determined based on the following formula: annual base salary of the executive officer
times (a)&nbsp;the executive officer&#146;s applicable target incentive bonus percentage, and times (b)&nbsp;the executive officer&#146;s performance goals score (based on degree of accomplishment of Company Financial MBOs and Individual MBOs as
determined by the Compensation Committee). The annual cash bonus amount is capped, and, as a percentage, can never exceed 130 percent of the executive officer&#146;s applicable target incentive bonus percentage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For fiscal year 2017, our pre-established financial performance targets were based on our revenues and adjusted operating income. We achieved
$771 million in revenues and adjusted operating income of $97 million. Based on these financial results, compared to the pre-established targets, the Compensation Committee determined that the Company Financial MBOs applicable to each executive
officer had been achieved at the 87 percent level. Each executive officer was then scored on his or her Individual MBOs, as discussed below for our NEOs under &#147;<I>Named Executive Officer Performance for Fiscal 2017&#148;</I>. The composite MBO
performance scores for the executive officer group ranged from 80 to 95 percent. Because we only partially achieved the revenue and adjusted operating income performance goals we set, and based on the accomplishment of Individual MBOs for the
executive officer group, the annual cash incentive bonus for fiscal year 2017 for the executive officer group was reduced by 5 to 20 percent, respectively, from target levels for each of the executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For our President and CEO, the Compensation Committee approved pre-determined, objective, formula-based financial performance metrics, along
with the achievement of Individual MBOs which cannot increase but may only reduce his cash incentive bonus. The annual cash incentive bonus for our President and CEO was granted under our 2013 Executive Incentive Plan (the &#147;Section 162(m)
Incentive Plan&#148;), which is a plan that permits qualifying executive compensation to be deducted for federal income tax purposes under Section&nbsp;162(m). Based on the responsibilities and experience of our President and CEO, and based on the
target incentive bonus percentages from our peer group, the Compensation Committee set the target incentive bonus as a percentage of base salary at 100% for our President and CEO. Accordingly, our President and CEO&#146;s cash incentive bonus for
fiscal year 2017 was determined based on the following formula: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Base Salary &times; Target Incentive Bonus Percentage (100%)&nbsp;&times;
Total Performance Factor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Total Performance Factor was based on fiscal year 2017 Company revenues and adjusted operating income and is
calculated as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(the Revenue Performance Factor &times; 0.50) + (the Adjusted Operating Income Performance Factor &times; 0.50).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Revenue Performance Factor equals the quotient of fiscal year 2017 total revenues divided by the designated total revenue target for
fiscal year 2017. The Adjusted Operating Income Performance Factor equals the quotient of fiscal year 2017 adjusted operating income divided by the designated adjusted operating income target for fiscal year 2017. However, as set forth in the
Section&nbsp;162(m) Incentive Plan in no event may the Total Performance Factor exceed 130% and so there is a separate cap on the total amount that can be paid. The Compensation Committee has the discretion to reduce the amount payable based on the
accomplishment of the Individual MBOs or for any other reason in the discretion of the Compensation Committee but it may not increase the amount of the award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our financial results for fiscal year 2017, the Compensation Committee determined that Mr.&nbsp;Capone had achieved a Total
Performance Factor of 87%. Accordingly, the Compensation Committee awarded an annual cash incentive bonus for Mr.&nbsp;Capone for fiscal year 2017 in the amount of $741,240. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee determined the annual cash incentive bonuses for our NEOs for fiscal year 2017 as set forth in the chart below.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:64.40pt; font-size:8pt; font-family:Times New Roman"><B>Name and Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target&nbsp;Incentive<BR>Bonus&nbsp;(as&nbsp;a&nbsp;%&nbsp;of<BR>Fiscal&nbsp;2017&nbsp;Base<BR>Salary)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>MBO<BR>Performance<BR>Goals&nbsp;Score<BR>(as a %)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal&nbsp;2017<BR>Bonus</B><br><B>Payment<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark C. Capone<BR>President and Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">741,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alexander Ford<BR>President, Myriad Genetic Laboratories, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">245,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R. Bryan Riggsbee<BR>Chief Financial Officer and Treasurer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jerry S. Lanchbury, Ph.D.<BR>Chief Scientific Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard M. Marsh, Esq.<BR>EVP, General Counsel and Secretary</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that this cash incentive bonus compensation is appropriate based on the performance of the
executive officer group for fiscal year 2017. The Compensation Committee believed the financial performance targets set for our annual cash incentive bonuses for our NEOs to be challenging, without any guarantee that the performance targets could be
accomplished. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For fiscal year 2018, the Compensation Committee has decided to utilize a comparable formulaic approach for determining the
annual cash incentive bonus for executive officers as used for fiscal year 2017. The Compensation Committee established the following target incentive bonus percentages for our NEOs which will be used in determining annual cash incentive bonus
amounts for fiscal year 2018 performance. These are unchanged from the targets established for fiscal year 2017. Additionally, Mr.&nbsp;Capone&#146;s fiscal year 2018 annual cash incentive bonus was granted under our 2013 Executive Incentive Plan
based on the predetermined financial performance metrics set by our Compensation Committee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="21%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:59.65pt; font-size:8pt; font-family:Times New Roman"><B>Executive Officer</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target&nbsp;Incentive&nbsp;Bonus<BR>(% of base salary for<BR>Fiscal Year 2018)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark C. Capone<BR>President and Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alexander Ford<BR>President, Myriad Genetic Laboratories, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R. Bryan Riggsbee<BR>Chief Financial Officer and Treasurer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jerry S. Lanchbury<BR>Chief Scientific Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard M. Marsh, Esq.<BR>Executive Vice President, General Counsel and Secretary</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Long-Term Incentive Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To incentivize and reward long-term performance by our executives, we currently provide two forms of long-term incentive compensation: a
three-year cash incentive bonus and the award of restricted stock units. These cash and equity-based incentive awards help ensure that our executive officers have a stake in our long-term success by providing an incentive to improve the overall
growth and value of Myriad. We believe that this fosters an executive culture that aligns our officers&#146; interests with the long-term interests of our stockholders. The Compensation Committee determines the terms of all equity incentive awards
for our NEOs, including our President and CEO. Beginning in fiscal year 2015, we granted our employees, executive officers and Board restricted stock units rather than stock options in order to reduce the dilutive effect of our equity compensation
program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Three-Year Cash Incentive Bonus</U>. In December 2012, the Compensation Committee established
a long-term cash incentive bonus program for our executive officers based on predetermined, objective financial formula-based performance targets to be accomplished at the end of the third ensuing fiscal year. For any amount to be paid, the minimum
predetermined financial metric thresholds must be surpassed; otherwise, no bonus amount will be paid. As reflected in the following table, the financial metrics for these payouts are reviewed and determined when each three-year award is established.
The three-year incentive bonus award amount is based on a target bonus amount as a percentage of base salary of 20 percent for our President and CEO and 15 percent for our other executive officers. For all executive officers, the target bonus
percentage and bonus amount is capped. Based on the Company&#146;s financial performance, we have only made a payout under our long-term cash incentive bonus program for the three-year performance period ending with FY2015. For the other three-year
performance periods ending in FY2016 and FY2017, none of the target thresholds were achieved, so no payouts were made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table summarizes each of the three-year cash incentive awards established for our executive officers. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:24.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date of<BR>Award</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three-Year<BR>Performance<BR>Period</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Performance Criteria</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Payout Under Plan</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">December 2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">FY&nbsp;2013-2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Revenue&nbsp;(50%),&nbsp;EBITDA&nbsp;(25%)&nbsp;and&nbsp;EPS&nbsp;(25%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Payout&nbsp;at&nbsp;47.55% of Target Award</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">September 2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">FY 2014-2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Revenue (50%) and EBITDA (50%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">No Payout</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">September 2014</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">FY 2015-2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Revenue (50%) and Net Income (50%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">No Payout</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">September 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">FY 2016-2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Revenue (50%) and EBITDA (50%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">TBD</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">September 2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">FY <FONT STYLE="white-space:nowrap">2017-2019</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Revenue (50%), Adjusted Operating Margin (25%)<BR>and Diversification of Product Revenue (25%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">TBD</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">September 2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">FY&nbsp;2018-2020</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Revenue (50%), Adjusted Operating Margin (25%)<BR>and Diversification of Product Revenue (25%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">TBD</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the three-year cash incentive bonus adds an additional long-term incentive metric to motivate
our executives to achieve financial metrics and operational goals, which will benefit long-term shareholder value. In particular, the recent performance objectives tied to adjusted operating margin and diversification of our product revenues are
aligned with our announced strategic, long-term goals. The Compensation Committee believes the financial performance targets to be challenging, without any guarantee that the performance targets could be accomplished, in light of growing
operational, reimbursement and competitive factors which may adversely affect the Company&#146;s financial performance. Thus, the performance targets are set at a level that, if obtained, the Company would have accomplished continued strong
financial performance. The three-year cash incentive bonus awards made to our NEOs in fiscal year 2017, and the maximum amount payable under these awards, are reported in the table for 2017 Fiscal Year Grants of Plan Based Awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Initial Equity Awards</U>. Executives who join us, who are granted equity, are granted restricted stock unit awards. The amount of the
initial restricted stock unit award is determined based on the executive&#146;s position and analysis of the competitive practices of the companies similar in size as represented in the compensation data that we review with the goal of creating a
total compensation package for new executives that is competitive with other similar companies and that will enable us to attract high quality management personnel. One-fourth of each initial equity award will vest on an annual basis over four-plus
years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Annual Equity Incentive Awards</U>. In response to continued comments from our stockholders, we will continue to issue
long-term equity incentive compensation grants in restricted stock units with one-fourth of the units granted vesting on an annual basis over four-plus years. Additionally, for our NEOs, the restricted stock units awarded are subject to achievement
of a predetermined, formula-based, one-year revenue target that must be achieved in order for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the award to commence vesting. Thus, for our NEOs, the actual number of restricted stock units earned will be determined based on the percentage achievement of the predetermined revenue target
with no award being earned if a minimum revenue threshold is not achieved; thereafter, and only if the minimum threshold has been achieved, vesting of the award is based on the NEO&#146;s continued employment with us. In determining the amount of
equity compensation to be awarded, the Compensation Committee will consider various factors, including our financial and operating performance for the applicable period; the executive officer&#146;s contribution to our performance; the anticipated
contribution of the executive officer to our future performance; the accomplishments of the executive officer as measured by achievement of MBOs; a review of compensation for comparable positions in our peer group from our benchmarking studies; and
the total compensation of the executive officer and the anticipated retentive effect of the grant of additional equity compensation. We also take into consideration the total number of our outstanding shares of our common stock, the relative
dilution to stockholders, as well as our gross equity burn rate, issued equity overhang and total equity overhang. The size of the restricted stock unit award generally increases as the rank and responsibilities of the executive officer increases.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted stock unit awards are made once a year at our Compensation Committee meeting held in connection with the Board of Director
meetings generally in September. The Board customarily determines the dates of its meetings for the ensuing year at a meeting of the Board in the preceding year. Thus, the dates on which equity compensation is granted are set well in advance. The
Compensation Committee does not time the grant of equity compensation with respect to the release of material nonpublic information, whether or not that information may favorably or unfavorably impact the price of our common stock. Restricted stock
unit awards for the executive officers, including our President and CEO, are approved by the Compensation Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the 2017
Mercer Executive Compensation Review, which calculated market annual guidelines at the 50th and 75th percentile, the long-term incentive value of the annual restricted stock unit awards made on September&nbsp;14, 2016, based on fiscal year 2016
performance, to our executive officers, including our President and CEO, and CFO and Treasurer, was below the 50th percentile, with two executive officers between the 50th and 75<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> percentile. For
our NEOs, it was determined that, based on our revenues for fiscal year 2017, that the financial performance metric for fiscal year 2017 associated with the grant of these restricted stock units was met; hence, there was no reduction in the number
of restricted stock units originally awarded. The long-term incentive value of the annual restricted stock unit awards made to our NEOs in fiscal year 2017 is reported in the table for 2017 Fiscal Year Grants of Plan Based Awards and was determined
at their grant date fair value calculated in accordance with ASC Topic 718 based on achieving 100% of the award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We felt the RSU award
levels were appropriate based on the comparative long-term peer group compensation data from the 2017 Mercer Executive Compensation Review, given the Company&#146;s performance relative to its peers, the individual accomplishments of our NEOs during
fiscal year 2016, including our President and CEO, relative to their MBOs and to continue to place an increased weighting of compensation on long term equity compensation. We also believe these equity awards, now moving to the 50<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> percentile for our President and CEO and CFO and Treasurer, were appropriate based on the Company&#146;s financial performance. Thus, these equity awards appropriately reward our executives for
their consistent past performance, and incentivize our executives to work hard to continue to deliver similar performance and to remain employed at the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Compensation Objectives </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary
objectives of our Compensation Committee in establishing and maintaining our executive compensation programs are to: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Attract and retain the best possible executive talent; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Motivate our executive officers to enhance our growth and profitability; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Increase long-term stockholder value; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Reward the executive officers for their contribution to our growth, profitability and increased stockholder value through the recognition of individual leadership, initiatives, achievements and other contributions.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The specific directives of the Compensation Committee are to provide appropriate short and long-term compensation and
incentives, in the form of cash and equity, that motivate and reward the accomplishment of individual and corporate objectives and that align executive officer compensation with the creation of stockholder value. To achieve these objectives, the
Compensation Committee has adopted and implemented a compensation plan that bases our executive officers&#146; compensation on a variety of factors set forth in MBOs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Establishment and Use of Management Business Objectives </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee has implemented an annual management performance program for the purpose of establishing annual performance
objectives for our executive officers to align their performance with the overall goals and objectives for the Company. This process commences in the fourth quarter of each fiscal year as each executive officer meets with our President and CEO to
establish annual MBOs for the ensuing fiscal year. After review and discussion, the President and CEO finalizes the executive officer&#146;s MBOs for the ensuing fiscal year. Similarly, our President and CEO meets with the Compensation Committee at
the end of each fiscal year to establish his MBOs for the ensuing fiscal year which, after review and discussion, are finalized by the Compensation Committee. During the fiscal year, additional MBOs may be established and assigned to an executive
officer, including our President and CEO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the end of the ensuing fiscal year, each executive officer&#146;s performance for the fiscal
year is reviewed, including an assessment by management and the Compensation Committee of the achievement of each executive officer&#146;s respective MBOs. At this time, the President and CEO calculates and recommends to the Compensation Committee
an annual cash incentive bonus amount and salary adjustment for the executive officers, other than himself. The Compensation Committee, after further review and discussion with our President and CEO, then determines the annual cash incentive bonus
for the concluding fiscal year and base salary amount for the ensuing fiscal year for the executive officers, other than the President and CEO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of our President and CEO, the Compensation Committee makes its review and determinations for the President and CEO&#146;s salary
and annual cash incentive compensation without any recommendations from our President and CEO, who is not present in any portions of the meetings of the Compensation Committee where his compensation is calculated, discussed and approved. At the end
of the fiscal year, the Compensation Committee determines the annual salary amount of our President and CEO for the ensuing fiscal year. The annual cash incentive bonus for our President and CEO&#146;s is based on the accomplishment of his
performance metrics as previously determined by our Compensation Committee as measured against our final, audited financial statements for the fiscal year. In determining the annual cash incentive bonus amount, the Compensation Committee also
reviews and discusses the accomplishment of the President and CEO&#146;s MBOs for the fiscal year in determining whether any reductions of the annual incentive bonus amount is appropriate. The annual cash incentive bonus amount, salary adjustments,
and long-term incentive compensation for our President and CEO are reported to the independent members of the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
MBOs for each executive officer for each fiscal year consist of (i)&nbsp;pre-established financial performance targets for the Company, which for fiscal year 2017 were based on total revenues and adjusted operating income, and (ii)&nbsp;individual
objectives tailored to each executive. Each executive officer receives the same Company Financial MBOs as part of their respective MBOs. The Company Financial MBOs represents 50 percent of the total weighting of each executive officer&#146;s MBOs.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, for those designated, an executive officer&#146;s incentive compensation may be awarded and administered under our
2013 Executive Incentive Plan, whereby 100 percent of short-term incentive cash compensation (annual cash incentive bonus) and grants of restricted stock units are based on pre-established, objective financial performance targets and are subject to
a cap. It is intended that incentive compensation paid under the 2013 Executive Incentive Plan will be deductible for tax purposes under Section&nbsp;162(m) of the Internal Revenue Code; however, the Compensation Committee may award compensation
which does not qualify under Section&nbsp;162(m) in order to accomplish the compensation goals of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MBOs for our NEOs for
fiscal year 2017 were as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Mark C. Capone, President and CEO</B>&nbsp;&#151;&nbsp;manage the Company to achieve designated
financial targets for total revenues and adjusted operating income for fiscal year 2017; achieve designated financial targets for non-hereditary product revenues; achieve financial targets for increased revenue potential resulting from new
reimbursement coverage decisions; and achieve designated milestones to advance the Company&#146;s product pipeline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Alexander Ford,
President Myriad Genetic Laboratories, Inc.&nbsp;&#151;</B>&nbsp;manage the Company to achieve designated financial targets for total revenues and adjusted operating income for fiscal 2017; achieve designated financial targets for Myriad Genetic
Laboratories; achieve designated targets for managed care contract coverage for designated products; and achieve designated financial targets for new products in specified indications. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>R. Bryan Riggsbee, Chief Financial Officer and Treasurer</B>&nbsp;&#151;&nbsp;manage the
Company to achieve designated financial targets for total revenues and adjusted operating income for fiscal year 2017; achieve designated financial target for cost savings; achieve designated financial targets relating to the integration of our
acquisitions; evaluate and complete at least one strategic, revenue generating new business opportunity; and manage Enterprise Risk Management function. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Jerry S. Lanchbury, Ph.D., Chief Scientific Officer</B>&nbsp;&#151;&nbsp;manage the Company to achieve designated financial targets for
total revenues and adjusted operating income for fiscal year 2017; advance product pipeline through approval of companion diagnostic tests; contribute to designated product launch; complete discovery phase for at least one Stage 1 discovery project;
and expand companion diagnostic programs into additional indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Richard M. Marsh, Executive Vice President, General Counsel and
Secretary</B>&nbsp;&#151;&nbsp;manage the Company to achieve designated financial targets for total revenues and adjusted operating income for fiscal year 2017; continue to develop and implement Company&#146;s intellectual property strategy; oversee
compliance plans for affiliated group, including international activities; and participate in industry intellectual property initiatives. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Named
Executive Officer Performance for Fiscal 2017 </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">President and CEO: Based on our financial results for fiscal year 2017, the Compensation
Committee determined that Mr.&nbsp;Capone had achieved 87% of the financial performance targets set for him under the Company Financial MBOs for fiscal year 2017. The Compensation Committee also determined that Mr.&nbsp;Capone had accomplished his
Individual MBOs based on the revenues generated from non-hereditary cancer products, the additional reimbursement coverage for new products, regulatory approvals for our companion diagnostics and advancements in our product pipeline. Additionally,
the Compensation Committee noted, under Mr.&nbsp;Capone&#146;s supervision, the accomplishments of the Company as discussed above under the caption: &#147;<I>Fiscal Year 2017 Performance</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other Named Executive Officers. The Compensation Committee determined that the other NEOs had substantially accomplished the Company Financial
MBOs and their respective Individual MBOs based on the accomplishments of the Company as discussed above under the caption: &#147;<I>Fiscal Year 2017 Performance</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Role of Management in Our Compensation Program </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management, including our President and CEO, supports the Compensation Committee, attends portions of its meetings upon request, and
performs various administrative functions at its request. Our President and CEO provides input to the Compensation Committee on the effectiveness of our compensation program and makes specific recommendations as to the base salary amounts, annual
cash incentive bonus amounts, long-term cash incentive bonus awards and equity incentive awards for the executive officers, other than for himself. At the end of each fiscal year, our President and CEO evaluates the annual performance of each of our
executive officers, including an assessment of the accomplishment of each executive officer&#146;s MBOs, and submits his calculations and recommendations to the Compensation Committee which then determines an annual cash incentive bonus amount for
the concluding fiscal year, the base salary amount for the ensuing fiscal year and long term equity incentive compensation for each of the executive officers. Except for our President and CEO, no executive officer is present when the Compensation
Committee discusses and determines the salary and bonus amounts and equity compensation to be awarded to the executive officers. Our President and CEO is excused from all meetings, and is not present, where matters pertaining to his compensation are
determined and approved by the Compensation Committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Compensation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain broad-based benefits that are provided to all employees, including health and dental insurance, life and disability insurance, a 401(k) plan, and a
discretionary December holiday bonus. Additionally, we may provide other benefits to new executive officers such as a relocation package or other related compensation as determined on a case-by-case basis. We may also provide certain compensation
benefits in connection with the retirement of our executive officers based on their accomplishments and tenure of employment with us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Termination and Change-of-Control-Based Compensation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize that, as is the case with many publicly-held corporations, the possibility of a change in control of the Company exists and that
such possibility, and the uncertainty and questions which it may raise among key personnel, may result in the departure or distraction of key personnel to the detriment of us and our stockholders. Therefore, we have entered into a retention
agreement with each of our executive officers to reinforce and encourage the continued employment and dedication of our executive officers without distraction from the possibility of a change in control of the Company and related events and
circumstances. We believe that the terms of our retention agreement are consistent with those historically maintained by others in our industry and therefore are important for attracting and retaining key employees who are critical to our long-term
success. The potential benefits provided under the retention agreement are in addition to the current compensation arrangements we have with our executive officers. In September 2015 in response to shareholder concerns, we entered into amendment to
these retention agreement with our executive officers in order to eliminate the tax gross-up set forth therein that allowed for payments to be made by the Company to the executive officers to offset any excise taxes incurred by the executive officer
in the event that any change of control payments are subject to excise tax under Section&nbsp;4999 of the Internal Revenue Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the
payments each of our NEOs is entitled to receive upon a change-in-control see &#147;Executive Compensation&nbsp;&#151;&nbsp;Potential Payments Upon Termination or Change-in-Control&#148; later in this proxy statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Relationship of Elements of Compensation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As noted above, our compensation structure is primarily comprised of a base salary, an annual cash incentive bonus, long-term incentive
compensation in the form of a three-year cash incentive bonus award and equity incentive awards. In setting executive compensation, the Compensation Committee considers the aggregate compensation payable to an executive officer and the form of the
compensation. The Compensation Committee seeks to achieve an appropriate balance between immediate cash rewards and long-term financial incentives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We utilize long term equity incentive compensation in the form of restricted stock units as a substantial component of compensation (prior to
fiscal year 2015 we utilized stock options). The Compensation Committee views the award of restricted stock units as a primary long-term retention benefit by tying the earning of these awards to a vesting schedule that will be over a period greater
than four years for full vesting of restricted stock units. If an employee leaves the Company before the completion of the vesting period, then that employee will not be entitled to any benefit from the non-vested portion of the award. Additionally,
for our NEOs, the restricted stock unit award also has a performance metric that, if not met, would require the NEO to forfeit a portion up to the entire restricted stock unit award regardless of the additional requirement of vesting. We believe
that this vesting feature makes it more attractive to remain as our employee and this arrangement does not require substantial cash payments by the Company. Similarly, our three-year cash incentive bonus awards promote long-term performance by
establishing significant growth performance targets that must be met over a three-year period. This long-term cash incentive bonus also promotes retention of our executives as no payment is made under our three-year cash incentive bonus awards if
the executive officer is not employed on the last day of the three-year performance period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee reviews from time
to time the mix of the compensation elements for executive officers against comparable companies in our industry as represented in the compensation data we utilize. The size and mix of each element in a compensation package is based on the impact of
the position on the Company, market practice and overall corporate and individual performance relative to stated corporate goals. The level of incentive compensation typically increases in relation to an executive officer&#146;s responsibilities and
ability to meet individual and corporate goals. The Compensation Committee believes that making a significant portion of an executive officer&#146;s compensation contingent on corporate performance more closely aligns the executive officer&#146;s
interests with those of our stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conclusion </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our compensation policies are designed and are continually being developed to retain and motivate our executive officers and to ultimately
reward them for outstanding individual and corporate performance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the total compensation paid or accrued during the fiscal years indicated to (1)&nbsp;our President and Chief
Executive Officer, (2)&nbsp;our Chief Financial Officer, and (3)&nbsp;our three next most highly compensated executive officers who earned more than $100,000 during the fiscal year ended June&nbsp;30, 2017 and were serving as executive officers as
of June&nbsp;30, 2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:97.90pt; font-size:8pt; font-family:Times New Roman"><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal<BR>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards ($)<BR>(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Non-Equity<BR>Incentive Plan<BR>Compensation<BR>($) (2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($) (3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark C. Capone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">852,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,613,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">741,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,217,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and Chief</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Officer*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,361,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">727,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,900,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,193,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">390,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,194,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alexander Ford</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">499,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,314,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">245,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,069,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President, Myriad</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Genetic Laboratories, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R. Bryan Riggsbee (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">432,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,314,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,985,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,037,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,628,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">265,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,050,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,565,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jerry S. Lanchbury, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">493,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,095,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,814,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Scientific Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">479,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,986,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,693,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">470,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,477,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,165,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard M. Marsh, Esq.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">493,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,095,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,822,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive VP, General</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Counsel&nbsp;&amp; Secretary</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">479,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,925,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">218,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,634,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">470,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,401,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,090,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Mark C. Capone commenced service as our President and CEO on July&nbsp;1, 2016. For fiscal years 2015, Mr.&nbsp;Capone served as the President of Myriad Genetic Laboratories, Inc. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Except as described in note 4 below, amounts shown reflect the aggregate grant date fair value of restricted stock unit awards granted in each year presented calculated in accordance with FASB ASC Topic 718. Amounts
reflect the maximum potential value of each award assuming the highest level of performance associated with the award and is based on the closing price of our common stock on the NASDAQ Global Market on the date of grant of the award. For fiscal
year 2017, based on our achievement of the applicable performance criteria established on the grant date for these restricted stock unit awards, the number of shares underlying these restricted stock units were not reduced. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">For Mr.&nbsp;Capone, for fiscal years 2016 and 2017, the amounts reported in this column reflect the actual cash awards paid under our 2013 Executive Incentive Plan to Mr.&nbsp;Capone pursuant to his annual cash
incentive bonus award, calculated based on measurement against plan metrics and performance results for fiscal years 2016 and 2017. For all other NEOs, for fiscal years 2016 and 2017, the amounts reported in this column reflect the actual annual
cash incentive awards paid. For fiscal year 2015, the amounts reported in this column reflect (i)&nbsp;the actual annual cash incentive bonus awards paid to our NEOs, and (ii)&nbsp;the actual cash awards paid under our long-term, three-year cash
incentive bonus plan which concluded in fiscal year 2015 to Mr.&nbsp;Capone ($57,060), Dr.&nbsp;Lanchbury ($33,523) and Mr.&nbsp;Marsh ($33,523). No payment was made under our long-term, three-year cash incentive bonus plan which concluded in fiscal
years 2016 and 2017 as our performance goals were not achieved. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">All amounts shown for fiscal year 2017 consist of $ 48.24&nbsp;per month of premiums paid by us with respect to term life insurance for the benefit of each NEO for their respective periods served and the balance of the
amount shown for matching contributions made under our 401(k) plan on behalf of each NEO. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">On October&nbsp;16, 2014, R. Bryan Riggsbee commenced service as our CFO. Mr.&nbsp;Riggsbee&#146;s fiscal year 2015 annual salary and annual bonus were prorated for the year based on his hire date. The Bonus amount
includes a $10,000 signing bonus awarded to Mr.&nbsp;Riggsbee upon his hire. Mr.&nbsp;Riggsbee&#146;s fiscal 2015 Stock Award represents the initial award of 30,000 restricted stock units made to him upon hiring, which vest one-fourth per year, and
is based on the closing price of our common stock on the NASDAQ Global Market of $35.03 on October&nbsp;17, 2014, the date of grant of the RSUs. The amounts reported in the All Other Compensation column for Mr.&nbsp;Riggsbee for fiscal year 2015
includes $114,179 paid to Mr.&nbsp;Riggsbee for relocation expenses. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2017 Fiscal Year Grants of Plan-Based Awards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables show information regarding grants of non-equity and equity awards that we made during the fiscal year ended June&nbsp;30,
2017 to each of the executive officers named in the Summary Compensation Table. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated Future Payouts Under<BR><FONT STYLE="white-space:nowrap">Non-Equity&nbsp;Incentive&nbsp;Plan&nbsp;Awards&nbsp;($)&nbsp;(1)</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated Future<BR>Payouts Under Equity<BR>Incentive Plan<BR>Awards (#)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date<BR>Fair Value<BR>of Stock<BR>and Option<BR>Awards<BR>($)(3)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Threshold</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Threshold</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark C. Capone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9/14/2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,613,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">FY19&nbsp;3-YR&nbsp;Award</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alexander Ford</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9/14/2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,314,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">FY19 3-YR Award</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R. Bryan Riggsbee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9/14/2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,314,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">FY19 3-YR Award</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jerry S. Lanchbury</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9/14/2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,095,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">FY19 3-YR Award</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard M. Marsh</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9/14/2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,095,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">FY19 3-YR Award</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The amounts represent the threshold, target, and maximum amounts awarded to our NEOs under our Three-Year Cash Incentive Bonus Plan for fiscal years 2017-2019. The metrics against which performance is to be measured are
discussed in the Compensation Discussion and Analysis under the heading &#147;Fiscal Year 2017 Named Executive Officer Compensation- Long Term Incentive Awards- Three Year Cash Incentive Bonus Plan.&#148; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The amounts represent the threshold and target (which is the maximum) number of our shares that may be awarded with respect to the restricted stock unit awards made to our NEOs on September&nbsp;14, 2016. Based on our
achievement of the revenue performance criteria established on the grant date for these awards, the number of shares underlying these restricted stock units were not reduced. These shares vest one-fourth per year beginning September&nbsp;30, 2017.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">The amounts represent the grant date fair value calculated in accordance with FASB ASC Topic 718 and is based on the closing price of our common stock on the NASDAQ Global Market on September&nbsp;14, 2016 of $21.90.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative Disclosure to Summary Compensation Table and 2017 Fiscal Year Grants of Plan-Based Awards Table
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into standard form employment agreements with no defined term with each of our NEOs. Pursuant to these agreements,
either party may terminate employment without cause at any time upon 15 days written notice to the other party or immediately with cause upon written notice to the other party. Each employment agreement also provides that the employee will not
disclose confidential information of ours during and after employment and will not compete with us during the term of employment. Since the dates of these agreements entered into with our NEOs, the compensation paid to each NEO has been increased
and equity awards have been granted, the most recent of which are as discussed below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Previously, we have entered into an Executive
Retention Agreement with each of our NEOs under which they are entitled to certain benefits upon a change-in-control, as discussed below under &#147;Executive Compensation&nbsp;&#151;&nbsp;Potential Payments Upon Termination or
Change-in-Control.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Capone was appointed to the position of President and CEO of the Company beginning July&nbsp;1, 2015.
He had previously entered into the Company&#146;s standard form of employment agreement when he was initially hired by the Company in October 2002 as the Vice President of Sales for MGL. Thereafter, in September 2005, he was appointed to the
position of Senior Vice President of Sales for MGL. In February 2006, he was appointed to the position of Chief Operating Officer for MGL, and then in March 2010 he was appointed President of MGL. As determined by our Compensation Committee, he
received an annual salary of $852,000 for the fiscal year ended June&nbsp;30, 2017. Mr.&nbsp;Capone will be paid an annual base salary of $852,000 as our President and CEO for the fiscal year ending June&nbsp;30, 2018. His annual cash incentive
bonus for fiscal 2017 was $741,240 as approved by our Compensation Committee based on the level of achievement of pre-established performance goals. Additionally, in September 2016, the Compensation Committee approved a three-year cash incentive
award under our 2013 Executive Incentive Plan pursuant to which Mr.&nbsp;Capone will be entitled to receive up to $255,600 as of the end of fiscal 2019 if we achieve the performance goals discussed above in the Compensation Discussion and Analysis
under the heading &#147;Fiscal Year 2017 Named Executive Officer Compensation&nbsp;&#151; Long-Term Incentive Awards&nbsp;&#151;&nbsp;Three-Year Cash Incentive Bonus.&#148; On September&nbsp;14, 2016, Mr.&nbsp;Capone was granted a restricted stock
unit award of 165,000 shares of the Company, subject to time-based and performance-based vesting requirements. Based on the level of accomplishment of the performance-based metric for fiscal 2017, the restricted stock unit award was not reduced. On
September&nbsp;13, 2017, he was granted a restricted stock unit award of 165,000 shares of the Company, subject to time-based and performance-based vesting requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Ford was appointed President of Myriad Genetic Laboratories, Inc. beginning July&nbsp;1, 2015. He had previously entered into the
Company&#146;s standard form of employment agreement when he was initialed hired by the Company in June 2010 as the Vice President of Sales for MGL. Thereafter, in July 2011, he was appointed to the position of GM Preventative Care, and thereafter
as MGL&#146;s Chief Commercial Officer in January 2013. As determined by our Compensation Committee, Mr.&nbsp;Ford received an annual salary of $499,200 for the fiscal year ended June&nbsp;30, 2017, and will be paid an annual base salary of $499,200
for the fiscal year ending June&nbsp;30, 2018. His annual cash incentive bonus for fiscal 2017 was $245,606 as determined by our Compensation Committee. Additionally, in September 2016, the Compensation Committee approved a three-year cash incentive
award under our 2013 Executive Incentive Plan pursuant to which Mr.&nbsp;Ford will be entitled to receive up to $112,320 as of the end of fiscal 2019 if we achieve the performance goals discussed above in the Compensation Discussion and Analysis
under the heading &#147;Fiscal Year 2017 Named Executive Officer Compensation&nbsp;&#151;&nbsp;Long-Term Incentive Awards&nbsp;&#151;&nbsp;Three-Year Cash Incentive Bonus.&#148; On September&nbsp;14, 2016, he was granted a restricted stock unit
award of 60,000 shares of the Company, subject to time-based and performance-based vesting requirements. Based on the level of accomplishment of the performance-based metric for fiscal 2017, the restricted stock unit award was not reduced. On
September&nbsp;13, 2017, Mr.&nbsp;Ford was granted a restricted stock unit award of 60,000 shares of the Company, subject to time-based and performance-based vesting requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Riggsbee was appointed to the position of Chief Financial Officer and Treasurer in October, 2014, and entered into the Company&#146;s
standard form of employment agreement at that time. As determined by our Compensation Committee, he received an annual salary of $432,000 for the fiscal year ended June&nbsp;30, 2017. Mr.&nbsp;Riggsbee will be paid an annual base salary of $432,000
for the fiscal year ending June&nbsp;30, 2018. His annual cash incentive bonus for fiscal 2017 was $230,688 as determined by our Compensation Committee. Additionally, in September 2016, the Compensation Committee approved a three-year cash incentive
award under our 2013 Executive Incentive Plan pursuant to which Mr.&nbsp;Riggsbee will be entitled to receive up to $97,200 as of the end of fiscal 2019 if we achieve the performance goals discussed above in the Compensation Discussion and Analysis
under the heading &#147;Fiscal Year 2017 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Named Executive Officer Compensation&nbsp;&#151;&nbsp;Long-Term Incentive Awards&nbsp;&#151;&nbsp;Three-Year Cash Incentive Bonus.&#148; On September&nbsp;14, 2016, he was granted a restricted
stock unit award of 60,000 shares of the Company, subject to time-based and performance-based vesting requirements. Based on the level of accomplishment of the performance-based metric for fiscal 2017, the restricted stock unit award was not
reduced. On September&nbsp;13, 2017, Mr.&nbsp;Riggsbee was granted a restricted stock unit award of 60,000 shares of the Company, subject to time-based and performance-based vesting requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Lanchbury was appointed to the position of Senior Vice President, Research in November 2002 and entered into the Company&#146;s
standard form of employment agreement at that time. In September 2005, he was promoted to Executive Vice President, Research. In February 2010, Dr.&nbsp;Lanchbury was appointed Chief Scientific Officer. As determined by our Compensation Committee,
he received an annual salary of $493,782 for the fiscal year ended June&nbsp;30, 2017. Dr.&nbsp;Lanchbury will be paid an annual base salary of $493,782 for the fiscal year ending June&nbsp;30, 2018<I>.</I> His annual cash incentive bonus for fiscal
2017 was $214,795 as determined by our Compensation Committee. Additionally, in September 2016, the Compensation Committee approved a three-year cash incentive award under our 2013 Executive Incentive Plan pursuant to which Dr.&nbsp;Lanchbury will
be entitled to receive up to $111,111 as of the end of fiscal 2019 if we achieve the performance goals discussed above in the Compensation Discussion and Analysis under the heading &#147;Fiscal Year 2017 Named Executive Officer
Compensation&nbsp;&#151;&nbsp;Long-Term Incentive Awards&nbsp;&#151;&nbsp;Three-Year Cash Incentive Bonus.&#148; On September&nbsp;14, 2016, he was granted a restricted stock unit award of 50,000 shares of the Company, subject to time-based and
performance-based vesting requirements. Based on the level of accomplishment of the performance-based metric for fiscal 2017, the restricted stock unit award was not reduced. On September&nbsp;13, 2017, Dr.&nbsp;Lanchbury was granted a restricted
stock unit award of 50,000 shares of the Company, subject to time-based and performance-based vesting requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Marsh was
appointed to the position of Vice President, General Counsel and Secretary in November 2002 and entered into the Company&#146;s standard form of employment agreement at that time. In September 2005, he was promoted to Executive Vice President,
General Counsel and Secretary. As determined by our Compensation Committee, Mr.&nbsp;Marsh received an annual salary of $493,782 for the fiscal year ended June&nbsp;30, 2017, and will be paid an annual base salary of $493,782 for the fiscal year
ending June&nbsp;30, 2018. His annual cash incentive bonus for fiscal 2017 was $222,202 as determined by our Compensation Committee. Additionally, in September 2016, the Compensation Committee approved a three-year cash incentive award under our
2013 Executive Incentive Plan pursuant to which Mr.&nbsp;Marsh will be entitled to receive up to $111,111 as of the end of fiscal 2019 if we achieve the performance goals discussed above in the Compensation Discussion and Analysis under the heading
&#147;Fiscal Year 2017 Named Executive Officer Compensation&nbsp;&#151;&nbsp;Long-Term Incentive Awards&nbsp;&#151;&nbsp;Three-Year Cash Incentive Bonus.&#148; On September&nbsp;14, 2016, he was granted a restricted stock unit award of 50,000 shares
of the Company, subject to time-based and performance-based vesting requirements. Based on the level of accomplishment of the performance-based metric for fiscal 2017, the restricted stock unit award was not reduced. On September&nbsp;13, 2017,
Mr.&nbsp;Marsh was granted a restricted stock unit award of 50,000 shares of the Company, subject to time-based and performance-based vesting requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All annual restricted stock unit awards granted to our NEOs are subject to a predetermined, formula-based financial performance metric that
must be met in order for these awards to vest annually over a four-plus year period. In addition to the annual cash incentive bonus paid to each of our NEOs, all employees, including the named executive officers, received a holiday bonus of $307 in
fiscal year 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2017, the Compensation Committee approved a three-year cash incentive award under our 2013 Executive
Incentive Plan pursuant to which our executive officers and other key management members may be entitled to receive compensation at the end of fiscal year 2020 if certain predetermined performance goals are achieved. Following are the amounts that
may be earned for our NEOs for the awards under our three-year cash incentive awards: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated Future Payouts Under<BR><FONT STYLE="white-space:nowrap">Non-Equity&nbsp;Incentive&nbsp;Plan&nbsp;Awards&nbsp;($)</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Award<BR>Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Threshold</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark C. Capone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">FY18-20</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alexander Ford</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">FY18-20</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R. Bryan Riggsbee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">FY18-20</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jerry S. Lanchbury, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">FY18-20</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard M. Marsh, Esq.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">FY18-20</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at 2017 Fiscal Year End </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the grants of stock options and restricted stock units outstanding on the last day of the fiscal year ended
June&nbsp;30, 2017, to each of our NEOs. We have not granted any stock options that are subject to performance conditions. The annual restricted stock units granted to our NEOs are subject to time and performance conditions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards&nbsp;(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date of<BR>Grant</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>Exercisable<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>Unexercisable<BR>(#)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B><br><B>or Units<BR>of&nbsp;Stock&nbsp;that<BR>Have not<BR>Vested<BR>(#)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market&nbsp;Value<BR>of Shares</B><br><B>or Units</B><br><B>of&nbsp;Stock&nbsp;that<BR>Have not<BR>Vested</B><br><B>($)(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity&nbsp;Incentive<BR>Plan Awards:<BR>Number of<BR>Unearned&nbsp;Shares,<BR>Units</B><br><B>or Other Rights<BR>that Have not<BR>Vested</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity&nbsp;Incentive<BR>Plan Awards:<BR>Market&nbsp;or&nbsp;Payout<BR>Value&nbsp;of&nbsp;Unearned<BR>Shares, Units</B><br><B>or Other Rights<BR>that Have
not<BR>Vested</B><br><B>($)(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Mark&nbsp;C. Capone</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/10/2008</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/10/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/18/2009</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/18/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/15/2009</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/15/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">03/03/2010</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/3/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/15/2010</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/15/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/23/2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/23/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/13/2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/13/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">03/07/2012</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/7/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/12/2012</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/12/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/17/2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">247,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/17/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/17/2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,284,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/15/2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,525,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/14/2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,263,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Alexander Ford</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">06/22/2010</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/22/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/13/2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/13/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">03/07/2012</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/7/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/12/2012</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/12/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/17/2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/17/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/17/2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/15/2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">319,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/14/2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,550,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">R. Bryan Riggsbee</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/17/2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">387,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/15/2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">924,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/14/2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,550,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Jerry&nbsp;S.&nbsp;Lanchbury,&nbsp;Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/18/2009</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/18/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/15/2009</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/15/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">03/03/2010</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/3/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/23/2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/23/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/13/2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/13/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">03/07/2012</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/7/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/12/2012</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/12/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/17/2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/17/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/17/2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">759,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/15/2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">901,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/14/2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,292,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Richard M . Marsh, Esq.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/18/2009</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/18/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/15/2009</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/15/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">03/03/2010</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/3/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/15/2010</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/15/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/23/2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/23/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/13/2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/13/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">03/07/2012</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/7/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/12/2012</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/12/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/17/2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/17/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/17/2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">735,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/15/2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">873,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/14/2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,292,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Stock Option Vesting Schedules: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Options granted on and between September&nbsp;14, 2005 through and including September&nbsp;15, 2010 were granted pursuant to our 2003 Employee, Director and Consultant Stock Option Plan, as amended (the &#147;2003
Plan&#148;) and vest 25 percent of the shares per year on each anniversary of the date of grant. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Options granted beginning on and after February&nbsp;23, 2011 were granted pursuant to our 2010 Plan and vest 25 percent of the shares per year on each anniversary date of the grant. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Restricted stock units vest <SUP STYLE="vertical-align:top">&nbsp;1</SUP>&#8260;<SUB STYLE="vertical-align:bottom">4</SUB> per year from the last day of the month in which the restricted stock units were granted.
Restricted stock units awarded to Mr.&nbsp;Riggsbee in connection with his commencement of employment vest <SUP STYLE="vertical-align:top">&nbsp;1</SUP>&#8260;<SUB STYLE="vertical-align:bottom">4</SUB> per year from the date of grant. The vesting of
unvested options and restricted stock unit awards held by our NEOs will accelerate upon a change of control of Myriad in accordance with the Executive Retention Agreements described below under &#147;Potential Payments Upon Termination or
Change-in-Control.&#148; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">The market value of stock awards is determined by multiplying the number of shares by $25.84, the closing price of our common stock on the NASDAQ Global Market on June&nbsp;30, 2017, the last day of our fiscal year.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">On September&nbsp;13, 2017, based on the degree of accomplishment of the revenue performance criteria for our fiscal year 2017, the number of shares actually earned was at 100% of the award. The restricted stock units
will vest <SUP STYLE="vertical-align:top">&nbsp;1</SUP>&#8260;<SUB STYLE="vertical-align:bottom">4</SUB> per year beginning on September&nbsp;30, 2017. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2017 Fiscal-Year Option Exercises and Stock Vested </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows information regarding exercises of options to purchase our common stock and vesting of restricted stock unit awards
by our NEOs during the fiscal year ended June&nbsp;30, 2017. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Restricted Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>Acquired on<BR>Exercise (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value&nbsp;Realized&nbsp;on<BR>Exercise&nbsp;($)&nbsp;(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>Acquired on<BR>Vesting (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value&nbsp;Realized<BR>on Vesting<BR>($)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark C. Capone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">924,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alexander Ford</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R. Bryan Riggsbee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">390,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jerry S. Lanchbury, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">546,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard M. Marsh, Esq.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">529,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Amounts shown in this column do not necessarily represent the actual value realized from the sale of the shares acquired upon exercise of the options because the shares may not be sold on exercise but continue to be
held by the executive officer exercising the option. The amounts shown represent the difference between the option exercise price and the market price on the date of exercise, which is the amount that would have been realized if the shares had been
sold immediately upon exercise. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Amounts shown in this column represent the market value of stock awards upon vesting as determined by multiplying the number of shares by $20.92, the closing price of our common stock on the NASDAQ Global Market on
September&nbsp;17, 2016, for shares which vested on that date, and by $20.58, the closing price of our common stock on the NASDAQ Global Market on September&nbsp;30, 2016, for shares which vested on that date. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pension Benefits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have any
qualified or non-qualified defined pension benefit plans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nonqualified Deferred Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have any nonqualified defined contribution plans or other deferred compensation plans. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Potential Payments Upon Termination or Change-in-Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;17, 2005 (and thereafter for subsequently appointed executive officers), we entered into Executive Retention Agreements, or
the Retention Agreements, with our executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Retention Agreements, if the employment of an executive
officer is terminated without &#147;Cause&#148; or if the executive officer separates from Myriad for &#147;Good Reason&#148; within 24 months of a &#147;Change in Control&#148; (each is defined in the agreement and set forth below), the executive
officer will receive: (i)&nbsp;all salary earned through the date of termination, as well as a prorated bonus and any compensation previously deferred; (ii)&nbsp;an amount equal to three times the executive&#146;s highest annual base salary and
three times the executive&#146;s highest annual bonus at Myriad during the three-year period prior to the Change in Control; (iii)&nbsp;continued benefits for 36 months after the date of termination; and (iv)&nbsp;outplacement services in an
aggregate amount of up to $25,000. If the employment of an executive officer is terminated by the executive officer for no reason, during the 90-day period beginning on the first anniversary of the &#147;Change in Control Date&#148; (as defined in
the agreement and set forth below), then the termination shall be deemed to be termination for Good Reason for all purposes of the Retention Agreement except that the payment of an amount equal to three times the executive&#146;s highest annual base
salary and bonus shall be reduced by one-half. In addition, upon the occurrence of a Change in Control, all of the executive&#146;s unvested equity incentive compensation shall become fully vested, whether or not the executive is terminated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;12, 2007, the Retention Agreements were amended to provide that all payments
under the agreement are to be made in a lump sum, in cash, six months following the date of termination of employment, unless an earlier payment, in whole or in part, following the date of termination of employment is permitted under
Section&nbsp;409A of the Internal Revenue Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;29, 2015, the Retention Agreements were amended to delete the tax
gross-up provision that previously allowed for a payment to be made by the Company to an executive officer in connection with a change in control of the Company to offset any excise taxes or penalties incurred by the executive officer under
Section&nbsp;4999 of the Internal Revenue Code in connection with a &#147;parachute payment&#148; within the meaning of Section&nbsp;280G of the Internal Revenue Code. No such payment is now permitted under the Retention Agreements and any excise
taxes due shall be borne solely by the executive officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the terms of the Retention Agreement are either satisfied or expire on a
date that is 24 months after a Change in Control, the Retention Agreement will renew annually for one-year terms unless we provide notice of non-renewal at least 90 days prior to the end of each term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As defined in the Retention Agreements: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;<I>Cause</I>&#148; means (a)&nbsp;the Executive&#146;s willful and continued failure to substantially perform his or her reasonable assigned duties (other than any such failure resulting from incapacity due to
physical or mental illness or any failure after the Executive gives notice of termination for Good Reason) that is not cured within 30&nbsp;days after a written demand for substantial performance is received by the Executive from the board of
directors, which specifically identifies the manner in which the board believes the Executive has not substantially performed the Executive&#146;s duties; or (b)&nbsp;the Executive&#146;s willful engagement in illegal conduct or gross misconduct
that is materially and demonstrably injurious to the Company. No act or failure to act by the Executive shall be considered &#147;willful&#148; unless it is done, or omitted, in bad faith and without reasonable belief that the Executive&#146;s
action or omission was in the best interests of the Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;<I>Good Reason</I>&#148; means the occurrence, without the Executive&#146;s written consent, of any of the following events or circumstances: (a)&nbsp;The assignment to the Executive of duties inconsistent in any
material respect with the Executive&#146;s position (including status, offices, titles and reporting requirements), authority or responsibilities in effect immediately prior to the earliest to occur of (i)&nbsp;the Change in Control Date;
(ii)&nbsp;the date of the execution by the Company of the initial written agreement or instrument providing for the Change in Control; or (iii)&nbsp;the date of the adoption by the board of directors of a resolution providing for the Change in
Control (with the earliest of such dates referred to herein as the &#147;Measurement Date&#148;), or any other action or omission by the Company that results in a material diminution in the Executive&#146;s position, authority or responsibilities.
(b)&nbsp;A reduction in the Executive&#146;s annual base salary that was in effect on the Measurement Date. (c)&nbsp;The failure by the Company to (i)&nbsp;continue in effect any material compensation, pension, retirement or benefit plan or program
(including without limitation any 401(k), life insurance, medical, health and accident or disability plan and any vacation program or policy) (a &#147;Benefit Plan&#148;) in which the Executive participates or that is applicable to the Executive
immediately prior to the Measurement Date, unless an equitable arrangement (embodied in an ongoing substitute or alternative plan) has been made with respect to such plan or program; (ii)&nbsp;continue the Executive&#146;s participation therein (or
in a substitute or alternative plan) on a basis not materially less favorable, both in terms of the amount of benefits provided and the level of the Executive&#146;s participation relative to other participants, than the basis that existed
immediately prior to the Measurement Date; or (iii)&nbsp;award cash bonuses to the Executive in amounts and in a manner substantially consistent with past practice. (d)&nbsp;A change by the Company in the location at which the Executive performs his
or her principal duties for the Company to a new location that is both (i)&nbsp;outside a radius of 50 miles from the Executive&#146;s principal residence immediately prior to the Measurement Date and (ii)&nbsp;more than 50 miles from the location
at which the Executive performed his or her principal duties for the Company immediately prior to the Measurement Date; or (iii)&nbsp;a requirement by the Company that the Executive travel on Company business to a substantially greater extent than
required immediately prior to the Measurement Date. (e)&nbsp;The failure by the Company to obtain the agreement from any successor to the Company to assume and agree to perform the Retention Agreement.; Or (f)&nbsp;any failure of the Company to pay
or provide to the Executive any portion of the Executive&#146;s compensation or benefits due under any Benefit Plan within seven days of the date such compensation or benefits are due, any material breach by the Company of the Retention Agreement,
or any employment agreement with the Executive. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;<I>Change in Control</I>&#148; means an event or occurrence set forth in any one or more of the following events (including an event or occurrence that constitutes a Change in Control under one of such subsections
but is specifically exempted from another subsection): (a)&nbsp;The acquisition by an individual, entity or group [within the meaning of Section&nbsp;13(d) or 14(d) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;)]
(a &#147;Person&#148;) of beneficial ownership of any capital stock of the Company if, after such acquisition, that Person beneficially owns (within the meaning of Rule&nbsp;13d-3 promulgated under the Exchange Act) 20 percent or more of either
(i)&nbsp;the then-outstanding shares of common stock of the Company (the &#147;Outstanding Company Common Stock&#148;) or (ii)&nbsp;the combined voting power of the then-outstanding securities of the Company entitled to vote generally in the
election of directors (the &#147;Outstanding Company Voting Securities&#148;); <I>provided</I>, however, that for purposes of this subsection (a), the following acquisitions shall not constitute a Change in Control: (i)&nbsp;any acquisition directly
from the Company (excluding an acquisition pursuant to the exercise, conversion or exchange of any security exercisable for, convertible into or exchangeable for common stock or voting securities of the Company, unless the Person exercising,
converting or exchanging such security acquired such security directly from the Company or an underwriter or agent of the Company); (ii)&nbsp;any acquisition by the Company; or (iii)&nbsp;any acquisition by any employee benefit plan (or related
trust) sponsored or maintained by the Company or any corporation controlled by the Company. Or (b)&nbsp;such time as the Continuing Directors (as defined below) do not constitute a majority of the board (or, if applicable, the board of directors of
a successor corporation to the Company), where the term &#147;Continuing Director&#148; means at any date a member of the board (i)&nbsp;who was a member of the board on the date of the execution of the Retention Agreement or (ii)&nbsp;who was
nominated or elected subsequent to such date by at least a majority of the directors who were Continuing Directors at the time of such nomination or election or whose election to the board was recommended or endorsed by at least a majority of the
directors who were Continuing Directors at the time of such nomination or election; <I>provided</I>, <I>however</I>, that excluded from this clause&nbsp;(ii) is any individual whose initial assumption of office occurred as a result of an actual or
threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents, by or on behalf of a person other than the board. (c)&nbsp;The consummation of a merger,
consolidation, reorganization, recapitalization or share exchange involving the Company or a sale or other disposition of all or substantially all of the assets of the Company in one or a series of transactions (a &#147;Business Combination&#148;),
unless, immediately following such Business Combination, the following condition is satisfied: all or substantially all of the individuals and entities who were the beneficial owners of the Outstanding Company Common Stock and Outstanding Company
Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50 percent of the then-outstanding shares of common stock and the combined voting power of the then-outstanding securities entitled
to vote generally in the election of directors, respectively, of the resulting or acquiring corporation in such Business Combination (which shall include, without limitation, a corporation that, as a result of the transaction, owns the Company or
substantially all of the Company&#146;s assets either directly or through one or more subsidiaries) in substantially the same proportions as their ownership, immediately prior to the Business Combination, of the Outstanding Company Common Stock and
Outstanding Company Voting Securities, respectively, or (d)&nbsp;approval by the stockholders of the Company of a complete liquidation or dissolution of the Company. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;<I>Change in Control Date</I>&#148; means the first date during the Term (as defined in the Retention Agreement) on which a Change in Control occurs. Anything in the Retention Agreement to the contrary
notwithstanding, if (a)&nbsp;a Change in Control occurs, (b)&nbsp;the Executive&#146;s employment with the Company is terminated prior to the date on which the Change in Control occurs, and (c)&nbsp;it is reasonably demonstrated by the Executive
that such termination of employment (i)&nbsp;was at the request of a third party who has taken steps reasonably calculated to effect a Change in Control or (ii)&nbsp;otherwise arose in connection with or in anticipation of a Change in Control, then
for all purposes of the Retention Agreement the &#147;Change in Control Date&#148; shall mean the date immediately prior to the date of the termination of employment. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the Retention Agreements is qualified in its entirety by the full text of the agreements, which has been filed as an
exhibit to our Annual Report on Form 10-K, as amended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the terms of the award agreements for options and restricted stock units
granted to our NEOs, all of the NEO&#146;s stock options and restricted stock units shall become fully vested upon the occurrence of a Change in Control, as defined in the Retention Agreements, whether or not the executive is terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the potential payments to each of our NEOs upon either a change in control or termination following a change in
control, assuming the occurrence of the different triggers of the Retention Agreement, as of the close of business on June&nbsp;30, 2017, the last business day of our most recent fiscal year<B>. </B> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Executive&nbsp;Benefits and&nbsp;Payments&nbsp;Upon
Termination</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change in<BR>Control ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change&nbsp;in&nbsp;Control<BR>and Involuntary<BR>Termination&nbsp;Without<BR>Cause or for Good<BR>Reason ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change in<BR>Control and<BR>Voluntary<BR>Termination&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark&nbsp;C.&nbsp;Capone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Base salary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,556,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,278,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bonus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,223,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,111,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock option and RSU acceleration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,230,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,230,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,230,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cobra benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outplacement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,230,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,100,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,710,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alexander Ford</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Base salary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,497,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">748,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bonus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">736,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">368,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock&nbsp;option&nbsp;and&nbsp;RSU acceleration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,074,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,074,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,074,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cobra benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outplacement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,074,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,399,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,282,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R.&nbsp;Bryan&nbsp;Riggsbee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Base salary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,296,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">648,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bonus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">692,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock option and RSU acceleration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,907,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,907,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,907,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cobra benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outplacement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,907,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,985,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,991,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jerry&nbsp;S.&nbsp;Lanchbury,&nbsp;Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Base salary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,481,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">740,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bonus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">644,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">322,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock option and RSU acceleration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,047,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,047,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,047,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cobra benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outplacement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,047,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,263,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,200,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard M. Marsh, Esq.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Base salary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,481,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">740,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bonus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">666,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock option and RSU acceleration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,990,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,990,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,990,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cobra benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outplacement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;Total</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,990,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,229,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,155,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a description of the assumptions that were used in creating the above table. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Vesting Acceleration Calculation &#151; The value of the vesting acceleration was calculated by multiplying the
number of unvested in-the-money stock options as of June&nbsp;30, 2017 by the spread </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
between the closing price of our common stock on the NASDAQ Global Market on June&nbsp;30, 2017, which was $25.84 per share, and the exercise price of such unvested option. Additionally, the
total includes the number of unvested restricted stock units multiplied by the closing price of our common stock on the NASDAQ Global Market on June&nbsp;30, 2017 which was $25.84. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table shows the total compensation paid or accrued during the fiscal year ended June&nbsp;30, 2017 to each of our nonemployee directors who served during fiscal year 2017. Directors who are employed by Myriad are not compensated for their service on
our board of directors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned&nbsp;or<BR>Paid&nbsp;in&nbsp;Cash&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Restricted&nbsp;Stock<BR>Unit&nbsp;Awards&nbsp;($)&nbsp;(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lawrence C. Best</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Heiner Dreismann, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Walter Gilbert, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">320,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John T. Henderson, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">432,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dennis H. Langer, M.D., J.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">340,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S. Louise Phanstiel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">347,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Amounts shown reflect the aggregate grant date fair value of 15,024 restricted stock units awarded to each nonemployee director who served during fiscal year 2017 calculated in accordance with FASB ASC Topic 718 and is
determined by multiplying the number of shares by $16.64, the closing price of our common stock on the NASDAQ Global Market on December&nbsp;1, 2016, the date of the grant. RSUs awarded to our nonemployee directors vest in full upon one year from
date of grant. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows outstanding and vested options and unvested RSUs for each nonemployee director as
of June&nbsp;30, 2017. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vested<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unvested<BR>RSUs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lawrence C. Best</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Heiner Dreismann, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Walter Gilbert, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John T. Henderson, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dennis H. Langer, M.D., J.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S. Louise Phanstiel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the grant date fair value for restricted stock unit awards granted to each
nonemployee director in our fiscal year ended June&nbsp;30, 2017. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Granted&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant&nbsp;Date<BR>Fair&nbsp;Value&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lawrence C. Best</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/1/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Heiner Dreismann, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/1/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Walter Gilbert, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/1/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John T. Henderson, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/1/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dennis H. Langer, M.D., J.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/1/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S. Louise Phanstiel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/1/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Director Compensation Policy </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our nonemployee directors are compensated on a role-based model and are paid cash fees based on the annual retainers (25 percent paid following
each quarter of service). The following is a description of the standard compensation arrangements under which our nonemployee directors are compensated for their service as directors, including as members of the various board committees: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:62.60pt; font-size:10pt; font-family:Times New Roman">Annual retainer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">All members</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$60,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chairman of the Board</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$100,000 additional</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chair of the Audit Committee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$28,000 additional</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chairman of the Compensation Committee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$20,000 additional</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chairman of the Nominating and Governance Committee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$15,000 additional</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Members of the Audit Committee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$13,500 additional</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Members of the Compensation Committee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$10,000 additional</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Members of the Nominating and Governance Committee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$7,500 additional</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Members of the Strategic Committee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$5,000 additional</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Attendance </I></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Board Meetings: In addition to the annual retainer amounts, we pay each nonemployee director a per-meeting cash fee of $2,000 for attendance at board meetings in excess of five in-person meetings and four telephonic
meetings per fiscal year. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Committee Meetings other than Strategic Committee: We also pay each nonemployee director a per-meeting cash fee of $2,000 for attendance at committee meetings in excess of four meetings (per each committee), whether in
person or telephonic, per fiscal year. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Strategic Committee: No per meeting fee will be paid for meetings of the Strategic Committee. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All directors are also reimbursed for their out-of-pocket expenses incurred in attending meetings. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Option, Restricted and Unrestricted Stock Grants and Other Stock-Based Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our 2010 Plan, our nonemployee directors may be awarded stock options, restricted and unrestricted stock grants and/or other stock-based
awards. Beginning in fiscal year 2017, as recommended and determined by our Compensation Committee, and approved by our Board of Directors, on each date of our annual meeting of stockholders, the Company shall grant to each nonemployee director,
other than new nonemployee directors appointed within six months of the annual meeting, a restricted stock unit award equal to $250,000 divided by the closing price of the Company&#146;s common stock on the applicable date of our annual meeting of
stockholders. In addition, depending on the proximity to our annual meeting of stockholders, it is our policy to grant a restricted stock unit award for shares of our common stock to each new nonemployee director upon initial appointment to the
Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options and restricted stock units granted to our nonemployee directors vest in full upon completion of one year of service on the
Board. Options granted to our nonemployee directors are exercisable after the termination of the director&#146;s service on the Board to the extent exercisable on the date of such termination for the remainder of the life of the option. All options
or restricted stock units granted to our nonemployee directors will become fully exercisable upon a change of control of Myriad or upon their death as provided for under the forms of award agreement for directors under our 2010 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning in fiscal year 2018, if our 2017 Plan is approved by our shareholders, our nonemployee directors will only receive restricted stock
unit awards as provided for under our 2017 Plan in the manner described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Compensation Policies and Practices </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the fiscal year ended June&nbsp;30, 2017, the Compensation Committee conducted a risk assessment of our compensation policies and
practices for our employees and concluded that our policies and practices do not create risks that are reasonably likely to have a material adverse effect on the Company. For this purpose, we considered the compensation structure of the Company for
its employees including executive officers, which is based on an annual salary, annual bonus (for bonus-eligible employees), three-year cash incentive bonuses for executive officers, sales commissions and bonuses (for sales staff and managers), and
equity incentive compensation in the form of stock option or restricted stock unit grants. We do not believe we offer any short-term incentives that might result in high-risk actions or conduct by our employees. For example, incentive compensation
for executive officers in the form of an annual cash bonus or long-term three-year cash incentive bonus is based on a predetermined formula and management objectives approved by the Compensation Committee and is subject to a cap. There is no unique
operational division or group of employees who are specially compensated, or who, as a group, are responsible for a material portion of our revenues or profits. We do not believe that the awarding of long-term incentive compensation under our
three-year cash incentive bonus or equity incentive compensation in the form of stock options or restricted stock units creates any undue compensation risks to the Company. Additionally, we believe that we have appropriate internal controls that
support the accurate and timely recognition of Company revenues. Accordingly, we believe that we have a balanced pay and performance program that does not promote undue or excessive risk taking. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tax Deductibility of Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;162(m) of the Internal Revenue Code limits the deduction a public company is permitted for compensation paid to the chief
executive officer and to the three most highly compensated executive officers other than the chief financial officer. Generally, amounts paid in excess of $1,000,000 to a covered executive cannot be deducted, unless the compensation is paid pursuant
to a plan that is performance related, nondiscretionary and has been approved by stockholders. In fiscal 2013, we adopted our 2013 Executive Incentive Plan under which incentive compensation paid to designated executive officers may be deductible
for purposes of Section&nbsp;162(m) of the Internal Revenue Code of 1986, as amended. On September&nbsp;14, 2017, our Board of Directors made certain amendments to our 2013 Executive Incentive Plan. We are now proposing that our 2013 Executive
Incentive Plan, as amended, be re-approved by our shareholders at our 2017 Annual Meeting of Stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In its deliberations, the
Compensation Committee considers ways to maximize the deductibility of executive compensation, but nonetheless retains the discretion to compensate executive officers at levels the Compensation Committee considers commensurate with their
responsibilities and achievements in which the compensation may not be deductible under Section&nbsp;162(m). We have not adopted a policy that all executive compensation be fully deductible. In order to retain flexibility to incentivize and reward
our executives, we may award compensation that is not deductible for purposes of Section&nbsp;162(m). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Equity Compensation Plan
Information </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides certain aggregate information with respect to all of the Company&#146;s equity compensation
plans in effect as of June&nbsp;30, 2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:46.85pt; font-size:8pt; font-family:Times New Roman"><B>Plan category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(a)</B><br><B>Number of<BR>securities<BR>to be issued<BR>upon<BR>exercise of<BR>outstanding<BR>options,<BR>warrants<BR>and rights</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(b)</B><br><B>Weighted-</B><br><B>average<BR>exercise</B><br><B>price of</B><br><B>outstanding</B><br><B>options,</B><br><B>warrants<BR>and rights</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(c)</B><br><B>Number&nbsp;of&nbsp;securities</B><br><B>remaining&nbsp;available&nbsp;for</B><br><B>future issuance under</B><br><B>equity
compensation</B><br><B>plans (excluding</B><br><B>securities reflected in</B><br><B>column(a))</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by security holders (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,954,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,628,472</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by security holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,954,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,628,472</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">These plans consist of our 2003 Employee, Director and Consultant Stock Option Plan, as amended (the &#147;2003 Plan&#148;), our 2010 Employee, Director and Consultant Equity Plan, as amended (the &#147;2010
Plan&#148;), and our Employee Stock Purchase Plan, as amended. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Column (c)&nbsp;includes 853,718 shares available for future issuance under our Employee Stock Purchase Plan and 2,774,754 shares available for future issuance under the 2010 Plan as of June&nbsp;30, 2017. No shares are
available for issuance under the 2003 Plan. On September&nbsp;13, 2017 we awarded 1,033,575 restricted stock units to our employees and executive officers under the 2010 Plan. Because we reduce the shares available for grant by two shares for each
restricted stock unit awarded, we further reduced the number of shares available for future issuance under our 2010 Plan by 2,067,150. Accordingly, the balance of shares available for future issuance under our 2010 Plan, as of October&nbsp;4, 2017,
was 1,029,066 shares. If our 2017 Employee, Director and Consultant Equity Plan is approved by our shareholders at our 2017 Annual Meeting of the Shareholders, then no future shares will be available under the 2010 Plan. </TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPENSATION COMMITTEE REPORT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Compensation Committee of our Board of Directors has reviewed and discussed the Compensation Discussion and Analysis required by Item&nbsp;402(b) of Regulation S-K, which appears elsewhere in this proxy statement, with our management. Based on this
review and discussion, the Compensation Committee has recommended to the Board that the Compensation Discussion and Analysis be included in this proxy statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:44%; text-indent:4%; font-size:10pt; font-family:Times New Roman">MEMBERS OF THE COMPENSATION COMMITTEE: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:44%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Heiner Dreismann, Ph.D., Chair </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:44%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Walter Gilbert, Ph.D. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:44%; text-indent:4%; font-size:10pt; font-family:Times New Roman">John T. Henderson, M.D. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AUDIT COMMITTEE REPORT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee of the Board of Directors, which consists entirely of directors who meet the independence and experience requirements of
the NASDAQ Stock Market LLC, has furnished the following report: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee assists the Board in overseeing and monitoring the
integrity of our financial reporting process, compliance with legal and regulatory requirements and the quality of internal and external audit processes. This committee&#146;s role and responsibilities are set forth in the Audit Committee Charter
adopted by the Board, which is available in the Investors &#151; Understanding Myriad/Corporate Governance section of our website at <I>www.myriad.com</I>. This committee reviews and reassesses the Audit Committee Charter annually and recommends any
changes to the Board for approval. The Audit Committee is responsible for overseeing our overall financial reporting process and for the appointment, compensation, retention, and oversight of the work of our independent registered public accounting
firm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In fulfilling its responsibilities for the financial statements for the fiscal year ended June&nbsp;30, 2017, the Audit Committee
took the following actions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Reviewed and discussed the audited financial statements for the fiscal year ended June&nbsp;30, 2017 with management and Ernst&nbsp;&amp; Young LLP, our independent registered public accounting firm; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Discussed with Ernst&nbsp;&amp; Young LLP the matters required to be discussed in accordance with Statement on Auditing Standards No.&nbsp;16, <I>Communications with Audit Committees</I>; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Received written disclosures and letters from Ernst&nbsp;&amp; Young LLP regarding its independence as required by PCAOB Ethics and Independence Rule 3526, <I>Communication with Audit Committees Concerning Independence,
</I>and has discussed with the independent auditors, the independent auditors&#146; independence; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Audit Committee also considered the status of pending litigation, taxation matters and other areas of oversight relating to the financial reporting and audit process that the committee determined appropriate.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the Audit Committee&#146;s review of the audited financial statements and discussions with management and
Ernst&nbsp;&amp; Young LLP, the Audit Committee recommended to the Board that the audited financial statements be included in our Annual Report on Form 10-K for the fiscal year ended June&nbsp;30, 2017 for filing with the SEC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:44%; text-indent:4%; font-size:10pt; font-family:Times New Roman">MEMBERS OF THE AUDIT COMMITTEE </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:44%; text-indent:4%; font-size:10pt; font-family:Times New Roman">S. Louise Phanstiel, Chair </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:44%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lawrence C. Best </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:44%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dennis H. Langer, M.D., J.D. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our records reflect that all reports that were required to be filed pursuant to Section&nbsp;16(a) of the Securities Exchange Act of 1934, as
amended, were filed on a timely basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An Annual Statement of Beneficial Ownership on Form 5 is not required to be filed if there are no
previously unreported transactions or holdings to report. Nevertheless, we are required to disclose the names of directors, officers and 10 percent stockholders who did not file a Form 5 unless we have obtained a written statement that no filing is
required or if we otherwise know that no Form 5 is required. We received either a written statement from our directors, officers and 10 percent stockholders or know from other means that no Forms 5 filings were required. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were not a party to any transactions with related persons since July&nbsp;1, 2017 that would be required to be disclosed pursuant to
Item&nbsp;404(a) of Regulation S-K. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Policy on Approval of Related Person Transactions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a Policy on Related Person Transactions (the &#147;Policy&#148;) under which the Audit Committee reviews, approves or ratifies
all related person transactions. Under our Policy, a related person transaction is one in which Myriad is a participant, and the amount involved exceeds $120,000, and in which any of the following persons have or will have a direct or indirect
material interest: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Executive officers of the Company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Members of the Board; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Beneficial holders of 5 percent or more of Myriad&#146;s securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Immediate family members, as defined by Item&nbsp;404 of Regulation S-K under the Securities Act, of any of the foregoing persons; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Any firm, corporation or other entity in which any of the foregoing persons is employed or is a partner or principal. is in a similar position or in which the person has a 5 percent or greater beneficial ownership
interest; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Any other persons whom the Board determines may be considered to be related persons as defined by Item&nbsp;404 of Regulation S-K under the Securities Act. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Policy, the Audit Committee will approve only those related person transactions that are determined to be in, or not inconsistent
with, the best interests of Myriad and its stockholders, taking into account all available facts and circumstances as the Audit Committee, determines in good faith to be necessary. These facts and circumstances will typically include, but not be
limited to, the benefits of the transaction to Myriad; the impact on a director&#146;s independence in the event the related person is a director, an immediate family member of a director or an entity in which a director is a partner, stockholder or
executive officer; the availability of other sources for comparable products or services; the terms of the transaction; and the terms of comparable transactions that would be available to unrelated third parties or to employees generally. No member
of the Audit Committee shall participate in any review, consideration or approval of any related person transaction with respect to which the member or any of his or her immediate family members is the related person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In reviewing and approving these transactions, the Audit Committee will obtain, or will direct management to obtain on its behalf, all
information that the Audit Committee believes to be relevant and important to a review of the transaction prior to its approval. Following receipt of the necessary information, a discussion of the relevant factors will be held if it is deemed to be
necessary by the Audit Committee prior to approval. If a discussion is not deemed to be necessary, approval may be given by written consent of the Audit Committee. This approval authority may also be delegated to the Chairperson of the Audit
Committee in some circumstances. It is contemplated that no related person transaction will be entered into prior to the completion of these procedures; however, where permitted, a related person transaction may be ratified upon completion of these
procedures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee may adopt any further policies and procedures relating to the approval of
related person transactions that it deems necessary or advisable from time to time. A copy of our Policy on Related Person Transactions is publicly available in the Investor Information &#151; Understanding Myriad/Corporate Governance section of our
website at <I>www.myriad.com</I>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROPOSAL 1: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELECTION OF DIRECTORS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Board of Directors currently consists of seven members, classified as follows: John T. Henderson, M.D. and S. Louise Phanstiel constitute a class with a term ending at the 2018 Annual Meeting (the &#147;Class I Directors&#148;); Mark C. Capone and
Heiner Dreismann, Ph.D. constitute a class with a term ending at the 2019 Annual Meeting (the &#147;Class II Directors&#148;); and Walter Gilbert, Ph.D., Dennis H. Langer, M.D., J.D. and Lawrence C. Best constitute a class with a term ending at the
2017 Annual Meeting (the &#147;Class III Directors&#148;). At each Annual Meeting, directors are elected for a term of three years to succeed those directors whose terms are expiring. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;14, 2017, the Board of Directors accepted the recommendation of the Nominating and Governance Committee and voted to
nominate Walter Gilbert, Ph.D., Dennis H. Langer, M.D., J.D. and Lawrence C. Best for election at the Annual Meeting for a term of three years to serve until the 2020 Annual Meeting, and until their successors have been elected and qualified, or
until their earlier death, resignation, retirement or removal. Unless the authority to vote for any of these nominees is withheld, the shares represented by a valid proxy will be voted FOR the election of Walter Gilbert, Ph.D., Dennis H. Langer,
M.D., J.D. and Lawrence C. Best as directors. In the event that any nominee should become unable or unwilling to serve, the shares represented by a valid proxy will be voted for the election of another person who the Board of Directors recommends,
unless the Board chooses to reduce the number of directors serving on the Board. We have no reason to believe that any nominee will be unable or unwilling to serve as a director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An affirmative vote of the plurality of the shares voted affirmatively or negatively at the Annual Meeting is required to elect each nominee
as a director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a policy on plurality votes for the election of directors. Under this policy, in non-contested elections,
if a director receives a greater number of WITHHOLD votes than FOR votes, the Board will decide, through a process managed by the Nominating and Governance Committee and excluding the nominee in question, whether it should request that the director
submit his or her resignation, maintain the director but address what the Nominating and Governance Committee believes is the underlying cause of the WITHHOLD votes, or resolve not to re-nominate the director in the future for election. A copy of
this policy is publicly available in the Investor Information &#151; Understanding Myriad/Corporate Governance section of our website at <I>www.myriad.com</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE BOARD OF DIRECTORS RECOMMENDS THE ELECTION OF WALTER GILBERT, PH.D., DENNIS H. LANGER, M.D., J.D. AND LAWRENCE C. BEST AS DIRECTORS,
AND PROXIES SOLICITED BY THE BOARD WILL BE VOTED IN FAVOR THEREOF UNLESS A STOCKHOLDER HAS INDICATED OTHERWISE ON THE PROXY. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROPOSAL 2: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPROVAL OF OUR 2017 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;14, 2017, our
Board of Directors unanimously approved, subject to your approval at the Annual Meeting, the adoption of the 2017 Employee, Director and Consultant Equity Incentive Plan (the &#147;2017 Plan&#148;). The 2017 Plan will allow for the issuance of up to
1,400,000 shares of our common stock pursuant to awards granted under the 2017 Plan and will allow for the issuance of up to a maximum of 9,851,092 shares of common stock that are represented by (i)&nbsp;2,187,611 options outstanding under our 2003
Employee, Director and Consultant Stock Option Plan (the &#147;2003 Plan&#148;) and (ii)&nbsp;7,663,481 options and restricted stock units (&#147;RSUs&#148;) outstanding under our 2010 Employee, Director and Consultant Equity Incentive Plan (the
&#147;2010 Plan&#148;), that expire or are cancelled without delivery of shares of common stock on or after the date of stockholder approval of the 2017 Plan. Upon approval of the 2017 Plan, the remaining shares available for grant under our 2010
Plan will be cancelled and not available for award; accordingly, no additional shares will be awarded under our 2010 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2017 Plan
is being submitted to you for approval at the Annual Meeting as required by the listing rules of The NASDAQ Stock Market LLC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board,
the Compensation Committee and management believe that the effective use of stock-based, long-term incentive compensation is vital to our ability to achieve strong performance in the future. The 2017 Plan maintains and enhances the key policies and
practices adopted by our management and Board of Directors to align employee and stockholder interests. In addition, our future success depends, in large part, upon our ability to maintain a competitive position in attracting, retaining and
motivating key personnel. We believe the authorization of 1,400,000 shares for issuance under our 2017 Plan is essential to permit our management to continue to provide long-term, equity-based incentives to present and future key employees,
consultants and directors.&nbsp;Additionally, in continued response to recommendations from our stockholders, we intend to issue only restricted stock and restricted stock unit awards to reduce the dilutive effect on stockholders from our equity
incentive compensation program.&nbsp;Accordingly, our Board of Directors believes approval of the 2017 Plan is in our best interests and those of its stockholders and recommends a vote &#147;FOR&#148; the approval of the 2017 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2017 Plan includes the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Types of Awards</I>&nbsp;&#151; any stock right awarded under the 2017 Plan must be in the form of a restricted stock unit or a restricted stock grant; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>No Liberal Share Recycling</I>&nbsp;&#151; shares that are withheld to satisfy any tax withholding obligation related to any award will not again become available for issuance under the 2017 Plan; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Cap on the number of shares to be issued per year</I>&nbsp;&#151; no participant may receive awards for more than 500,000 shares of common stock in any fiscal year and non-employee directors may not receive awards
that exceed $500,000 in aggregate grant date fair value in any calendar year (other than pursuant to an election to receive equity in lieu of cash for all or a portion of fees received for service on the Board of Directors or any committee thereof);
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Minimum Vesting Period</I> &#151; all stock rights awarded must have a minimum vesting period of at least one year (we have historically provided for a four year vesting period for our equity incentive awards, and
intend to continue that practice); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Limited Acceleration of Vesting</I> &#151; the vesting of any stock right awarded under the 2017 Plan cannot be accelerated from the original grant vesting schedule except in connection with death, disability or a
change in control; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>No Dividends </I>&#151; we may not pay dividends or dividend equivalents before the vesting of the underlying award; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Clawback Policy&nbsp;</I><B>&#151;</B> awards will be subject to recoupment in accordance with the Company&#146;s clawback policy then in effect.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A complete copy of the 2017 Plan is attached as Appendix B.&nbsp;The following summary
description of the 2017 Plan is qualified in its entirety by reference to Appendix B. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Equity Plan Information for Stock Options Previously
Issued </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;4, 2017, there were 7,480,444 stock options outstanding with a weighted average exercise price of $24.75 and
a weighted average remaining life of 3.58 years. All options granted vest 25 percent per year on the anniversary of the grant date. The following table provides additional information regarding vested stock options outstanding as of that date: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vested&nbsp;Options<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;Average<BR>Exercise Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;Average<BR>Remaining&nbsp;Years&nbsp;of<BR>Contractual Life</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Substantially in-the-money options outstanding in excess of four years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,320,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other options outstanding in excess of four years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All options outstanding less than four years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total vested options outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,480,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Essentially all of the company&#146;s outstanding options are in the money based upon the closing stock price of $36.37 on
October&nbsp;4, 2017. Additional information regarding these options is a follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:38.85pt; font-size:8pt; font-family:Times New Roman"><B>Grant Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Remaining<BR>Contractual&nbsp;Life<BR>(years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vested<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">02/28/08</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">05/28/08</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">06/17/08</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">08/05/08</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">09/10/08</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11/13/08</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">02/18/09</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">04/07/09</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">04/21/09</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">06/10/09</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">09/15/09</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">521,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">09/16/09</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11/04/09</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11/05/09</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">03/03/2010</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">389,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">06/22/2010</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">08/03/2010</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">09/14/2010</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">09/15/2010</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">271,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12/03/2010</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">01/04/2011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">01/15/2011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">02/23/2011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">433,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">03/22/2011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">04/01/2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">05/25/2011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">05/28/2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">06/04/2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">09/13/2011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">910,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">09/17/2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,736,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12/02/2011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">03/07/2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">09/12/2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,457,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10/08/2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12/05/2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total substantially in-the-money- options outstanding in excess of four years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,320,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material Features of the 2017 Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Eligibility. </B>The 2017 Plan allows us, under the direction of our Compensation Committee, to make grants of restricted stock units and
restricted stock awards, to employees, consultants and directors who, in the opinion of the Compensation Committee, are in a position to make a significant contribution to our long-term success. The purpose of these awards is to attract and retain
key individuals, further align employee and stockholder interests and to closely link compensation with Company performance. The 2017 Plan provides an essential component of the total compensation package, reflecting the importance that we place on
aligning the interests of key individuals with those of our stockholders. All employees, members of the Board of Directors and consultants of the Company and its affiliates are eligible to participate in the 2017 Plan. As of October&nbsp;4, 2017 we
had approximately 2,155 individuals eligible to participate.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Limitations on Grants. </B>If this Proposal 2 is approved by our
stockholders, the 2017 Plan will provide for the issuance of up to 1,400,000 shares (as approved by shareholders in this proposal). Additionally, up to 2,187,611 additional shares may be issued under the 2017 Plan if options outstanding under our
2003 Plan are cancelled or expire in the future without the issuance of shares of common stock, and up to 7,663,481 additional shares may be issued under the 2017 Plan if options and RSUs outstanding under our 2010 Plan are cancelled or expire in
the future without the issuance of shares of common stock. No additional shares may be issued under our 2003 Plan or 2010 Plan (upon approval of the 2017 Plan). Under the 2017 Plan, each share of common stock issued as a restricted stock unit,
counts against the number of total shares available for issuance under the 2017 Plan as one share. In addition, shares of common stock reserved for awards under the 2017 Plan that lapse or are canceled will be added back to the share reserve
available for future awards on a one-to-one basis. However, shares of common stock tendered in payment for an award or shares of common stock withheld for taxes will not be available again for grant. The 2017 Plan provides that no participant may
receive awards for more than 500,000 shares of common stock in any fiscal year. Additionally, for non-employee directors, the 2017 Plan provides that the aggregate grant date fair value of any stock rights granted in any calendar year cannot exceed
$500,000 other than pursuant to an election to receive equity in lieu of cash for all or a portion of fees received for service on the Board of Directors or any committee thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Restricted Stock Units and Restricted Stock.</B> Restricted stock is common stock, and a restricted stock unit is a right to receive common
stock, that is subject to restrictions, including a prohibition against transfer and a substantial risk of forfeiture, until the end of a &#147;restricted period&#148; during which the grantee must satisfy certain vesting conditions. If the grantee
does not satisfy the vesting conditions by the end of the restricted period, the restricted stock is forfeited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the restricted
period, the holder of restricted stock has the rights and privileges of a regular stockholder, except that the restrictions set forth in the applicable award agreement apply. For example, the holder of restricted stock may vote; but he or she may
not sell the shares until the restrictions are lifted. During the restricted period, the holder of a restricted stock unit does not have the rights and privileges of a regular stockholder until all restrictions set forth in the applicable award
agreement have lapsed and the RSU is converted into common stock. With respect to any dividends which the Company may pay, no dividend payment will be made with respect to any restricted stock or restricted stock unit until the end of the applicable
restricted period when the underlying vesting conditions have been met. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Plan Administration</B>. In accordance with the terms of the 2017 Plan, our Board of Directors
has authorized our Compensation Committee to administer the 2017 Plan. The Compensation Committee may delegate part of its authority and powers under the 2017 Plan to one or more of our directors and/or officers, but only the Compensation Committee
can make awards to participants who are directors or executive officers of the Company. In accordance with the provisions of the 2017 Plan, our Compensation Committee determines the terms of awards, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Which employees, directors and consultants will be granted awards; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The number of shares subject to each award; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The vesting provisions of each award with a minimum one year vesting; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The termination or cancellation provisions applicable to awards; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All other terms and conditions upon which each award may be granted in accordance with the 2017 Plan. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All equity grants must have a minimum of a one year vesting period. Historically, our equity grants have been granted under a four-year
vesting schedule. The 2017 Plan specifically prohibits the acceleration of vesting except in the case of death, disability or a change in control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Stock Dividends and Stock Splits</B>. If our common stock is subdivided or combined into a greater or smaller number of shares or if we
issue any shares of common stock as a stock dividend, the number of shares of our common stock deliverable upon issuance of an award will be appropriately increased or decreased proportionately, and adjustments will be made, including in the
purchase price per share, if any, to reflect the subdivision, combination or stock dividend. <B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Corporate Transactions</B>. Upon
a merger or other reorganization event, our Board of Directors or an authorized committee, may, in its sole discretion, take any one or more of the following actions pursuant to the 2017 Plan, as to some or all outstanding awards: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Provide that all outstanding awards will be assumed or substituted by the successor corporation, become realizable or deliverable, or restrictions applicable to an award will lapse, in whole or in part, prior to or upon
the merger or reorganization event; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">With respect to stock grants and in lieu of any of the foregoing policy, the Board of Directors or an authorized committee may provide that, upon consummation of the transaction, each outstanding stock grant will be
terminated in exchange for payment of an amount equal to the consideration payable upon consummation of such transaction to a holder of the number of shares of common stock comprising such award (to the extent the stock grant is no longer subject to
any forfeiture or repurchase rights then in effect or, at the discretion of the Board of Directors or an authorized committee, all forfeiture and repurchase rights being waived upon such transaction). </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Amendments and Termination</B>. The 2017 Plan may be amended by our stockholders. It may also be amended by our Compensation Committee,
provided that any amendment approved by the Board that is of a scope that requires stockholder approval as required by the rules of The NASDAQ Stock Market LLC, or for any other reason is subject to obtaining such stockholder approval. However, no
such action may adversely affect any rights under an outstanding award without the holder&#146;s consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Duration of 2010 Stock
Plan</B>. The 2017 Plan will expire on September&nbsp;14, 2027. Upon approval by the stockholders of the 2017 Plan, no additional shares will be awarded under the 2010 Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New Plan Benefits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than grants to
our nonemployee directors as described above under &#147;Executive Compensation, Director Compensation, Restricted and Unrestricted Stock Grants,&#148; the amounts of future awards under the 2017 Plan are not determinable and will be granted at the
sole discretion of the Board of Directors or authorized committee, and we cannot determine at this time either the persons who will receive awards under the 2017 Plan although we anticipate that most of our grants will be in the form of RSUs and we
will use most of the 1,400,000 shares authorized to make grants in fiscal year 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Federal Income Tax Considerations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The material Federal income tax consequences of the issuance and vesting of restricted stock and restricted stock units under the 2017 Plan,
based on the current provisions of the Code and regulations, are as follows. Changes to these laws could alter the tax consequences described below. This summary assumes that all awards granted under the 2017 Plan are exempt from or comply with, the
rules under Section&nbsp;409A of the Code related to nonqualified deferred compensation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Stock Grants:</B> </P></TD>
<TD>With respect to stock grants involving the issuance of shares that are restricted as to transferability and subject to a substantial risk of forfeiture, the grantee must generally recognize ordinary income equal to the fair market value of the
shares received at the first time the shares become transferable or are not subject to a substantial risk of forfeiture, whichever occurs earlier. A grantee may elect to be taxed at the time of receipt of shares rather than upon lapse of
restrictions on transferability or substantial risk of forfeiture, but if the grantee subsequently forfeits the shares, the grantee would not be entitled to any tax deduction, including as a capital loss, for the value of the shares on which he or
she previously paid tax. The grantee must file such election with the Internal Revenue Service within 30 days of the receipt of the shares. We generally will be entitled to a deduction in an amount equal to the ordinary income recognized by the
grantee. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Stock Units:</B> </P></TD>
<TD>The grantee recognizes no income until the issuance of unrestricted shares. At that time, the grantee must generally recognize ordinary income equal to the fair market value of the shares received. We generally will be entitled to a deduction in
an amount equal to the ordinary income recognized by the grantee. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The affirmative vote of a majority of the shares voted
affirmatively or negatively for the proposal at the Annual Meeting is required to approve the adoption of the 2017 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE BOARD OF
DIRECTORS RECOMMENDS APPROVAL OF THE 2017 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN. PROXIES SOLICITED BY THE BOARD WILL BE VOTED IN FAVOR OF THE APPROVAL OF THE 2017 PLAN UNLESS A STOCKHOLDER HAS INDICATED OTHERWISE ON THE PROXY.
</B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROPOSAL 3: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RE-APPROVAL OF THE 2013 EXECUTIVE INCENTIVE PLAN, AS AMENDED </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;12, 2012 the Compensation Committee of our Board of Directors adopted the 2013 Executive Incentive Plan (the &#147;Incentive
Plan&#148;), which was approved by our stockholders on December&nbsp;15, 2012 at our 2012 Annual Meeting. On September&nbsp;14, 2017, our Board of Directors authorized certain amendments to the Incentive Plan, and recommended the Incentive Plan, as
amended, for approval by the stockholders at our 2017 Annual Meeting in order for the Incentive Plan to continue to qualify as &#147;performance-based compensation&#148; within the meaning of Section&nbsp;162(m) of the Internal Revenue Code
(&#147;Section 162(m)&#148;). If such approval is not obtained by our stockholders, the awards granted thereunder beginning in Fiscal 2018 will no longer qualify as &#147;performance-based compensation&#148; under Section&nbsp;162(m) therefore, if
such approval is not obtained, the Incentive Plan will be terminated. The Incentive Plan has been amended as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following three
additional performance objectives have been added: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adjusted operating income </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adjusted operating margins </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues from new products, designated products or categories of products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The maximum payment pursuant to the Incentive Plan in any performance period has been increased to $10&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A complete copy of the Incentive Plan, as amended, is attached hereto as Appendix C. The following summary description of the Incentive Plan,
as amended, is qualified in its entirety by reference to Appendix C. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Purpose </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Incentive Plan provides for incentive compensation to our key officers and employees, who, from time to time may be selected for
participation. The Incentive Plan is intended to provide incentives and rewards for the contributions of such employees toward the successful achievement of our financial and business goals established for the applicable performance period. Our
policy is to have a significant portion of a participant&#146;s total compensation tied to our performance. Payments pursuant to the Incentive Plan are intended to qualify as &#147;performance-based compensation&#148; within the meaning of
Section&nbsp;162(m). Under Section&nbsp;162(m), we may not receive a federal income tax deduction for compensation paid to certain executive officers to the extent that compensation exceeds $1 million per year. However, if compensation is deemed to
be performance based under Section&nbsp;162(m), we may still receive a federal income tax deduction even if the compensation exceeds the $1 million threshold. The Incentive Plan is intended to allow us to pay incentive, performance-based
compensation that is fully deductible on our federal income tax return. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Incentive Plan will be administered by the Compensation Committee, who designates the eligible participants, the beginning and ending dates
of the performance period (generally our fiscal year), the target award amounts and the performance objectives to be achieved during a performance period. Executive officers and other key employees who otherwise make comparable contributions are
eligible to participate. However, a participant for a given performance period is not guaranteed of participation in subsequent periods. For our 2018 fiscal year, for annual cash incentive bonus awards, the Compensation Committee has determined that
the only participant will be Mark C. Capone, our President and Chief Executive Officer. For our 2018 fiscal year, for equity incentive awards, the Compensation Committee has determined that only our five NEOs will be participants for restricted
stock unit awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Performance Objectives </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the first 90 days of each performance period and at a time when the achievement of such performance objective is substantially unknown,
the Compensation Committee will establish one or more performance objectives from the list set forth below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Net income; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Earnings per share; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Total revenue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Return on equity, including return on invested capital; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Adjusted operating income; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Adjusted operating margins; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Return on assets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Return on investments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Increase in sales, including sales growth; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Stock performance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Earnings before interest, taxes, depreciations and amortization; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Gross or operating margin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">New product introductions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Revenues from new products, designated products or categories of products; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Completion of acquisitions. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where applicable, performance objectives will be calculated from our audited
financial statements but may be modified to take into consideration changes in accounting principles; extraordinary, unusual or infrequent events; significant dispositions; gains or losses from certain claims, litigation and insurance recoveries;
the impact of impairment on intangible assets; restructuring, investments or acquisitions; and certain corporate capitalization events. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Awards
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Target awards are established by the Compensation Committee during the first 90 days of the performance period, expressed as a
percentage of the participant&#146;s eligible salary with payments ranging from 0 to 130% of the target award, or in the case of an equity award as a designated number of restricted stock units. Award payments are made as soon as practicable after
completion of the performance period based on the receipt by the Compensation Committee of our audited financial statements for a performance period and the certification by the Compensation Committee that the participants achieved the performance
objectives. Awards may be paid in cash, shares of our common stock, restricted stock, or restricted stock units of our common stock issued pursuant to a stockholder approved equity plan. The Compensation Committee may reduce performance awards at
its discretion, but it may not increase awards for the performance period. No participant may receive an award payment greater than $10 million for any performance period. To the extent that a target award is expressed by reference to a number of
shares of the Company&#146;s stock, then for purposes of applying the maximum award limitation, the value of the stock award shall be calculated based upon the maximum potential number of award shares and the closing price of our common stock on the
date of grant of the award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Participants whose employment is terminated for any reason other than death or disability will receive no
payment for that performance period. Participants who die or become disabled during a performance period will receive a prorated payment. All or part of a target award may be paid upon a change in control provided that the participant remains
employed through the date of the change in control, as defined in the Incentive Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendment and Termination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee has authority to make rules and adopt administrative procedures not specifically addressed in the Incentive Plan,
provided the new procedures are consistent with the purposes of the Incentive Plan. The Compensation Committee or the Board may also suspend, discontinue, or terminate the Incentive Plan at any time.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>
New Plan Benefits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because awards under the Incentive Plan are determined based
on actual performance it is not possible to determine the amounts, if any, that may be paid to participants under the Incentive Plan for fiscal 2018 or other future periods. For fiscal 2018, our President and CEO is the only executive officer who
has been designated to participate in the Incentive Plan for an annual cash incentive bonus award. If the Incentive Plan is approved by our stockholders, our President and CEO&#146;s annual cash bonus for fiscal 2018 will be awarded under the
Incentive Plan and will be based on the following formula: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Base Salary &times; Target Incentive Bonus Percentage of 100% &times; Total
Performance Factor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Total Performance Factor is based on the Company&#146;s fiscal year 2018 total revenues and adjusted operating income and is
calculated as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(the Revenue Performance Factor &times; .5) + (the Adjusted Operating Income Factor &times; .5). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For fiscal year 2018, our five NEOs have been designated as the only participants in the Incentive Plan with respect to equity incentive
awards in the form of restricted stock units that have a performance objective and a vesting requirement. If the Incentive Plan is approved by our stockholders, the restricted stock units awarded to our NEOs will be awarded under the Incentive Plan
and will be based on the achievement of our total revenues for fiscal year 2018 with a minimum revenue threshold objective, which if not surpassed, no restricted stock units will be awarded. Additionally, each restricted stock unit award is subject
to a pro rata, four year vesting requirement. On September&nbsp;13, 2017, our Compensation Committee made the following awards of restricted stock units to our NEOs subject to a pro rata, four year vesting requirement, as well as a performance-based
objective (total revenues for our fiscal year 2018) and a minimum revenue threshold requirement (of fiscal year 2018 total revenues): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Restricted Performance<BR>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of Shares</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Market<BR>Value ($)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark C. Capone, President and Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,374,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alexander Ford, President, Myriad Genetic Laboratories, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,954,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R. Bryan Riggsbee, Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,954,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jerry S. Lanchbury, Ph.D., Chief Scientific Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,628,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard M. Marsh, Esq., Executive Vice President, General Counsel and Secretary</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,628,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Amounts reflect the maximum potential value of each award assuming the highest level of performance associated with the award and is based on the closing price of our common stock on the NASDAQ Global Market on the date
of grant of the award on September&nbsp;13, 2017 of $32.57. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our stockholders do not approve the Incentive Plan, then the
Compensation Committee will need to establish a new short term incentive compensation program for our President and CEO, and a new equity incentive program for our NEOs, for fiscal year 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The affirmative vote of a
majority of the shares voted affirmatively or negatively for the proposal at the Annual Meeting is required to re-approve the 2013 Executive Incentive Plan, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE BOARD OF DIRECTORS RECOMMENDS RE-APPROVAL OF THE 2013 EXECUTIVE INCENTIVE PLAN, AS AMENDED. PROXIES SOLICITED BY THE BOARD WILL BE VOTED IN FAVOR OF
PLAN APPROVAL UNLESS A STOCKHOLDER HAS INDICATED OTHERWISE ON THE PROXY. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROPOSAL 4: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee has appointed Ernst&nbsp;&amp; Young LLP (&#147;EY&#148;) as our independent registered public accounting firm, to audit
our financial statements for the fiscal year ending June&nbsp;30, 2018. The Board proposes that the stockholders ratify this selection, although such ratification is not required under Delaware law or our Restated Certificate of Incorporation, as
amended, or our Restated By-Laws. EY has audited our financial statements since our fiscal year ended June&nbsp;30, 2007. We expect that representatives of EY will be present at the Annual Meeting, will be able to make a statement if they so desire,
and will be available to respond to appropriate questions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In deciding to appoint EY, the Audit Committee reviewed auditor independence
issues and existing commercial relationships with EY and concluded that EY has no commercial relationship with Myriad that would impair its independence for the fiscal year ending June&nbsp;30, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents fees for professional audit services provided by EY during the last two fiscal years: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:40.00pt; font-size:8pt; font-family:Times New Roman"><B>Type of Fee</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal&nbsp;Year&nbsp;Ended<BR>June&nbsp;30, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal&nbsp;Year&nbsp;Ended<BR>June&nbsp;30, 2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,074,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">800,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Related Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All Other Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,089,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">800,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Audit Fees</I> &#151; Fees include audits of consolidated financial statements, quarterly reviews, reviews
of registration statement filings, and consents related to SEC filings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Audit-Related Fees</I> &#151; Fees include services for
assurance and related services that are reasonably related to the performance of the audit or review of our financial statements that are not reported under &#147;audit fees.&#148; Fees include consultations related to the adoption of ASC 606,
Revenue Recognition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Tax Fees</I> &#151; We did not engage EY to perform any tax related services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>All Other Fees</I> &#151; We did not engage EY to perform any other services other than those listed separately above for the fiscal years
indicated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policy on Audit Committee Preapproval of Audit and Permissible Non-Audit Services of Independent Public Accountant </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consistent with SEC policies regarding auditor independence, the Audit Committee has responsibility for appointing, setting compensation and
overseeing the work of the independent public accounting firm. In recognition of this responsibility, the Audit Committee has established a policy to preapprove all audit and permissible non-audit services provided by our independent public
accounting firm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to engagement of an independent registered public accounting firm for the next year&#146;s audit, management will
submit an aggregate of services expected to be rendered during that year for each of four categories of services to the Audit Committee for approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;Audit services include audit work performed in the preparation of
financial statements, as well as work that generally only an independent registered public accounting firm can reasonably be expected to provide, including comfort letters, statutory audits, and attest services and consultation regarding financial
accounting and/or reporting standards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;Audit-Related services are for assurance and related services that are
traditionally performed by an independent registered public accounting firm, including due diligence related to mergers and acquisitions, employee benefit plan audits, and special procedures required to meet certain regulatory requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;Tax services include all services performed by an independent registered public accounting firm&#146;s tax personnel
except those services specifically related to the audit of the financial statements, and includes fees in the areas of tax compliance, tax planning, and tax advice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;Other Fees are those associated with services not captured in the other categories. The Company generally does not
request such services from our independent registered public accounting firm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to engagement of the independent registered public
accounting firm, engagement letters describing the scope of service and the anticipated fees are negotiated and approved by the Audit Committee. During the year, circumstances may arise in which it may become necessary to engage our independent
registered public accounting firm for additional services not contemplated in the original preapproval. In those instances, the Audit Committee requires specific preapproval before engaging our independent registered public accounting firm. The
Audit Committee may delegate preapproval authority to one or more of its members. The member to whom such authority is delegated must report, for informational purposes only, any pre-approval decisions to the Audit Committee at its next scheduled
meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The affirmative vote of a majority of the shares voted affirmatively or negatively at the Annual Meeting is required to ratify
the selection of our independent registered public accounting firm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our stockholders ratify the selection of EY, the Audit Committee
may still, in its discretion, decide to select a different independent auditor at any time during the fiscal year ending June&nbsp;30, 2018, if it concludes that such a change would be in the best interests of Myriad and our stockholders. If our
stockholders fail to ratify the selection, the Audit Committee will reconsider, but not necessarily rescind, the selection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE BOARD
OF DIRECTORS RECOMMENDS A VOTE TO RATIFY THE SELECTION OF ERNST&nbsp;&amp; YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM, AND PROXIES SOLICITED BY THE BOARD WILL BE VOTED IN FAVOR OF SUCH RATIFICATION UNLESS A STOCKHOLDER HAS
INDICATED OTHERWISE ON THE PROXY. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROPOSAL 5: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THIS PROXY STATEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are seeking your approval, on advisory basis, as required by Section&nbsp;14A of the Securities Exchange Act of 1934, as amended, of the
compensation of our named executive officers, as disclosed in this proxy statement. More specifically, we ask that you support the compensation of our named executive officers as disclosed in the Compensation Discussion and Analysis section, the
compensation tables and any related material contained in this proxy statement with respect to our executive officers named in the Summary Compensation Table. Because your vote is advisory, it will not be binding on our Compensation Committee or our
Board of Directors. However, the Compensation Committee and our Board will review the voting results and take them into consideration when making future decisions regarding the compensation of our named executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our compensation philosophy is designed to align each executive&#146;s compensation with our short- and long-term performance and to provide
the compensation and incentives needed to attract, motivate and retain key executives who are crucial to our long-term success. Consistent with this philosophy, a significant portion of the total compensation opportunity for each of our named
executive officers is directly related to performance factors that measure our progress against the goals of our strategic and operating plans, as well as our performance against that of our peer companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders are urged to read the Compensation Discussion and Analysis section of this proxy statement, which discusses how our compensation
policies and procedures implement our compensation philosophy. The Compensation Committee and the Board of Directors believe that these policies and procedures are effective in implementing our compensation philosophy and in achieving its goals.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed in the Compensation Discussion and Analysis section, we believe the compensation paid to our President and CEO and other
named executive officers is appropriate as supported by our accomplishments in fiscal 2017. This is evidenced by our financial and operational performance where, among other accomplishments, delivered our second consecutive year of top line growth
in fiscal year 2017 with revenues up 2% to $771 million despite hereditary cancer headwinds. We have made substantial progress on our strategic objectives that we believe position the Company for long-term growth, as well as progress on our five
strategic imperatives to: i) stabilize hereditary cancer revenue, ii) grow new product volume, iii) expand reimbursement coverage for new products, iv) increase RNA kit revenue internationally, and v) improve profitability with Elevate 2020. For
example, we completed the acquisitions of Sividon Diagnostics and Assurex Health, integrating both businesses, and achieving profitability for Assurex Health in less than nine months. Additionally, we returned our hereditary cancer business to
year-over-year volume growth with six percent volume growth in the fourth quarter. Additionally, we signed long-term contracts covering 86 percent of our hereditary cancer revenue. New product volumes increased 20 percent on a year-over-year basis
and now represent greater than two-thirds of total volume. We saw significant increases in reimbursement coverage for both Prolaris and EndoPredict and laid the foundation for further reimbursement expansion in fiscal year 2018 by completing several
key clinical studies. Additionally, we grew EndoPredict kit revenue 69 percent year-over-year and received broader coverage for the test in international markets. Finally we launched the Elevate 2020 program with a goal of increasing operating
income by $50 million by fiscal year 2020. We ended the year with $199 million in cash, cash equivalents, and marketable investment securities and plan to continue to exercise a balanced approach to capital deployment, including investing for future
growth, business development activities and returning cash to stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on this performance, we believe that the salary and
annual cash incentive bonus paid to our President and CEO and our other named executive officers are in line with our compensation philosophy and goals. Similarly, we believe that the equity compensation awarded to our President and CEO and our
other named executive officers is consistent with our multi-year growth in revenue, operating income and stock performance, and provides the appropriate incentives to reward and foster long-term growth and stockholder value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As evidence of our pay for performance philosophy, fiscal year 2017 total compensation paid to
three of our five NEOs, including our President and CEO, was below the 50<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> percentile of total compensation of our peer group as determined by Mercer under the 2017 Mercer Executive Compensation
Review; and the other two NEO&#146;s total compensation for fiscal year 2017 was between the 50<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> and 75<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> percentiles of total compensation of
our peer group. With respect to the annual cash incentive bonus paid to our NEOs for fiscal year 2017, we paid between 82% and 90%, respectively, of the target awards, based on the level of accomplishment of the pre-determined incentive goals.
Similarly, we made no payouts under our three-year cash incentive awards for fiscal year 2017 as the threshold targets were not met. We believe these actions are demonstrative of our pay for performance practices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the rules of the SEC, the following resolution, commonly known as a &#147;Say-on-Pay&#148; vote, is being submitted for a
stockholder vote at the Annual Meeting: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;RESOLVED, that the compensation paid to the named executive officers of Myriad Genetics,
Inc., as disclosed pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis, the compensation tables and any related material disclosed in this proxy statement, is
hereby APPROVED.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The affirmative vote of a majority of the shares voted affirmatively or negatively at the Annual Meeting is
required to approve, on an advisory basis, this resolution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE TO APPROVE, ON AN ADVISORY BASIS,
THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AND PROXIES SOLICITED BY THE BOARD WILL BE VOTED IN FAVOR OF SUCH APPROVAL UNLESS A STOCKHOLDER HAS INDICATED OTHERWISE ON THE PROXY. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROPOSAL 6: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADVISORY VOTE ON THE FREQUENCY OF HOLDING AN ADVISORY VOTE ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are seeking your input with regard to the frequency of holding future stockholder advisory votes on the compensation of our named executive
officers. Since 2011, we have had an advisory vote on the compensation of our named executive officers every year. We are required to seek an advisory vote on the frequency of holding an advisory vote every six years. Accordingly, we are again
asking whether the advisory vote on the compensation of our named executive officers should occur every year, every two years or every three years. Because your vote is advisory, it will not be binding on our Compensation Committee or our Board of
Directors. However, the Compensation Committee and the Board will review the voting results and take them into consideration when making its decision regarding how frequently it should present the advisory vote on the compensation of our named
executive officers to our stockholders for the next six years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee, Board of Directors and management believe that
it is appropriate and in our best interests for our shareholders to vote in favor of an annual advisory vote on the compensation of our named executive officers. An advisory vote each year will permit our shareholders to provide annual feedback to
us on our compensation policies, practices and compensation awards for our named executive officers. This is consistent with our policy of giving shareholders the opportunity to voice concerns with management or our Board under our previously
established policy on communications with our Board of Directors. An annual advisory vote will give the Board, the Compensation Committee and management more timely feedback from the shareholders to allow us to evaluate and adjust, when we consider
appropriate, the compensation of our named executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proxy card provides stockholders with the opportunity to choose among
four options (holding the vote every one, two or three years, or abstaining) and, therefore, stockholders will not be voting to approve or disapprove the Board&#146;s recommendation. The choice that receives the highest number of votes will be
deemed the frequency approved, on an advisory basis, by our stockholders. However, because the vote on the frequency of holding future advisory votes on the compensation of our named executive officers is not binding, the Compensation Committee and
the Board of Directors will review the voting results and take them into consideration when making a decision regarding the frequency of holding future advisory votes on the compensation of our named executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE TO APPROVE, ON AN ADVISORY BASIS, THE FREQUENCY OF HOLDING AN ADVISORY VOTE ON THE COMPENSATION OF
OUR NAMED EXECUTIVE OFFICERS EVERY YEAR, AND PROXIES SOLICITED BY THE BOARD WILL BE VOTED IN FAVOR OF HOLDING AN ADVISORY VOTE EACH YEAR UNLESS A STOCKHOLDER HAS INDICATED OTHERWISE ON THE PROXY CARD. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CORPORATE CODE OF CONDUCT AND ETHICS AND WHISTLEBLOWER POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a Corporate Code of Conduct and Ethics and Whistleblower Policy that applies to all of our employees, including our Chief
Executive Officer and Chief Financial Officer, and every member of our Board of Directors. A copy of the Corporate Code of Conduct and Ethics and Whistleblower Policy is publicly available in the Investor Information &#150; Understanding
Myriad/Corporate Governance section of our website at <I>www.myriad.com</I>. Disclosure regarding any amendments to, or waivers from, provisions of our Corporate Code of Conduct and Ethics and Whistleblower Policy that apply to our directors and
principal executive and financial officers will be included in a Current Report on Form 8-K within four business days following the date of the amendment or waiver, unless website posting or the issuance of a press release of such amendments or
waivers is then permitted by the rules of The NASDAQ Stock Market LLC. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OTHER MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors knows of no other business that will be presented at the Annual Meeting. If any other business is properly brought
before the Annual Meeting, proxies will be voted in accordance with the judgment of the persons voting the proxies. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCKHOLDER
PROPOSALS AND NOMINATIONS FOR DIRECTOR </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To be considered for inclusion in the proxy statement relating to our Annual Meeting of
Stockholders being held in 2018 (the &#147;2018 Meeting&#148;), we must receive stockholder proposals (other than for director nominations) no later than June&nbsp;14, 2018. To be considered for presentation at the 2018 Meeting, although not
included in the proxy statement, proposals (including director nominations that are not requested to be included in our proxy statement) must be received no earlier than September&nbsp;1, 2018 and no later than October&nbsp;1, 2018. Notwithstanding
the foregoing, in the event that the number of directors is to be increased at the 2018 Meeting and we do not issue a public announcement naming the nominees and specifying the size of the increase by September&nbsp;21, 2018, to be considered for
presentation at the 2018 Meeting, although not included in the proxy statement, nominations must be received no later than the tenth day following the day on which such public announcement is made. Proposals not received in a timely manner will not
be voted on at the 2018 Meeting. If a proposal is received in a timely manner, the proxies that management solicits for the 2018 Meeting may still exercise discretionary voting authority on the proposal under circumstances consistent with the proxy
rules of the SEC. All stockholder proposals must also comply with our Restated By-Laws, a copy of which is available by contacting our Secretary, and the corporate governance policies applicable to recommendations for the nomination of directors,
copies of which are available in the Investor Information &#151; Understanding Myriad/Corporate Governance section of our website at www.myriad.com. All stockholder proposals should be marked for the attention of: Secretary, Myriad Genetics, Inc.,
320 Wakara Way, Salt Lake City, Utah 84108. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHETHER OR NOT YOU INTEND TO BE PRESENT AT THE ANNUAL MEETING, YOU ARE URGED TO VOTE YOUR
SHARES AT YOUR EARLIEST CONVENIENCE. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Salt Lake City, Utah </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October&nbsp;12, 2017 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>OUR ANNUAL REPORT ON
FORM 10-K FOR THE FISCAL YEAR ENDED JUNE 30, 2017, AS AMENDED, (OTHER THAN EXHIBITS THERETO) FILED WITH THE SECURITIES AND EXCHANGE COMMISSION, WHICH PROVIDES ADDITIONAL INFORMATION ABOUT US, IS AVAILABLE ON THE INTERNET AT
</B><B><I>WWW.MYRIAD.COM</I></B><B> AND IS AVAILABLE IN PAPER FORM TO BENEFICIAL OWNERS OF OUR COMMON STOCK WITHOUT CHARGE UPON WRITTEN REQUEST TO: RICHARD M. MARSH, SECRETARY, MYRIAD GENETICS, INC., 320 WAKARA WAY, SALT LAKE CITY, UTAH 84108
(801-584-3600). </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>GAAP to Non-GAAP Reconciliation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Condensed Consolidated
Statements of Income &#151; Operating Basis </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(Unaudited data in millions, except per share amount) </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>GAAP Net Income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition &#151; integration related costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition &#151; amortization of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elevate 2020 costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrual for legal expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax impact related to equity compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax expense associated with R&amp;D tax credit reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Potential future consideration related to acquisitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">One-time debt restructuring charges</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">One-time non-deductible costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impairment of Raindance Investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax expense associated with non-GAAP adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Non-GAAP Net Income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">119.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>GAAP Diluted EPS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustment to net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">0.08</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Non-GAAP Diluted EPS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Non-GAAP Financial Measures</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We supplement our consolidated financial statements presented on a GAAP basis by providing additional measures which may be considered &#147;non-GAAP&#148;
financial measures under applicable SEC rules. We believe that the disclosure of these non-GAAP financial measures provides additional insight into the ongoing economics of our business and reflects how we manage our business internally, set
operational goals and forms the basis of our management incentive programs. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be viewed in isolation or as a
substitute for reported, or GAAP, net income and diluted earnings per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our &#147;Non-GAAP Net Income&#148; and &#147;Non-GAAP diluted EPS&#148;
financial measures exclude the following items from GAAP net income and diluted earnings per share: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B><I>1. Acquisitions &#151; integration
related costs </I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costs related to closing and integration of acquired companies </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B><I>2. Acquisitions &#151; amortization of intangible assets</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Represents recurring amortization charges resulting from the acquisition of intangible assets, including developed technology and database rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B><I>3. Elevate 2020 costs</I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Expenses tied
to Elevate 2020 program. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>4. Accrual for legal expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrual associated with anticipated future legal expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>5. Tax impact related to equity compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in effective tax rate based upon ASU 2016-09. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B><I>6. Tax expense associated with R&amp;D tax credit reserves</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One time net benefits associated with the release of R&amp;D tax credit reserves. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>7. Potential future consideration related to acquisitions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-cash expenses related to valuation adjustments of earn-out and milestone payments tied to recent acquisitions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>8. One-time debt restructuring charges </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charges
related to the restructuring of the company&#146;s debt from a one-year term loan to a revolving credit facility. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>9. One-time non-deductible costs
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One-time non-deductible tax items. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>10.
Impairment of RainDance Investment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One-time impairment charge associated with Myriad&#146;s investment in RainDance Technologies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Appendix B </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MYRIAD GENETICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2017 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.<U></U></TD>
<TD ALIGN="left" VALIGN="top"><U>DEFINITIONS.</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise specified or unless the context otherwise requires, the
following terms, as used in this Myriad Genetics, Inc. 2017 Employee, Director and Consultant Equity Incentive Plan have the following meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><U>Administrator</U> means the Board of Directors, unless it has delegated power to act on its behalf to the Committee, in which case the term
Administrator means the Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><U>Affiliate</U> means a corporation which, for purposes of Section&nbsp;424 of the Code, is a parent
or subsidiary of the Company, direct or indirect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><U>Agreement</U> means an agreement between the Company and a Participant delivered
pursuant to the Plan and pertaining to a Stock Right, in such form as the Administrator shall approve. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><U>Board of Directors</U> means
the Board of Directors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><U>Cause</U> means, with respect to a Participant (a)&nbsp;dishonesty with respect to the Company
or any Affiliate, (b)&nbsp;insubordination, substantial malfeasance or <FONT STYLE="white-space:nowrap">non-feasance</FONT> of duty, (c)&nbsp;unauthorized disclosure of confidential information, (d)&nbsp;breach by a Participant of any provision of
any employment, consulting, advisory, nondisclosure, non-competition or similar agreement between the Participant and the Company or any Affiliate, and (e)&nbsp;conduct substantially prejudicial to the business of the Company or any Affiliate;
provided, however, that any provision in an agreement between a Participant and the Company or an Affiliate, which contains a conflicting definition of Cause for termination and which is in effect at the time of such termination, shall supersede
this definition with respect to that Participant. The determination of the Administrator as to the existence of Cause will be conclusive on the Participant and the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><U>Change of Control</U> means the occurrence of any of the following events: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"><I>Ownership</I>. Any &#147;Person&#148; (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becomes the &#147;Beneficial Owner&#148; (as defined in Rule 13d-3 under the Exchange Act), directly or
indirectly, of securities of the Company representing 50% or more of the total voting power represented by the Company&#146;s then outstanding voting securities (excluding for this purpose any such voting securities held by the Company or its
Affiliates or by any employee benefit plan of the Company) pursuant to a transaction or a series of related transactions which the Board of Directors does not approve; or </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"><I>Merger/Sale of Assets</I>. (A)&nbsp;A merger or consolidation of the Company whether or not approved by the Board of Directors, other than a merger or consolidation which would result in the voting securities of the
Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation) more than 50% of the total voting power
represented by the voting securities of the Company or such surviving entity or parent of such corporation, as the case may be, outstanding immediately after such merger or consolidation; or (B)&nbsp;the sale or disposition by the Company of all or
substantially all of the Company&#146;s assets in a transaction requiring stockholder approval; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">&#147;Change of Control&#148; shall be interpreted, if applicable, in a manner, and limited to the extent necessary, so that it will not cause adverse tax consequences under Section&nbsp;409A. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><U>Code</U> means the United States Internal Revenue Code of 1986, as amended including any successor statute, regulation and guidance
thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><U>Committee</U> means the committee of the Board of Directors to which the Board of Directors has delegated power to act under
or pursuant to the provisions of the Plan, the composition of which shall at all times satisfy the provisions of Section&nbsp;162(m) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><U>Common Stock</U> means shares of the Company&#146;s common stock, $.01 par value per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><U>Company</U> means Myriad Genetics, Inc., a Delaware corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><U>Consultant</U> means any natural person who is an advisor or consultant that provides bona fide services to the Company or its Affiliates,
provided that such services are not in connection with the offer or sale of securities in a capital raising transaction, and do not directly or indirectly promote or maintain a market for the Company&#146;s or its Affiliates&#146; securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><U>Disability</U> or <U>Disabled</U> means permanent and total disability as defined in Section&nbsp;22(e)(3) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><U>Employee</U> means any employee of the Company or of an Affiliate (including, without limitation, an employee who is also serving as an
officer or director of the Company or of an Affiliate), designated by the Administrator to be eligible to be granted one or more Stock Rights under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><U>Exchange Act</U> means the Securities Exchange Act of 1934, as amended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><U>Fair Market Value</U> of a Share of Common Stock means: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) If the Common Stock is listed on a national securities exchange or traded in the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market and sales prices are regularly reported for the Common Stock, the closing or, if not applicable, the last price of the Common Stock on the composite tape or other comparable reporting
system for the trading day on the applicable date and if such applicable date is not a trading day, the last market trading day prior to such date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) If the Common Stock is not traded on a national securities exchange but is traded on the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, if sales prices are not regularly reported for the Common Stock for the trading day referred to in clause&nbsp;(1), and if bid and asked prices for the Common Stock are regularly
reported, the mean between the bid and the asked price for the Common Stock at the close of trading in the over-the-counter market for the trading day on which Common Stock was traded on the applicable date and if such applicable date is not a
trading day, the last market trading day prior to such date; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) If the Common Stock is neither listed on a national
securities exchange nor traded in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, such value as the Administrator, in good faith, shall determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><U>Participant</U> means an Employee, director or Consultant of the Company or an Affiliate to whom one or more Stock Rights are granted under
the Plan. As used herein, &#147;Participant&#148; shall include &#147;Participant&#146;s Survivors&#148; where the context requires. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><U>Plan</U> means this Myriad Genetics, Inc. 2017 Employee, Director and Consultant Equity Incentive Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><U>Restricted Stock Grant</U> means a grant by the Company of Shares under the Plan that are subject to a lapsing forfeiture or repurchase
right. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><U>Restricted Stock Unit Award</U> means a grant by the Company under the Plan of an unfunded, unsecured commitment by the Company
to deliver a pre-determined number of Shares to a Participant at a future time in accordance with the terms and conditions of the award agreement and the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><U>Securities Act</U> means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><U>Shares</U> means shares of the Common Stock as to which Stock Rights have been or may be granted under the Plan or any shares of capital
stock into which the Shares are changed or for which they are exchanged within the provisions of Paragraph&nbsp;3 of the Plan. The Shares issued under the Plan may be authorized and unissued shares or shares held by the Company in its treasury, or
both. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><U>Stock Right</U> means a right to Shares or the value of Shares of the Company granted pursuant to the Plan &#151; a Restricted
Stock Grant or a Restricted Stock Unit Award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><U>Survivor</U> means a deceased Participant&#146;s legal representatives and/or any person or
persons who acquired the Participant&#146;s rights to a Stock Right by will or by the laws of descent and distribution. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.<U></U></TD>
<TD ALIGN="left" VALIGN="top"><U>PURPOSES OF THE PLAN.</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan is intended to encourage ownership of Shares by
Employees and directors of and certain Consultants to the Company and its Affiliates in order to attract and retain such people, to induce them to work for the benefit of the Company or of an Affiliate and to provide additional incentive for them to
promote the success of the Company or of an Affiliate. The Plan provides for the granting of Restricted Stock Grants and Restricted Stock Unit Awards and shall not allow for the grant of stock options. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"><U>SHARES SUBJECT TO THE PLAN.</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The number of Shares which may be issued from time to
time pursuant to this Plan shall not exceed one million four hundred thousand (1,400,000)&nbsp;shares of Common Stock plus (ii)&nbsp;any shares of Common Stock that are represented by options previously granted under the Company&#146;s 2003
Employee, Director and Consultant Stock Option Plan, as amended, or awards previously granted under the 2010 Employee, Director and Consultant Equity Incentive Plan, as amended, that are forfeited, expire or are cancelled without delivery of shares
of Common Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If any Restricted Stock Unit Award expires or is forfeited, cancelled, or otherwise terminated or results in any
Shares not being issued or the Company shall reacquire (at not more than its original issuance price) any Shares issued pursuant to a Restricted Stock Grant, the unissued or reacquired Shares which were subject to such Stock Right shall again be
available for issuance from time to time pursuant to this Plan. Notwithstanding the foregoing, if the Company or an Affiliate&#146;s tax withholding obligation is satisfied by withholding Shares, the number of Shares deemed to have been issued under
the Plan for purposes of the limitation set forth in Paragraph 3(a) above shall be the number of Shares that were subject to the Stock Right or portion thereof, and not the net number of Shares actually issued. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"><U>ADMINISTRATION OF THE PLAN.</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator of the Plan will be the Board of
Directors, except to the extent the Board of Directors delegates its authority to the Committee, in which case the Committee shall be the Administrator. Subject to the provisions of the Plan, the Administrator is authorized to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Interpret the provisions of the Plan and all Stock Rights and to make all rules and determinations which it deems necessary
or advisable for the administration of the Plan; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Determine which Employees, directors and Consultants shall be granted
Stock Rights; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Determine the number of Shares for which a Stock Right or Stock Rights shall
be granted, provided, however, that in no event shall: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Stock Rights with respect to more than 500,000 Shares be
granted to any Participant in any fiscal year; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the aggregate grant date fair value of Shares to be granted to any
non-employee director under the Plan in any calendar year may not exceed $500,000; provided however that the foregoing limitation shall not apply to Stock Rights made pursuant to an election to receive equity in lieu of cash for all or a portion of
fees received for service on the Board of Directors or any Committee thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Specify the terms and conditions upon
which a Stock Right or Stock Rights may be granted; provided, however, that except in the case of death, disability or Change of Control, Stock Rights shall not vest, and any right of the Company to restrict or require Shares subject to a Stock
Grant shall not lapse, less than one year from the date of grant and no dividends or dividend equivalents shall be paid on any Stock Right prior to the vesting of the underlying Shares; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Amend any term or condition of any outstanding Stock Right, provided that no such change shall impair the rights of a
Participant under any grant previously made without such Participant&#146;s consent; provided however, the Administrator is not authorized to accelerate the vesting schedule of an outstanding Stock Right except in the case of death, disability or
Change of Control; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Adopt any sub-plans applicable to residents of any specified jurisdiction as it deems necessary
or appropriate in order to comply with or take advantage of any tax or other laws applicable to the Company, any Affiliate or to Participants or to otherwise facilitate the administration of the Plan, which sub-plans may include additional
restrictions or conditions applicable to Stock Rights or Shares issuable pursuant to a Stock Right; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided, however, that all such interpretations,
rules, determinations, terms and conditions shall be made and prescribed in the context of potential tax consequences under Section&nbsp;409A of the Code. Subject to the foregoing, the interpretation and construction by the Administrator of any
provisions of the Plan or of any Stock Right granted under it shall be final, unless otherwise determined by the Board of Directors, if the Administrator is the Committee. In addition, if the Administrator is the Committee, the Board of Directors
may take any action under the Plan that would otherwise be the responsibility of the Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent permitted under applicable
law, the Board of Directors or the Committee may allocate all or any portion of its responsibilities and powers to any one or more of its members and may delegate all or any portion of its responsibilities and powers to any other person selected by
it. The Board of Directors or the Committee may revoke any such allocation or delegation at any time. Notwithstanding the foregoing, only the Board of Directors or the Committee shall be authorized to grant a Stock Right to any director of the
Company or to any &#147;officer&#148; of the Company (as defined by Rule 16a-1 under the Exchange Act). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"><U>ELIGIBILITY FOR PARTICIPATION.</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator will, in its sole discretion, name the
Participants in the Plan; provided, however, that each Participant must be an Employee, director or Consultant of the Company or of an Affiliate at the time a Stock Right is granted. Notwithstanding the foregoing, the Administrator
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may authorize the grant of a Stock Right to a person not then an Employee, director or Consultant of the Company or of an Affiliate; provided, however, that the actual grant of such Stock Right
shall be conditioned upon such person becoming eligible to become a Participant at or prior to the time of the execution of the Agreement evidencing such Stock Right. The granting of any Stock Right to any individual shall neither entitle that
individual to, nor disqualify him or her from, participation in any other grant of Stock Rights or any grant under any other benefit plan established by the Company or any Affiliate for Employees, directors or Consultants. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"><U>TERMS AND CONDITIONS OF RESTRICTED STOCK GRANTS.</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Restricted Stock Grant to a
Participant shall state the principal terms in an Agreement duly executed by the Company and, to the extent required by law or requested by the Company, by the Participant. The Agreement shall be in a form approved by the Administrator and shall
contain terms and conditions which the Administrator determines to be appropriate and in the best interest of the Company, subject to the following minimum standards: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Each Agreement shall state the purchase price per share, if any, of the Shares covered by each Restricted Stock Grant,
which purchase price shall be determined by the Administrator but shall not be less than the minimum consideration required by the Delaware General Corporation Law, if any, on the date of grant of the Restricted Stock Grant; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each Agreement shall state the number of Shares to which the Restricted Stock Grant pertains; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Each Agreement shall include the terms of any right of the Company to restrict or reacquire the Shares subject to the
Restricted Stock Grant, including the time and events upon which such rights shall accrue and the purchase price therefor, if any within the parameters set forth in the Plan; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Dividends (other than stock dividends to be issued pursuant to Section&nbsp;18 of the Plan) may accrue but shall not be
paid prior to the time, and only to the extent that, the restrictions or rights to reacquire the Shares subject to the Restricted Stock Grant lapse. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"><U>TERMS AND CONDITIONS OF RESTRICTED STOCK UNIT AWARDS.</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Restricted Stock Unit Award
to a Participant shall state the principal terms in an Agreement duly executed by the Company and, to the extent required by law or requested by the Company, by the Participant. The Agreement shall be in a form approved by the Administrator and
shall contain terms and conditions which the Administrator determines to be appropriate and in the best interest of the Company. Each Agreement shall include the terms of any right of the Company including the right to terminate the Restricted Stock
Unit Award without the issuance of Shares, the terms of any vesting conditions within the parameters set forth in the Plan, or events upon which Shares shall be issued provided that dividends (other than stock dividends to be issued pursuant to
Section&nbsp;18 of the Plan) or dividend equivalents may accrue but shall not be paid prior to and only to the extent that, the Shares subject to the Restricted Stock Unit Award vest. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company intends that the Plan and any Restricted Stock Unit Awards granted hereunder be
exempt from the application of Section&nbsp;409A of the Code or meet the requirements of paragraphs (2), (3)&nbsp;and (4)&nbsp;of subsection (a)&nbsp;of Section&nbsp;409A of the Code, to the extent applicable, and be operated in accordance with
Section&nbsp;409A so that any compensation deferred under any Restricted Stock Unit Award (and applicable investment earnings) shall not be included in income under Section&nbsp;409A of the Code. Any ambiguities in the Plan shall be construed to
effect the intent as described in this Paragraph 7. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"><U>PAYMENT IN CONNECTION WITH THE ISSUANCE OF RESTRICTED STOCK GRANTS AND ISSUE OF SHARES FOR STOCK RIGHTS.</U> </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any Restricted Stock Grant requiring payment of a purchase price for the Shares as to which such Restricted Stock Grant is being granted shall
be made (a)&nbsp;in United States dollars in cash or by check, or (b)&nbsp;at the discretion of the Administrator, through delivery of shares of Common Stock held for at least six months (if required to avoid negative accounting treatment) and
having a Fair Market Value equal as of the date of payment to the purchase price of the Restricted Stock Grant, or (c)&nbsp;at the discretion of the Administrator, by any combination of (a)&nbsp;and (b)&nbsp;above; or (d)&nbsp;at the discretion of
the Administrator, by payment of such other lawful consideration as the Administrator may determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall when required by
the applicable Agreement, reasonably promptly deliver the Shares as to which such Stock Right was made to the Participant (or to the Participant&#146;s Survivors, as the case may be), subject to any escrow provision set forth in the applicable
Agreement. In determining what constitutes &#147;reasonably promptly,&#148; it is expressly understood that the issuance and delivery of the Shares may be delayed by the Company in order to comply with any law or regulation (including, without
limitation, state securities or &#147;blue sky&#148; laws) which requires the Company to take any action with respect to the Shares prior to their issuance. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"><U>RIGHTS AS A SHAREHOLDER.</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No Participant to whom a Stock Right has been granted shall
have rights as a shareholder with respect to any Shares covered by such Stock Right, except after issuance of Shares as set forth in any Agreement and tender of the aggregate purchase price, if any, for the Shares being purchased, and registration
of the Shares in the Company&#146;s share register in the name of the Participant. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"><U>ASSIGNABILITY AND TRANSFERABILITY OF STOCK RIGHTS.</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By its terms, a Stock Right granted
to a Participant shall not be transferable by the Participant other than (i)&nbsp;by will or by the laws of descent and distribution, or (ii)&nbsp;as approved by the Administrator in its discretion and set forth in the applicable Agreement provided
that no Stock Right may be transferred by a Participant for value. The designation of a beneficiary of a Stock Right by a Participant, with the prior approval of the Administrator and in such form as the Administrator shall prescribe, shall not be
deemed a transfer prohibited by this Paragraph. Except as provided above during the Participant&#146;s lifetime, a Stock Right shall only be exercisable by or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
issued to such Participant (or his or her legal representative) and shall not be assigned, pledged or hypothecated in any way (whether by operation of law or otherwise) and shall not be subject
to execution, attachment or similar process. Any attempted transfer, assignment, pledge, hypothecation or other disposition of any Stock Right or of any rights granted thereunder contrary to the provisions of this Plan, or the levy of any attachment
or similar process upon a Stock Right, shall be null and void. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"><U>EFFECT OF TERMINATION OF SERVICE ON UNACCEPTED RESTRICTED STOCK GRANTS AND RESTRICTED STOCK UNIT AWARDS.</U> </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a termination of service (whether as an Employee, director or Consultant) with the Company or an Affiliate for any reason
before the Participant has accepted a Restricted Stock Grant or a Restricted Stock Unit Award and paid the purchase price, if required, such grant shall terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Paragraph 11 and Paragraph 12 below, a Participant to whom a Stock Right has been issued under the Plan who is absent
from work with the Company or with an Affiliate because of temporary disability (any disability other than a Disability as defined in Paragraph 1 hereof), or who is on leave of absence for any purpose, shall not, during the period of any such
absence, be deemed, by virtue of such absence alone, to have terminated such Participant&#146;s employment, director status or consultancy with the Company or with an Affiliate, except as the Administrator may otherwise expressly provide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, for purposes of this Paragraph 11 and Paragraph 12 below, any change of employment or other service within or among the Company
and any Affiliates shall not be treated as a termination of employment, director status or consultancy so long as the Participant continues to be an Employee, director or Consultant of the Company or any Affiliate. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"><U>EFFECT ON RESTRICTED STOCK GRANTS AND RESTRICTED STOCK UNIT AWARDS OF TERMINATION OF SERVICE OTHER THAN FOR CAUSE OR DEATH OR DISABILITY.</U> </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in a Participant&#146;s Agreement, in the event of a termination of service for any reason (whether as an
Employee, director or Consultant), other than termination for Cause, Disability, or death for which events there are special rules in Paragraphs 13, 14, and 15, below, before all forfeiture provisions or Company rights of repurchase shall have
lapsed, then the Company shall have the right to cancel or repurchase that number of Shares subject to a Restricted Stock Grant as to which the Company&#146;s forfeiture or repurchase rights have not lapsed or cancel a Restricted Stock Unit Award
without the issuance of any additional Shares thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"><U>EFFECT ON RESTRICTED STOCK GRANTS AND RESTRICTED STOCK UNIT AWARDS OF TERMINATION OF SERVICE FOR CAUSE.</U> </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in a Participant&#146;s Agreement, the following rules apply if the Participant&#146;s service (whether as an
Employee, director or Consultant) with the Company or an Affiliate is terminated for Cause: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) All Shares subject to any Restricted Stock
Grant that remain subject to forfeiture provisions or as to which the Company shall have a repurchase right and Restricted Stock Unit Awards for which Shares have not been issued shall be immediately forfeited to the Company as of the time the
Participant is notified his or her service is terminated for Cause. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Cause is not limited to events which have occurred prior to a
Participant&#146;s termination of service, nor is it necessary that the Administrator&#146;s finding of Cause occur prior to termination. If the Administrator determines, subsequent to a Participant&#146;s termination of service, that either prior
or subsequent to the Participant&#146;s termination the Participant engaged in conduct which would constitute Cause, then all Shares subject to any Restricted Stock Grant that remained subject to forfeiture provisions or as to which the Company had
a repurchase right and Restricted Stock Unit Awards for which Shares have not been issued on the date of termination shall be immediately forfeited to the Company. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"><U>EFFECT ON RESTRICTED STOCK GRANTS AND RESTRICTED STOCK UNIT AWARDS OF TERMINATION OF SERVICE FOR DISABILITY.</U> </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in a Participant&#146;s Agreement, the following rules apply if a Participant ceases to be an Employee, director
or Consultant of the Company or of an Affiliate by reason of Disability: to the extent the forfeiture provisions or the Company&#146;s rights of repurchase have not lapsed on the date of the Participant&#146;s termination due to Disability, they
shall be exercisable; provided, however, that in the event such forfeiture provisions or rights of repurchase lapse periodically, such provisions or rights shall lapse to the extent of a pro rata portion of the Shares subject to such Stock Right
through the date of the Participant&#146;s termination due to Disability as would have lapsed had the Participant not been terminated due to Disability. The proration shall be based upon the number of days accrued prior to the date of the
Participant&#146;s termination due to Disability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator shall make the determination both as to whether Disability has
occurred and the date of its occurrence (unless a procedure for such determination is set forth in another agreement between the Company and such Participant, in which case such procedure shall be used for such determination). If requested, the
Participant shall be examined by a physician selected or approved by the Administrator, the cost of which examination shall be paid for by the Company. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"><U>EFFECT ON RESTRICTED STOCK GRANTS AND RESTRICTED STOCK UNIT AWARDS OF DEATH WHILE AN EMPLOYEE, DIRECTOR OR CONSULTANT.</U> </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in a Participant&#146;s Agreement, the following rules apply in the event of the death of a Participant while the
Participant is an Employee, director or Consultant of the Company or of an Affiliate: to the extent the forfeiture provisions or the Company&#146;s rights of repurchase have not lapsed on the date of death, they shall lapse in full on the
Participant&#146;s date of death. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"><U>PURCHASE FOR INVESTMENT.</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the offering and sale of the Shares shall have been
effectively registered under the Securities Act, the Company shall be under no obligation to issue the Shares under the Plan unless and until the following conditions have been fulfilled: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The person who receives a Stock Right shall warrant to the Company, prior to the receipt of such Shares, that such person is acquiring such
Shares for his or her own account, for investment, and not with a view to, or for sale in connection with, the distribution of any such Shares, in which event the person acquiring such Shares shall be bound by the provisions of the following legend
(or a legend in substantially similar form) which shall be endorsed upon the certificate evidencing the Shares issued pursuant to such Stock Right: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;The shares represented by this certificate have been taken for investment and they may not be sold or otherwise transferred by any
person, including a pledgee, unless (1)&nbsp;either (a)&nbsp;a Registration Statement with respect to such shares shall be effective under the Securities Act of 1933, as amended, or (b)&nbsp;the Company shall have received an opinion of counsel
satisfactory to it that an exemption from registration under such Act is then available, and (2)&nbsp;there shall have been compliance with all applicable state securities laws.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) At the discretion of the Administrator, the Company shall have received an opinion of its counsel that the Shares may be issued in
compliance with the Securities Act without registration thereunder. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"><U>DISSOLUTION OR LIQUIDATION OF THE COMPANY.</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the rights of a Participant or a
Participant&#146;s Survivors have not otherwise terminated and expired, the Participant or the Participant&#146;s Survivors will have the right immediately prior to such dissolution or liquidation to accept any Stock Right to the extent that the
Stock Right is exercisable or subject to acceptance as of the date immediately prior to such dissolution or liquidation. Upon the dissolution or liquidation of the Company, all Restricted Stock Grants and Restricted Stock Unit Awards which have not
been accepted, to the extent required under the applicable Agreement, will terminate and become null and void and any outstanding Restricted Stock Unit Awards shall immediately terminate unless otherwise determined by the Administrator or
specifically provided in the applicable Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18.</TD>
<TD ALIGN="left" VALIGN="top"><U>ADJUSTMENTS.</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the occurrence of any of the following events, a Participant&#146;s
rights with respect to any Stock Right granted to him or her hereunder shall be adjusted as hereinafter provided, unless otherwise specifically provided in a Participant&#146;s Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Stock Dividends and Stock Splits</U>. If (i)&nbsp;the shares of Common Stock shall be subdivided or combined into a
greater or smaller number of shares or if the Company shall issue any shares of Common Stock as a stock dividend on its outstanding Common Stock, or (ii)&nbsp;additional shares or new or different shares or other securities of the Company or other
non-cash assets are distributed with respect to such shares of Common Stock, each Stock Right and the number of shares of Common Stock deliverable thereunder shall be appropriately increased or decreased proportionately, and appropriate adjustments
shall be made including, in the purchase price per share, to reflect such events. The number of Shares subject to the limitations in Paragraph 3(a) and 4(c) shall also be proportionately adjusted upon the occurrence of such events. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Corporate Transactions</U>. If the Company is to be consolidated with or acquired by another entity in a merger,
consolidation, or sale of all or substantially all of the Company&#146;s assets other than a transaction to merely change the state of incorporation (a &#147;Corporate Transaction&#148;), the Administrator or the board of directors of any entity
assuming the obligations of the Company hereunder (the &#147;Successor Board&#148;), shall: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) as to outstanding
Restricted Stock Unit Awards, either (a)&nbsp;make appropriate provision for the continuation of such Restricted Stock Unit Awards by substituting on an equitable basis for the Shares then subject to such Restricted Stock Unit Awards either the
consideration payable with respect to the outstanding shares of Common Stock in connection with the Corporate Transaction or securities of any successor or acquiring entity; or (b)&nbsp;terminate such Restricted Stock Unit Awards in exchange for
payment of an amount equal to the consideration payable upon consummation of such Corporate Transaction to a holder of the number of shares of Common Stock which would have been issued pursuant to such Restricted Stock Unit Award. For purposes of
determining the payments to be made in the case of a Corporate Transaction the consideration for which, in whole or in part, is other than cash, the consideration other than cash shall be valued at the fair value thereof as determined in good faith
by the Board of Directors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) as to outstanding Restricted Stock Grants either, (a)&nbsp;make appropriate provision for
the continuation of such Restricted Stock Grants on the same terms and conditions by substituting on an equitable basis for the Shares then subject to such Restricted Stock Grants either the consideration payable with respect to the outstanding
Shares of Common Stock in connection with the Corporate Transaction or securities of any successor or acquiring entity; or (b)&nbsp;terminate such Restricted Stock Grants in exchange for payment of an amount equal to the consideration payable upon
consummation of such Corporate Transaction to a holder of the number of shares of Common Stock comprising such Restricted Stock Grant; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">In taking any of the actions permitted under this Paragraph 18(b), the Administrator shall not be obligated by the Plan to
treat all Stock Rights, all Stock Rights held by a Participant, or all Stock Rights of the same type, identically. The Administrator or the Successor Board shall determine the specific adjustments to be made under this Paragraph 18, including, but
not limited to the effect of any, Corporate Transaction or Change of Control and, subject to Paragraph 4, its determination shall be conclusive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Recapitalization or Reorganization</U>. In the event of a recapitalization
or reorganization of the Company other than a Corporate Transaction pursuant to which securities of the Company or of another corporation are issued with respect to the outstanding shares of Common Stock, a Participant shall be entitled to receive
after the recapitalization or reorganization for the price paid, if any, the number of replacement securities which would have been received if such Shares had been issued prior to such recapitalization or reorganization. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">19.</TD>
<TD ALIGN="left" VALIGN="top"><U>ISSUANCES OF SECURITIES.</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as expressly provided herein, no issuance by the
Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number or price of shares subject to Stock Rights. Except as
expressly provided herein, no adjustments shall be made for dividends paid in cash or in property (including without limitation, securities) of the Company prior to any issuance of Shares pursuant to a Stock Right. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">20.</TD>
<TD ALIGN="left" VALIGN="top"><U>FRACTIONAL SHARES.</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional shares shall be issued under the Plan and the
Participant shall receive from the Company cash in lieu of such fractional shares equal to the Fair Market Value thereof. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">21.</TD>
<TD ALIGN="left" VALIGN="top"><U>WITHHOLDING.</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that any federal, state, or local income taxes, employment
taxes, Federal Insurance Contributions Act withholdings or other amounts are required by applicable law or governmental regulation to be withheld from the Participant&#146;s salary, wages or other remuneration in connection with the issuance of a
Stock Right or Shares under the Plan or for any other reason required by law, the Company may withhold from the Participant&#146;s compensation, if any, or may require that the Participant advance in cash to the Company, or to any Affiliate of the
Company which employs or employed the Participant, the statutory minimum amount of such withholdings unless a different withholding arrangement, including the use of shares of the Company&#146;s Common Stock or a promissory note, is authorized by
the Administrator (and permitted by law). For purposes hereof, the fair market value of the shares withheld for purposes of payroll withholding shall be determined in the manner set forth under the definition of Fair Market Value provided in
Paragraph 1 above, as of the most recent practicable date. If the Fair Market Value of the shares withheld is less than the amount of payroll withholdings required, the Participant may be required to advance the difference in cash to the Company or
the Affiliate employer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">22.</TD>
<TD ALIGN="left" VALIGN="top"><U>TERMINATION OF THE PLAN.</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan will terminate on September&nbsp;14, 2027, the date
which is ten years from the <U>earlier</U> of the date of its adoption by the Board of Directors and the date of its approval by the shareholders of the Company. The Plan may be terminated at an earlier date by vote of the shareholders or the Board
of Directors of the Company; provided, however, that any such earlier termination shall not affect any Agreements executed prior to the effective date of such termination. Termination of the Plan shall not affect any Stock Rights theretofore
granted. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">23.</TD>
<TD ALIGN="left" VALIGN="top"><U>AMENDMENT OF THE PLAN AND AGREEMENTS.</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan may be amended by the shareholders of
the Company. The Plan may also be amended by the Administrator; provided that any amendment approved by the Administrator which the Administrator determines is of a scope that requires shareholder approval shall be subject to obtaining such
shareholder approval. Any modification or amendment of the Plan shall not, without the consent of a Participant, adversely affect his or her rights under a Stock Right previously granted to him or her. With the consent of the Participant affected,
the Administrator may amend outstanding Agreements in a manner which may be adverse to the Participant but which is not inconsistent with the Plan. In the discretion of the Administrator, outstanding Agreements may be amended by the Administrator in
a manner which is not adverse to the Participant. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">24.</TD>
<TD ALIGN="left" VALIGN="top"><U>EMPLOYMENT OR OTHER RELATIONSHIP.</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nothing in this Plan or any Agreement shall be deemed
to prevent the Company or an Affiliate from terminating the employment, consultancy or director status of a Participant, nor to prevent a Participant from terminating his or her own employment, consultancy or director status or to give any
Participant a right to be retained in employment or other service by the Company or any Affiliate for any period of time. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">25.</TD>
<TD ALIGN="left" VALIGN="top"><U>SECTION 409A.</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a Participant is a &#147;specified employee&#148; as defined in
Section&nbsp;409A of the Code (and as applied according to procedures of the Company and its Affiliates) as of his separation from service, to the extent any payment under this Plan or pursuant to the grant of a Restricted Stock Unit Award
constitutes deferred compensation (after taking into account any applicable exemptions from Section&nbsp;409A of the Code), and to the extent required by Section&nbsp;409A of the Code, no payments due under this Plan or pursuant to a Restricted
Stock Unit Award may be made until the earlier of: (i)&nbsp;the first day of the seventh month following the Participant&#146;s separation from service, or (ii)&nbsp;the Participant&#146;s date of death; provided, however, that any payments delayed
during this six-month period shall be paid in the aggregate in a lump sum, without interest, on the first day of the seventh month following the Participant&#146;s separation from service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator shall administer the Plan with a view toward ensuring that Stock Rights under the Plan that are subject to Section&nbsp;409A
of the Code comply with the requirements thereof, but neither the Administrator nor any member of the Board, nor the Company nor any of its Affiliates, nor any other person acting hereunder on behalf of the Company, the Administrator or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Board shall be liable to a Participant or any Survivor by reason of the acceleration of any income, or the imposition of any additional tax or penalty, with respect to a Stock Right, whether
by reason of a failure to satisfy the requirements of Section&nbsp;409A of the Code or otherwise. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">26.</TD>
<TD ALIGN="left" VALIGN="top"><U>INDEMNITY.</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither the Board nor the Administrator, nor any members of either, nor any
employees of the Company or any parent, subsidiary, or other Affiliate, shall be liable for any act, omission, interpretation, construction or determination made in good faith in connection with their responsibilities with respect to this Plan, and
the Company hereby agrees to indemnify the members of the Board, the members of the Committee, and the employees of the Company and its parent or subsidiaries in respect of any claim, loss, damage, or expense (including reasonable counsel fees)
arising from any such act, omission, interpretation, construction or determination to the full extent permitted by law. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">27.</TD>
<TD ALIGN="left" VALIGN="top"><U>CLAWBACK.</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary contained in this Plan, the Company
may recover from a Participant any compensation received from any Stock Right (whether or not settled) or cause a Participant to forfeit any Stock Right (whether or not vested) in the event that the Company&#146;s Clawback Policy then in effect is
triggered. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">28.</TD>
<TD ALIGN="left" VALIGN="top"><U>GOVERNING LAW.</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Plan shall be construed and enforced in accordance with the law of
the State of Delaware. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Appendix C </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MYRIAD GENETICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2013 EXECUTIVE INCENTIVE PLAN </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Adopted effective: September&nbsp;12, 2012 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Approved by the Stockholders: December&nbsp;5, 2012 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Amended September&nbsp;14, 2017 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proposed To be Re-Approved by the Stockholders: November&nbsp;30, 2017 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;1 &#151; Purposes. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Myriad Genetics
2013 Executive Incentive Plan, as amended (the &#147;<B><I>Plan</I></B>&#148;), provides for incentive compensation to those key officers and employees of Myriad Genetics, Inc. or any affiliated entity (collectively, the &#147;<B><I>Company</I></B>
&#147;), who, from time to time may be selected for participation. The Plan is intended to provide incentives and rewards for the contributions of such employees toward the successful achievement of the Company&#146;s financial and business goals
established for the applicable performance period. The Company&#146;s policy is to have a significant portion of a participant&#146;s total compensation tied to the Company&#146;s performance. Payments pursuant to the Plan are intended to qualify as
&#147;performance-based compensation&#148; within the meaning of Section&nbsp;162(m) of the Internal Revenue Code (&#147;<B><I>Section 162(m)</I></B>&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;2 &#151; Administration. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Plan shall be
administered by the Compensation Committee (the &#147;<B><I>Committee</I></B>&#148;) of the Board of Directors of Myriad Genetics, Inc. (&#147;<B><I>Myriad</I></B>&#148;) which has been designated to administer programs intended to qualify as
&#147;performance-based compensation&#148; within the meaning of Section&nbsp;162(m). The Committee shall have authority to make rules and adopt administrative procedures in connection with the Plan and shall have discretion to provide for
situations or conditions not specifically provided for herein consistent with the purposes of the Plan. The Committee shall determine the beginning and ending dates for each performance period. Unless otherwise determined by the Committee, the
performance period shall correspond to Myriad&#146;s fiscal year. Notwithstanding any other provision of the Plan to the contrary, the Plan shall be administered and its provisions interpreted so that payments pursuant to the Plan qualify as
&#147;performance-based compensation&#148; within the meaning of Section&nbsp;162(m). Determinations by the Committee shall be final and binding on the Company and all participants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3 &#151; Selection of Participants. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The executive officers of the Company as well as those other key employees of the Company who, in the opinion of the Committee, may become executive officers
of the Company or who otherwise may make comparable contributions to the Company shall be eligible to participate in the Plan. Each performance period, the Committee may designate from among those employees who are eligible to participate in the
Plan those employees who shall participate in the Plan for such performance period. Accordingly, an employee who is a participant for a given performance period in no way is guaranteed or assured of being selected for participation in any subsequent
performance period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4 &#151; Establishing Performance Objectives. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the first ninety (90)&nbsp;days of each performance period, and at a time when the achievement of such performance objective is substantially unknown,
the Committee shall establish one or more performance objectives, at least one of which shall be based on a shareholder approved business criteria. The performance objectives may differ from participant to participant and from target award to target
award. The maximum possible payout shall be based solely on shareholder approved business criteria. The shareholder approved business criteria, which shall be based on or derived from the Company&#146;s audited financial statements, are as follows:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Net income </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Earnings per share </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Total revenue </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Return on equity, including return on invested capital </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Adjusted operating income </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Adjusted operating margins </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Return on assets </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Return on investments </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Increase in sales, including sales growth </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Stock performance </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Earnings before interest, taxes, depreciations and amortization </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Gross or operating margin </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">New product introductions </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Revenues from new products, designated products or categories of products </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Completion of acquisitions </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All criteria that are based on Myriad&#146;s audited financial statements may be
modified by the Committee at the time the specific criteria are selected to take into consideration one or more of the following: (1)&nbsp;changes in accounting principles that become effective during the performance period, (2)&nbsp;extraordinary,
unusual or infrequently occurring events, (3)&nbsp;the disposition of a business or significant assets, (4)&nbsp;gains or losses from all or certain claims and/or litigation and insurance recoveries, (5)&nbsp;the impact of impairment of intangible
assets, (6)&nbsp;restructuring activities, (7)&nbsp;the impact of investments or acquisitions, and/or (8)&nbsp;changes in corporate capitalization such as stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
splits and certain reorganizations. Notwithstanding the foregoing, the Committee must select criteria that collectively satisfy the requirements of performance-based compensation for the purposes
of Section&nbsp;162(m), including by establishing the targets at a time when the performance relative to such targets is substantially uncertain. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5 &#151; Establishing Target Awards. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During
the first ninety (90)&nbsp;days of each performance period the Committee shall establish a target award, expressed as a percentage of eligible salary for that performance period, or in the case of an equity award as a designated number of Restricted
Stock Units, for each participant in the Plan. Unless otherwise determined by the Committee, eligible salary shall be annual base salary determined at the time the Committee establishes the target award, excluding pay for disability, overtime,
bonuses, sick pay and other reimbursements and allowances. Individual participants may earn an award payout ranging from zero percent to a maximum of one hundred thirty percent of their target award. The Committee will establish an award payout
schedule based upon the extent to which the Company performance objectives and/or other performance objectives are or are not achieved or exceeded. Pursuant to Section&nbsp;4, entitlement to an award shall be based solely on shareholder approved
business criteria; however, non-shareholder approved criteria may be used to reduce the amount of an award payable to one or more participants. Notwithstanding the foregoing, no participant shall receive a payment pursuant to the Plan that exceeds
$10 million for any performance period. To the extent that a target award is expressed by reference to a number of shares of the Company&#146;s common stock, for the purpose of applying the limitations on a maximum award as set forth in this
Section&nbsp;5, the value of such stock award shall be the Value of Common Stock on the grant date of the maximum number of shares subject to such award. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6 &#151; Determining Final Awards. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No later
than forty-five (45)&nbsp;days after the receipt by the Committee of the audited financial statements for a performance period, the Committee shall determine whether the established performance objectives for each participant in the Plan were
achieved. The Committee shall have discretion to reduce final awards from the target award depending on (a)&nbsp;the extent to which the Company performance objective(s) is either exceeded or not met, and (b)&nbsp;the extent to which other
objectives,<I> e.g.</I> subsidiary, division, department, unit or other performance objectives are attained. The Committee shall have full discretion to reduce individual final awards based on individual performance as it considers appropriate in
the circumstances. The Committee shall not have discretion to increase awards for the performance period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7 &#151; Termination of
Employment. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Participants whose employment by the Company is terminated for any reason other than death or disability during any performance period
will receive no payment under the Plan for such performance period. Participants who die or become totally and permanently disabled during any performance period will receive prorated payments under the Plan based on the number of whole
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
months of employment completed during the performance period. Except as provided in Section&nbsp;9, participants whose employment by the Company is terminated for any reason after the close of
the performance period but before the distribution of payments under the Plan will be paid all amounts applicable under this Plan for such performance period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8 &#151; Time of and Payment of Awards. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of awards shall be made as soon as practicable following the later of (a)&nbsp;the receipt by the Committee of the audited financial statements for the
applicable performance period or (b)&nbsp;the certification by the Committee that the performance and other criteria for payment have been satisfied (the &#147;<B><I> Certification Date</I></B> &#147;). The Committee shall have the discretion to pay
awards in the form of (i)&nbsp;cash, (ii)&nbsp;Common Stock, (iii)&nbsp;Restricted Stock, (iv)&nbsp;Stock Units, (v)&nbsp;Restricted Stock Units, or (vi)&nbsp;a combination of the foregoing. Payroll and other taxes shall be withheld as determined by
the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of this Section&nbsp;8, the following definitions shall apply: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Common Stock</I></B>&#148; shall mean common stock of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Restricted Stock</I></B>&#148; shall mean Common Stock that is subject to Vesting as set forth in the Restricted Stock Agreement
adopted by the Committee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Stock Units</I></B>&#148; shall mean an unfunded, unsecured commitment by the Company to deliver a
pre-determined number of shares of Common Stock (or the cash equivalent of such Common Stock) to a participant at a future time in accordance with the terms and conditions of a Stock Unit Agreement adopted by the Committee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Restricted Stock Unit</I></B>&#148; shall mean a Stock Unit that is subject to Vesting as set forth in the Restricted Stock Unit
Agreement adopted by the Committee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Vesting</I></B>&#148; shall mean a requirement that a participant remain an employee of
the Company, or an affiliate of the Company, for an additional period of time in order to retain the Common Stock (in the case of Restricted Stock) or the Stock Unit (in the case of a Restricted Stock Unit). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Value of Common Stock</I></B>&#148; shall mean: (a)&nbsp;if the Common Stock is listed on any established stock exchange or a
national market system, the closing sales price of the Common Stock as quoted on such exchange or system (or the exchange with the greatest volume of trading in the Common Stock) on the day of valuation, as reported in<I> The Wall Street Journal</I>
or such other source as the Committee deems reliable; and (b)&nbsp;if there is no closing sales price for the Common Stock on the day of valuation, the closing sales price on the last preceding day for which such quotation exists. Vesting shall not
be taken into account in determining the Value of Common Stock for this purpose. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event the Committee does not specify the form of the payment at the time the Committee establishes the
target award, the form of payment shall be in the form of cash unless the Committee determines (a &#147;<B><I>Retroactive Determination</I></B>&#148;) on or before the Certification Date that the form of payment will include some non-cash
consideration. In the event the Committee makes a Retroactive Determination, the total value of the payment shall not exceed the value if the payment were made only in cash. The Committee shall be deemed to be in compliance with the preceding
sentence if the sum of (i)&nbsp;the Value of Common Stock, (ii)&nbsp;the Value of Common Stock that is Restricted Stock, (iii)&nbsp;the Value of Common Stock that is subject to Stock Units or Restricted Stock Units, and (iv)&nbsp;the cash in the
payment pursuant to the Retroactive Determination would be less than or equal to an all-cash payment on both the last day of the performance period and the Certification Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares of Common Stock issued directly or as Restricted Stock or pursuant to Stock Units or Restricted Stock Units shall be issued pursuant to a shareholder
approved equity incentive plan, unless otherwise determined by the Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is the intent of the company that this Plan is exempt from
Section&nbsp;409A of the Internal Revenue Code of 1986, as amended under the &#147;short-term deferral&#148; rule and any ambiguities or inconsistencies herein will be interpreted in a manner consistent with the short-term deferral rule. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;9 &#151; Forfeiture. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It shall be an
overriding precondition to the payment of any award (a)&nbsp;that the participant not engage in any activity that, in the opinion of the Committee, is in competition with any activity of the Company or any affiliated entity or otherwise inimical to
the best interests of the Company and (b)&nbsp;that the participant furnish the Committee with all such information confirming satisfaction of the foregoing condition as the Committee shall reasonably request. If the Committee makes a determination
that a participant has engaged in any such competitive or otherwise inimical activity, such determination shall operate to immediately cancel all then unpaid award amounts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;10 &#151; Death. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any award remaining
unpaid, in whole or in part, at the death of a participant shall be paid to the participant&#146;s legal representative or to a beneficiary designated by the participant in accordance with the rules established by the Committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;11 &#151; Change in Control. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A target award may, in accordance with Treasury Regulation &#167;1.162-27(e)(2)(v), provide that all or a portion of the target award may be paid upon a change
in control, provided that the participant remains employed through the date of the change in control. A change in control shall mean a transaction in which any one person, entity or group acquires (i)&nbsp;stock in the Company that, together with
the stock in the Company already held by such person, entity or group, constitutes more than 50% of the total fair market value or total voting power of the stock of the Company or (ii)&nbsp;more than 80% of the assets of the Company. The definition
of change in control for purposes of this Plan be interpreted, to the extent applicable, to comply with Section&nbsp;409A(a)(2)(A)(v) of the Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;12 &#151; No Right to Employment or Award. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No person shall have any claim or right to receive an award, and selection to participate in the Plan shall not confer upon any employee any right with respect
to continued employment by the Company or continued participation in the Plan. Further the Company reaffirms its at-will relationship with its employees and expressly reserves the right at any time to dismiss a participant free from any liability or
claim for benefits pursuant to the Plan, except as provided under this Plan or other written plan adopted by the Company or written agreement between the Company and the participant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13 &#151; Discretion of Company, Board of Directors and Committee. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any decision made or action taken by the Company or by the Board of Directors of Myriad or by the Committee arising out of or in connection with the creation,
amendment, construction, administration, interpretation or effect of the Plan shall be within the absolute discretion of the Company, the Board of Directors, or the Committee, as the case may be, and shall be conclusive and binding upon all persons.
To the maximum extent possible, no member of the Committee shall have any liability for actions taken or omitted under the Plan by such member or any other person. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;14 &#151; No Funding of Plan. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
shall not be required to fund or otherwise segregate any cash or any other assets which may at any time be paid to participants under the Plan. The Plan shall constitute an &#147;unfunded&#148; plan of the Company. The Company shall not, by any
provisions of the Plan, be deemed to be a trustee of any property, and any rights of any participant or former participant shall be no greater than those of a general unsecured creditor or shareholder of the Company, as the case may be. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;15 &#151; Non-Transferability of Benefits and Interests. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as expressly provided by the Committee, no benefit payable under the Plan shall be subject in any manner to anticipation, alienation, sale, transfer,
assignment, pledge, encumbrance or charge, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any such attempted action shall be void, and no such benefit shall be in any manner liable for or subject to debts, contracts, liabilities, engagements or torts of any participant or former
participant. This Section&nbsp;15 shall not apply to an assignment of a contingency or payment due (i)&nbsp;after the death of a participant to the deceased participant&#146;s legal representative or beneficiary or (ii)&nbsp;after the disability of
a participant to the disabled participant&#146;s personal representative. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;16 &#151; Law to Govern. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All questions pertaining to the construction, regulation, validity and effect of the provisions of the Plan shall be determined in accordance with the laws of
the State of Utah. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;17 &#151; Non-Exclusivity. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Plan does not limit the authority of the Company, the Board of Directors or the Committee, or any current or future subsidiary of the Company to grant
awards or authorize any other compensation to any person under any other plan or authority, other than that specifically prohibited herein. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;18 &#151; Section&nbsp;162(m) Conditions; Bifurcation of Plan. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is the intent of the Company that the Plan and all payments made hereunder satisfy and be interpreted in a manner that, in the case of participants who are
persons whose compensation is subject to Section&nbsp;162(m), satisfies any applicable requirements as performance-based compensation. Any provision, application or interpretation of the Plan inconsistent with this intent to satisfy the standards in
Section&nbsp;162(m) shall be disregarded. Notwithstanding anything to the contrary in the Plan, the provisions of the Plan may at any time be bifurcated by the Board of Directors or the Committee in any manner so that certain provisions of the Plan
or any payment intended (or required in order) to satisfy the applicable requirements of Section&nbsp;162(m) are only applicable to persons whose compensation is subject to Section&nbsp;162(m). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;19 &#151; Arbitration of Disputes. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>The Federal Arbitration Act shall apply to and govern all disputes arising under or pursuant to the Plan. Any disputes with respect to the terms of this
Plan or any rights granted hereunder, including, without limitation, the scope of this arbitration, shall be subject to arbitration pursuant to the rules of the American Arbitration Association governing commercial disputes. Arbitration shall occur
in Salt Lake City, Utah. Judgment on any arbitration award may be entered in any court having jurisdiction. A single arbitrator shall be used unless the amount in dispute exceeds $200,000 and a party to the arbitration proceeding requests that the
arbitration be heard by a panel of three arbitrators. If a panel of three arbitrators is used, the arbitration decision shall be made by a majority of the three arbitrators. By electing to participate in the Plan, the Company and each participant<B>
<U>EXPRESSLY AGREE TO ARBITRATION AND WAIVE ANY RIGHT TO TRIAL BY</U> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>
<U></U><U>JURY, JUDGE, OR ADMINISTRATIVE PROCEEDING.</U> </B>An arbitrator shall have the same powers that a judge for a United States District Court located in the State of Utah may exercise in
comparable circumstances. Nothing in this Plan shall limit or restrict any right of offset a party may have.<B> </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;20 &#151; Effective
Date. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Plan, as amended, is effective as of September&nbsp;14, 2017, subject to approval by the Company&#146;s stockholders at the 2017 Annual
Meeting of Stockholders of the Company. However, if the Plan does not receive stockholder approval, no future awards will be made under the Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;21 &#151; Amendment or Termination. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Board of Directors of the Company and the Committee each reserves the right at any time to make any changes in the Plan as it may consider desirable or may suspend, discontinue or terminate the Plan at any time. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Myriad Genetics, Inc., a Delaware corporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Mark C. Capone</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Mark C. Capone</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Richard M. Marsh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Richard M. Marsh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Secretary</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><B><I>MYRIAD GENETICS, INC.</I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><B><I>ATTN: CORPORATE SECRETARY</I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><B><I>320 WAKARA WAY</I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><B><I>SALT LAKE CITY, UT 84108</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>VOTE BY INTERNET <FONT STYLE="white-space:nowrap">-</FONT> <U>www.proxyvote.com</U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 P.M. Eastern Time on November 29, 2017. Have
your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form.</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>ELECTRONIC DELIVERY OF FUTURE PROXY MATERIALS</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If you would
like to reduce the costs incurred by our company in mailing proxy materials, you can consent to receiving all future notices of availability of proxy materials or proxy statements, proxy cards and annual reports electronically via e-mail or the
Internet. To sign up for electronic delivery, please follow the instructions above to vote using the Internet and, when prompted, indicate that you agree to receive or access proxy materials electronically in future years.</P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>VOTE BY PHONE - 1-800-690-6903</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Use any touch-tone telephone to transmit your voting instructions up until 11:59 P.M. Eastern Time on November 29, 2017. Have your proxy card in hand when you
call and then follow the instructions.</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>VOTE BY MAIL</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge,
51&nbsp;Mercedes Way, Edgewood, NY 11717.</P></TD></TR>
</TABLE> <P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">E33275-P97723&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;KEEP THIS PORTION FOR YOUR RECORDS
</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px dashed #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">DETACH AND RETURN THIS PORTION ONLY
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1.50pt;background-color:;;padding-top:2pt;padding-bottom:3pt">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>&nbsp;&nbsp;MYRIAD GENETICS, INC.</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:1pt; margin-left:1.50em; font-size:8pt; font-family:Times New Roman"><B>The Board of Directors recommends that you vote FOR the following:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>For</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>All</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Withhold</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>All</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:8pt"><B>For&nbsp;All Except</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ROWSPAN="2" VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:8pt">To withhold authority to vote for any individual nominee(s), mark &#147;For All Except&#148; and write the number(s) of the nominee(s) on the line below.</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="3"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g462900snap1.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; font-size:8pt; font-family:Times New Roman"><B>Vote on Directors</B></P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:8pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:8pt; font-family:Times New Roman">1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Election of three Class III Directors (or if any nominee is not available for election, such substitute as the Board of Directors may
designate) for a three-year term.</P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Nominees:</B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">01)&nbsp;&nbsp;Walter Gilbert Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">02)&nbsp;&nbsp;Dennis H. Langer M.D., J.D.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">03)&nbsp;&nbsp;Lawrence
C. Best</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:1.50em; font-size:8pt; font-family:Times New Roman"><B>Vote on Proposals</B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:1pt; margin-left:1.50em; font-size:8pt; font-family:Times New Roman"><B>The Board of Directors recommends you vote FOR the following
proposals:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>For</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Against</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Abstain</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt"><B>The Board of Directors recommends you vote 1&nbsp;year on the following proposal:</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>1&nbsp;Year</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2&nbsp;Years</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>3&nbsp;Years</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Abstain</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:2pt; margin-bottom:1pt; margin-left:1.50em; font-size:8pt; font-family:Times New Roman">2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:2pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">To approve the proposed 2017 Employee, Director and Consultant Equity
Incentive Plan.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:2pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:2pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:2pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:2pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:8pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To approve, on an advisory basis, on the frequency of holding an advisory vote on the
compensation of our named executive officers.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:2pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:2pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:2pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:2pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:8pt; font-family:Times New Roman">3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:8pt">To re-approve our 2013 Executive Incentive Plan, as amended.</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="3"> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">In their discretion, the proxies are authorized to vote upon
such other matters as may properly come before the meeting or any adjournments or postponements thereof. This Proxy, when executed, will be voted in the manner directed herein. If no direction is made, this proxy will be voted in accordance with the
Board of Directors&#146; recommendations.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:2pt; margin-bottom:1pt; margin-left:1.50em; font-size:8pt; font-family:Times New Roman">4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:2pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">To ratify the selection of Ernst &amp; Young LLP as our independent
registered public accounting firm for the fiscal year ending June&nbsp;30, 2018.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:2pt; margin-bottom:1pt; margin-left:1.50em; font-size:8pt; font-family:Times New Roman">5.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:2pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">To approve, on an advisory basis, the compensation of our named executive
officers, as disclosed in the proxy statement.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="15"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="15"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:1.50em; font-size:8pt; font-family:Times New Roman"><B>PLEASE MARK, SIGN, DATE AND RETURN
PROMPTLY IN THE ENCLOSED ENVELOPE.</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:1.50em; font-size:8pt; font-family:Times New Roman"><B>NOTE: </B>Please sign
exactly as name(s) appear(s) hereon. Joint owners should each</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; font-size:8pt; font-family:Times New Roman">sign. When signing as attorney, executor, administrator, trustee or
guardian, please</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; font-size:8pt; font-family:Times New Roman">give full title as such.</P> <P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>


<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Signature&nbsp;[PLEASE&nbsp;SIGN&nbsp;WITHIN&nbsp;BOX]</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">Signature (Joint Owners)</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV> </div>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting:
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The Notice and Proxy Statement and Annual Report are available at www.proxyvote.com. </P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px dashed #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">E33276-P97723&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="92%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:2.00pt solid #000000; BORDER-TOP:2.00pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000"> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>MYRIAD
GENETICS, INC.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">320 Wakara Way</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">Salt Lake City, Utah 84108</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>ANNUAL MEETING OF STOCKHOLDERS NOVEMBER 30, 2017</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>THIS PROXY IS BEING SOLICITED BY MYRIAD GENETICS, INC.&#146;S</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>BOARD OF DIRECTORS</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-RIGHT:2.00pt solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:2.00pt solid #000000; BORDER-BOTTOM:2.00pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #000000"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">The
undersigned, revoking any previous proxies relating to these shares, hereby acknowledges receipt of the Notice Regarding the Availability of Proxy Materials in connection with the 2017 Annual Meeting of Stockholders to be held at 9:00 a.m., MST, on
Thursday, November 30, 2017, at the offices of Myriad Genetics, Inc., 320 Wakara Way, Salt Lake City,<B> </B>Utah 84108 and hereby appoints Mark C. Capone and R. Bryan Riggsbee, and each of them (with full power to act alone),<B> </B>the attorneys
and proxies of the undersigned, with power of substitution to each, and authorizes each of them to represent the undersigned and to vote all shares of the Common Stock of MYRIAD GENETICS, INC. registered in the name provided herein which the
undersigned is/are entitled to vote at the 2017 Annual Meeting of Stockholders, and at any adjournments or postponements thereof, with all the powers the undersigned would have if personally present. Without limiting the general authorization hereby
given, said proxies are, and each of them is, instructed to vote or act on the proposals set forth in said Proxy as specified by the undersigned.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SEE REVERSE SIDE FOR ALL PROPOSALS. <B>The proxies will vote in accordance with the Board of Directors&#146; recommendations where a choice is not specified
and in their discretion on any other matters as may properly come before the meeting or any adjournments or postponements thereof.</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Continued and to be signed on reverse side</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:2.00pt solid #000000; BORDER-BOTTOM:2.00pt solid #000000; padding-right:2pt">&nbsp;</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g462900g05h24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g462900g05h24.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@!&8(I9B
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MO)&6#2K_ 'F5@-OZ9_NCN ;M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M9SF.%5/Z"@"[0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 A(4$D@ =2: ,^77]&@D\N75K*-_[K7" ^G3/N* (_\
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MRA_X]E(Y /\ ST(Z#^'.X]@P!LV]O#:6T5M;QK'#"@2-%Z*H& !^% $E !0
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MA9W.[[1:0R[NN^,-G\Z )(H(8,^5$D>>NU0,T 24 % !0 4 % !0 4 % !0
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M1_I'G^=Y<'^D3;/M.WR/W$W[X;(%V_*_&=O;'[L ^Q_"?_(FZ'_UX0?^BUH
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M@S$IQ@#.,L?X!G^)L#@\\' !B0_&GP-/]GV:OCSY3$F^,IAOEY;.-J_,/F;
MZ\\'  0_&GP-/]GV:OCSY3$F^,IAOEY;.-J_,/F; Z\\'  ZV^,W@B[DM8X=
M5.ZYF\B,-&5.[Y?O9^Z/F'S' Z\\' !WU !0 4 % !0!\\?'IMGCS2TQ"//L
M$CV-/L6Z_P!(SY4_[Q=D0QN#X'.>>,H >3V]QYGD?Z1Y_G>7!_I$VS[3M\C]
MQ-^^&R!=OROQG;VQ^[ "WN/,\C_2//\ .\N#_2)MGVG;Y'[B;]\-D"[?E?C.
MWMC]V 3:9<>9>V)^TM-YTD4&9I=IN-I@_<3#S1LA3;\K\9VCIC]V ?;- !0
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M9V]L?NP"SH]QYFIZ<?M32^=-#!F67:UQM,'[B4>;\D*;?E; SM'3'[L ^UJ
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M_P!(FV?:=OD?N)OWPV0+M^5^,[>V/W8!]C^$_P#D3=#_ .O"#_T6M &Q0 4
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M[9H * "@ H * /GOX]ML\:Z2F(1Y]DL>QI]BW7^D ^5.?,79$,;@_'(Z\90
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MV1<;MW'(Z\90 \AM[CS/(_TCS_.\N#_2)MGVG;Y'[B;]\-D"[?E?C.WMC]V
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M@ H * "@ H * /GCX]-L\>:6F(1Y]@D>QI]BW7^D9\J?]XNR(8W!\#G//&4
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M!_I$VS[3M\C]Q-^^&R!=OROQG;VQ^[ /L?PG_P B;H?_ %X0?^BUH V* "@
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MR!=OROQG;VQ^[ 'V5QYDUK_I!F\YHH/W\VPW&WR/W$W[X;($V_*_&=O;'[L
M^W* "@ H * "@#Y^^/C;?%^C)^Z'GV@C\MIMB7/[]3Y<Q\Q=D7&[=QR.O&4
M/(;>X\SR/](\_P [RX/](FV?:=OD?N)OWPV0+M^5^,[>V/W8 6]QYGD?Z1Y_
MG>7!_I$VS[3M\C]Q-^^&R!=OROQG;VQ^[ "WN/,\C_2//\[RX/\ 2)MGVG;Y
M'[B;]\-D"[?E?C.WMC]V ?9?AK_D5=(_Z\X?_0!0!J4 % !0 4 > _'UMOBG
M1(\QCS[;R_+:;8ES^_0^7,?,79'QNW<<CKQE0#QZWN/,\C_2//\ .\N#_2)M
MGVG;Y'[B;]\-D"[?E?C.WMC]V %O<>9Y'^D>?YWEP?Z1-L^T[?(_<3?OAL@7
M;\K\9V]L?NP M[CS/(_TCS_.\N#_ $B;9]IV^1^XF_?#9 NWY7XSM[8_=@'V
M/X3_ .1-T/\ Z\(/_1:T ;% !0 4 % !0 4 ?/'QZ;9X\TM,0CS[!(]C3[%N
MO](SY4_[Q=D0QN#X'.>>,H >3V]QYGD?Z1Y_G>7!_I$VS[3M\C]Q-^^&R!=O
MROQG;VQ^[ "WN/,\C_2//\[RX/\ 2)MGVG;Y'[B;]\-D"[?E?C.WMC]V 6='
MN/,U/3C]J:7SIH8,RR[6N-I@_<2CS?DA3;\K8&=HZ8_=@'VM0 4 % !0 4 ?
M/'QZ;9X\TM,0CS[!(]C3[%NO](SY4_[Q=D0QN#X'.>>,H >3V]QYGD?Z1Y_G
M>7!_I$VS[3M\C]Q-^^&R!=OROQG;VQ^[ "WN/,\C_2//\[RX/](FV?:=OD?N
M)OWPV0+M^5^,[>V/W8!-IEQYE[8G[2TWG2109FEVFXVF#]Q,/-&R%-OROQG:
M.F/W8!]LT % !0 4 % 'SW\>VV>-=)3$(\^R6/8T^Q;K_2 ?*G/F+LB&-P?C
MD=>,H >26]QYGD?Z1Y_G>7!_I$VS[3M\C]Q-^^&R!=OROQG;VQ^[ "WN/,\C
M_2//\[RX/](FV?:=OD?N)OWPV0+M^5^,[>V/W8 ^RN/,FM?](,WG-%!^_FV&
MXV^1^XF_?#9 FWY7XSM[8_=@'VY0 4 % !0 4 ?/WQ\;;XOT9/W0\^T$?EM-
ML2Y_?J?+F/F+LBXW;N.1UXR@!Y#;W'F>1_I'G^=Y<'^D3;/M.WR/W$W[X;(%
MV_*_&=O;'[L +>X\SR/](\_SO+@_TB;9]IV^1^XF_?#9 NWY7XSM[8_=@!;W
M'F>1_I'G^=Y<'^D3;/M.WR/W$W[X;(%V_*_&=O;'[L ^R_#7_(JZ1_UYP_\
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MYGD?Z1Y_G>7!_I$VS[3M\C]Q-^^&R!=OROQG;VQ^[ "WN/,\C_2//\[RX/\
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M3O/S3_XF@"&:UNK9[=XKVZE_?*K*VTC:3SG"T :M !0 4 % !0 4 % !0 4
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M'O0!<H * (VGA6X2W:5!,ZEEC+#<P&,D#N!D9^HH#S"2>&%XDEE1&E;9&&8
MNV"<#U. 3CT!H#S)* "@ H * "@".&>&X0O#*DB*S(2C @,I(8<=P00?<4/1
M78=;!!/%<P1SV\J2PR*&21&#*P/0@CJ*;36C DI % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0!XW\?I-MAH,7F?ZZ=D\AWV0W'S1
MG9*^]-J<9)SP5'3[P /*/AQ=;O'GA]OMLS>;/'#YA;,DVT0_N9%\P[8DV_(V
MWDJ..,1@'U1XDED@\+ZM+#(T<J6DK(Z'!4A#@@CH:SJWY'8UHI.I%/N<!I^K
MZYH%MK ^SR&\!LHK>TFU"2^!,K%?.#S,AP<XV;E&8^HSFMWK[JWYFO2RO;SV
MT]>^ASQ>BD_Y;^O^5NOEY69K_P#"6>(M*MU;7M+C@>:.9+?Y%0RS+M,:D++(
M%W;F&-Q/R$]\"-_=CN[6^^S_ #B_O[%K3WI?"GKZ6O\ HU]Q+%XA\57'B>:S
MM]*CFT^SN([>YD5$'5%9WW&8,N-^0OEMD#KSPFTHN?3WK?*Z7K=KRW^].Z27
M6RO\]_P]=58JV_B[7XM"_M*\_L^0W&B2ZG D4#IY3(JG:Q+G>#O'3;C'?K6C
MBHR<7T<?Q;O]UM_P1JHWJJ/2[7W,OZ]XLO\ 3WOX;"WAN)HDLQ"O!.^>1DYR
MZ@X ! W+GU&<B+-NR_F:^Z*E_7]7QC)."D_Y;_C;[N_S-GPW=:S=::[:[9"T
MNUE*J JKO3C#;5DD"]2,;STSQG%4[65OZ_I KW=_Z_IFQ4E&!XQ\/W/BC0O[
M'AU&2PM[B51=R0_?>#G<BGL6X'I@G.1P0#@[>=O%]S%X1\# :;X+TEQ'?ZC!
MTN"#DP0G^+/5GYSDDY!'F '<>.25\+2E]_V030_;-@)_T?S%\W..=NS=GVS2
M]WGCS;7_ $=OQMY=]!KFY9<F]M/^!YVO;SL<UK&JZ1I6CVY\#W>AZ?:3W8CO
M+RTDAAAC_=L0&D$<B*Q(4?,IZ@<9!I^]=)Z+7YO3]-?EY6"RLVEKI\EW_3YB
M7.JZK%9Z=J<=U::CJ<>BZ@\<]J_G12,'AVD%57=T&<*.0<#M3EIS=/@OTM>]
MWUTZ]=!T_>CKK[WZ2LNFO0S%U>[NHM.FU#Q?I\EM#J2D7UI>07+6P-O.&WL(
M8T4'C&Y3C)R3QAZ)ZZ:/_P!MTOM>_P":2U=R(MN,EOI'_P!*WMZ?DSH=(U/5
MM6N]&MUUN;[-(MY(;F*&+==I%-&L;<H5 *L>5 !SD8XP175K91=O6_Y[VW\^
M[E91:3ZI7^3;\M'I\C.AE*^)-"N)M7.FP-?:C $C6&*.5Q<85#E.6<#!P=QQ
MD<Y)FE\27]Q:?=>WY_+M<JMHGZK7_MS?^N_I;H-#U;4[OQ!-I%S/N?3#*;MP
M@'F!FS!VX^3)..XHAK#F?9+Y]7^%_22)GI*RZN_RMM][M?\ NLRO%7A]_$7B
MZXM(]/TZ9SIL:B[NB?,L\R2?O(@$.6'7[R\@<TJ>DG+:SCKUTN[?U]S*D[1B
MM_BT>WV=_P"OFBS>^*7L=6O=*DU.-+T:G:16T#A?,:W<0AR%QDJ29!N['C(P
M*N%IN-O[U_DFU^A$ER1_[=7WW:_+_,SM!U.2WUR.RM]<,LLVJWJSZ5LC_=Q>
M9,WF_=WCY@OS%MISC&:QWI6W]S[M%;^GO>ZT+JZ2;V^&WGHD_NUV[>HRWU"Z
MTWPOX=N+..)KB+PU/,C-"'8,JP8P<;L<G(!YXST%=%6WM)W=E>-WV3;N_DM=
M="FKMV5WSRT[_%I\VDKFH+J"\30Q8^)!K:RZB\?VTK;2-$?LTIPA2,*I! /3
M/)!X.*AIZV5O=?YHSBUR-O7X?_2D8&A:[?Z-X5TUH-9;4A/')8B*3RF:VO3C
MRT.Q01_%D-D]*2]Y1BM.:,;/_P!*];)W_P"W7?6]W*T92D^CE==U=V^]JW_;
MQVVNJ\<WAQ7D,CK?J&<@ L?)DYP.*F<K2<HZ:2_(235)I_W?_2HG)6M[XDGT
MJTN7\478:XT1M1;9;6XVR*%PJYC/RG?R#D\#!'(IUG[&-22UY;/[^;\-/7S9
MHDG64.C<E\DTOOU_X':;7?%-U'*Y_P"$A&E2#28+NUMUCB/VF=S)^[^=26SM
M4;5PWH:TE'EJ2BM;2LEW6G]7Z7UW1E2M*G"4G:Z=WVT7RZLEN/%5V/B!9V%O
MJ3*AN5M[K3YYH0PS%NW)&(_,*YQ\[.!G@ BIIZRMNGS?A?[MM-V^VS%)M4TW
MH]/Q:[[[]-K;W31G:WJDFIZ%JKR^+YH+ZVNLS:=%]G7[+&ER%#$&,N % ;<S
M8.<].*B.U.5]+QN^S>Z^3[]M>I<MYQMTE9=U9_FM=-KVW/3+!XY-/MGBO/ML
M;1J5N<J?.&/OY4!3GKP /2M):-W5B5MN6*D84 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0!1U/1M-UJ P:E917<)&TI*NX$9!P1W&54_51Z4 5+7PEX?L;P7
M=KI%M#<A$C\Q$PVU-NQ<^@V)@=!M'H* -:6*.>%X9HUDB=2K(XR&!Z@CN*+7
M&FT[HKW&EZ?=HZ7-C;S+)%Y+B2)6#1]=AR.5]NE)J][_ -6V^X2TM;H0V^@:
M-9VL=K;:1906\4HGCBCMT5$D'1P ,!O?K57=T^PK+5=Q9]!T>ZU./4[C2;*6
M_BQLN9+=&E7'3#$9&*25KVZ_\-^0WKHR=-/LHTC1+.!4BB,**(P D9QE!Z+P
M..G H?O7OUW'=IW*MOX<T*TLIK*VT6PAM9UVRPQVR*D@YX90,$<GKZT/56>P
MEH[HL:?I>GZ1;?9M,L;:RM]Q;RK>)8UR>IPH S3;;W$DEL6Z0R&[M(+ZTFM+
MJ)9;>92DD;='4\$'U!'&* (+?2-.L]*&EVME#!8!2HMXD")@G)&!ZDG/KDYZ
MT 7: "@ H * "@ H KV]C;VMQ<SQ(1+<N'E8L3N(4*.O08 X''YFA:*R_K^O
M^ #U=_E_7WEB@ H * "@ H KW-C;W<MM).A=K:3S8OF( ;!&2!P>&/7Z]10M
M'?\ K^OZZATM_7<L4 % %=;*W34);Y8\7,L:1.^3RJEBHQTX+M^="T5@>MO+
M]?\ ABQ0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
/ 4 % !0 4 % !0 4 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g462900g08i11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g462900g08i11.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M2?\ 0*TS_P &,G_QB@ ^T^)/^@5IG_@QD_\ C% !]I\2?] K3/\ P8R?_&*
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M /M/B3_H%:9_X,9/_C% !]I\2?\ 0*TS_P &,G_QB@ ^T^)/^@5IG_@QD_\
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M2?\ 0*TS_P &,G_QB@ ^T^)/^@5IG_@QD_\ C% !]I\2?] K3/\ P8R?_&*
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M /M/B3_H%:9_X,9/_C% !]I\2?\ 0*TS_P &,G_QB@ ^T^)/^@5IG_@QD_\
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M%<6\D$B@YPVR15;:<$!L8)5@#P< &A0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M (Y0 ?VC=?\ 0&O?^^X?_CE !_:-U_T!KW_ON'_XY0 ?VC=?] :]_P"^X?\
MXY0 ?VC=?] :]_[[A_\ CE !_:-U_P! :]_[[A_^.4 ']HW7_0&O?^^X?_CE
M !_:-U_T!KW_ +[A_P#CE !_:-U_T!KW_ON'_P".4 ']HW7_ $!KW_ON'_XY
M0 ?VC=?] :]_[[A_^.4 ']HW7_0&O?\ ON'_ ..4 ']HW7_0&O?^^X?_ (Y0
M ?VC=?\ 0&O?^^X?_CE !_:-U_T!KW_ON'_XY0 ?VC=?] :]_P"^X?\ XY0
M?VC=?] :]_[[A_\ CE !_:-U_P! :]_[[A_^.4 ']HW7_0&O?^^X?_CE !_:
M-U_T!KW_ +[A_P#CE !_:-U_T!KW_ON'_P".4 ']HW7_ $!KW_ON'_XY0 ?V
MC=?] :]_[[A_^.4 ']HW7_0&O?\ ON'_ ..4 ']HW7_0&O?^^X?_ (Y0 ?VC
M=?\ 0&O?^^X?_CE !_:-U_T!KW_ON'_XY0 ?VC=?] :]_P"^X?\ XY0 ?VC=
M?] :]_[[A_\ CE !_:-U_P! :]_[[A_^.4 ']HW7_0&O?^^X?_CE !_:-U_T
M!KW_ +[A_P#CE !_:-U_T!KW_ON'_P".4 ']HW7_ $!KW_ON'_XY0 ?VC=?]
M :]_[[A_^.4 -?59(BAFTN[B1Y$CWLT1 +,%&<.3U([4 .U[_D7M3_Z]9?\
MT$T &@_\B]IG_7K%_P"@B@"/Q+_R*NK_ /7G-_Z : -2@"NEC;QZC-?K'BZF
MB2&1\GE$+E1CIP9'_/V% %/3?#NF:3<-/9P.C[?+0/,\BPID'9$K$B-.%^5
M!\J\?*, !#X=TRWU0ZC' XGW-(JF9S$CMG<Z1$[$<Y;+* 3N;)^8Y +%SI=I
M>6]S;W"/)'<,'8-*WRL NTH<Y0@JI!7&&&X<\T 1VNB:=9Z=/8);^;;W&[SQ
M<.T[39&T^8SDE_E 7YB> !T % !IFBV6D>:;59FDEQOEN+B2>1@,X7?(S-M&
M20N< LQ Y.0#0H P?&__ "(/B/\ [!MQ_P"BFH V+3_CS@_ZYK_*@":@ H *
M "@ H * "@ H * .,T+0K;6;.[OKZ]U9IVU&]3]WJUU$H5+F5% 5) H 50.!
MVH T_P#A#=+_ .?K6?\ P=WG_P =H /^$-TO_GZUG_P=WG_QV@ _X0W2_P#G
MZUG_ ,'=Y_\ ': #_A#=+_Y^M9_\'=Y_\=H /^$-TO\ Y^M9_P#!W>?_ !V@
M _X0W2_^?K6?_!W>?_': #_A#=+_ .?K6?\ P=WG_P =H /^$-TO_GZUG_P=
MWG_QV@ _X0W2_P#GZUG_ ,'=Y_\ ': #_A#=+_Y^M9_\'=Y_\=H /^$-TO\
MY^M9_P#!W>?_ !V@ _X0W2_^?K6?_!W>?_': #_A#=+_ .?K6?\ P=WG_P =
MH /^$-TO_GZUG_P=WG_QV@ _X0W2_P#GZUG_ ,'=Y_\ ': #_A#=+_Y^M9_\
M'=Y_\=H /^$-TO\ Y^M9_P#!W>?_ !V@ _X0W2_^?K6?_!W>?_': #_A#=+_
M .?K6?\ P=WG_P =H /^$-TO_GZUG_P=WG_QV@ _X0W2_P#GZUG_ ,'=Y_\
M': #_A#=+_Y^M9_\'=Y_\=H S=9T.WT4:;=V-YJJR_VA;1D2ZK<RJRM*JL"K
MR%2"">HH [*@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H S]9_X\8_^OJW_P#1R4 &O?\ (O:G
M_P!>LO\ Z": #0?^1>TS_KUB_P#010!'XE_Y%75_^O.;_P! - &I0 4 % !0
M 4 % !0 4 8/C?\ Y$'Q'_V#;C_T4U &Q:?\><'_ %S7^5 $U !0 4 % !0
M4 % !0 4 <_X-_Y =S_V%-0_]+)J .@H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H Y_Q=_QXZ;_ -A2T_\ 1RT =!0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M, 1CAE(*GW!!% !!!#:V\5O;Q)#!$H2..-0JHH&  !P !VH DH * "@ H *
M"@ H KV]C;VD]W-!'LDNY1-,<D[G"*@//3Y44<>GUH L4 % !0 4 % !0 4
M<_XN_P"/'3?^PI:?^CEH Z"@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H S]9_X\8_^OJW_P#1
MR4 &O?\ (O:G_P!>LO\ Z": #0?^1>TS_KUB_P#010!'XE_Y%75_^O.;_P!
M- &I0 4 % !0 4 % !0 4 8/C?\ Y$'Q'_V#;C_T4U &Q:?\><'_ %S7^5 $
MU !0 4 % !0 4 % !0 4 <_X-_Y =S_V%-0_]+)J .@H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H Y_Q=_QXZ;_ -A2T_\ 1RT =!0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 9^L_\>,?_ %]6_P#Z.2@ U[_D7M3_ .O67_T$T &@
M_P#(O:9_UZQ?^@B@"/Q+_P BKJ__ %YS?^@&@#4H * "@ H * "@ H * ,'Q
MO_R(/B/_ +!MQ_Z*:@#8M/\ CS@_ZYK_ "H FH * "@ H * "@ H * "@#G_
M  ;_ ,@.Y_["FH?^EDU '04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 <_XN_X\=-_["EI_Z.6@#H* "@ H * "@ H * "@ H * "@
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M_HY: .@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M6TCB$BQRXBW&1 Q20%5PVW+*C5!F4_#7A+6-/U+3Y-1T9Y+N"=U%RUQ"\44
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MT M&_P#!O+_\C4 'VSQA_P! +1O_  ;R_P#R-0 ?;/&'_0"T;_P;R_\ R-0
M?;/&'_0"T;_P;R__ "-0 ?;/&'_0"T;_ ,&\O_R-0 ?;/&'_ $ M&_\ !O+_
M /(U !]L\8?] +1O_!O+_P#(U !]L\8?] +1O_!O+_\ (U !]L\8?] +1O\
MP;R__(U !]L\8?\ 0"T;_P &\O\ \C4 'VSQA_T M&_\&\O_ ,C4 'VSQA_T
M M&_\&\O_P C4 'VSQA_T M&_P#!O+_\C4 'VSQA_P! +1O_  ;R_P#R-0 ?
M;/&'_0"T;_P;R_\ R-0 ?;/&'_0"T;_P;R__ "-0 ?;/&'_0"T;_ ,&\O_R-
M0 ?;/&'_ $ M&_\ !O+_ /(U !]L\8?] +1O_!O+_P#(U !]L\8?] +1O_!O
M+_\ (U !]L\8?] +1O\ P;R__(U !]L\8?\ 0"T;_P &\O\ \C4 'VSQA_T
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M_P#84U#_ -+)J .@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M ,BKJ_\ UYS?^@&@#4H * "@ H * "@ H * ,'QO_P B#XC_ .P;<?\ HIJ
M-BT_X\X/^N:_RH FH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * ,_6?\
MCQC_ .OJW_\ 1R4 &O?\B]J?_7K+_P"@F@ T'_D7M,_Z]8O_ $$4 1^)?^15
MU?\ Z\YO_0#0!J4 % !0 4 % !0 4 % &#XW_P"1!\1_]@VX_P#134 ;%I_Q
MYP?]<U_E0!-0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MA0I#;@&/"LRA6.-I.Y-P!H:EJ4.F6ZR2*\LDC>7#!$ 9)G()"*"0,X!.20
M6) !( *</B2S^QW,U['-I\UKM\ZUN%!E7<<)@(6#[SPNPMELJ/F!4 $FFZT+
MVX:TN;"ZTV\"^8MO=&,M(@(!=3&S*0"0" <C*Y #+D U* ,'QO\ \B#XC_[!
MMQ_Z*:@#8M/^/.#_ *YK_*@":@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H K7>H6EB%^TW"1LWW5)RS?11R?PK6G2G4^!&U*A4
MJ_ K_E\WLBK]NO[KBRL#&G_/6[.P?@@^8_CMK3V5.'\25_):_CM]US;V-&G_
M !)W?:.OX[?=</[)>XYU"]EN?^F:?NH_^^1R?HQ-'MU#^%%+SW?X_HD'UE0_
M@Q4?/=_>_P!$ATV@Z1.D:2Z;;,L0P@\H84>U*.*KQ;:F]?,4,;B8-N-1Z^9<
MMK:"SMTM[:%(H4^ZB# '>LISE4ES2=V<]2I.K)SF[MDM00% !0 4 % !0 4
M% !0 4 % !0 4 9^L_\ 'C'_ -?5O_Z.2@ U[_D7M3_Z]9?_ $$T &@_\B]I
MG_7K%_Z"* (_$O\ R*NK_P#7G-_Z : -">>&UMY;BXE2&")2\DDC!510,DDG
M@ #O0!Q?B*PO-;\/>(]5-I,&DT:XM-.M3&?.VNI+L5ZAI"L6$()41C[K,R@
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M_P _VC?^ <O_ ,<H /)\8?\ /]HW_@'+_P#'* #R?&'_ #_:-_X!R_\ QR@
M\GQA_P _VC?^ <O_ ,<H /)\8?\ /]HW_@'+_P#'* #R?&'_ #_:-_X!R_\
MQR@ \GQA_P _VC?^ <O_ ,<H /)\8?\ /]HW_@'+_P#'* #R?&'_ #_:-_X!
MR_\ QR@ \GQA_P _VC?^ <O_ ,<H /)\8?\ /]HW_@'+_P#'* #R?&'_ #_:
M-_X!R_\ QR@ \GQA_P _VC?^ <O_ ,<H /)\8?\ /]HW_@'+_P#'* #R?&'_
M #_:-_X!R_\ QR@ \GQA_P _VC?^ <O_ ,<H /)\8?\ /]HW_@'+_P#'* #R
M?&'_ #_:-_X!R_\ QR@ \GQA_P _VC?^ <O_ ,<H /)\8?\ /]HW_@'+_P#'
M* #R?&'_ #_:-_X!R_\ QR@ \GQA_P _VC?^ <O_ ,<H /)\8?\ /]HW_@'+
M_P#'* #R?&'_ #_:-_X!R_\ QR@ \GQA_P _VC?^ <O_ ,<H /)\8?\ /]HW
M_@'+_P#'* #R?&'_ #_:-_X!R_\ QR@ \GQA_P _VC?^ <O_ ,<H /)\8?\
M/]HW_@'+_P#'* #R?&'_ #_:-_X!R_\ QR@ \GQA_P _VC?^ <O_ ,<H /)\
M8?\ /]HW_@'+_P#'* #R?&'_ #_:-_X!R_\ QR@ \GQA_P _VC?^ <O_ ,<H
M /)\8?\ /]HW_@'+_P#'* #R?&'_ #_:-_X!R_\ QR@ \GQA_P _VC?^ <O_
M ,<H /)\8?\ /]HW_@'+_P#'* #R?&'_ #_:-_X!R_\ QR@ \GQA_P _VC?^
M <O_ ,<H /)\8?\ /]HW_@'+_P#'* #R?&'_ #_:-_X!R_\ QR@ \GQA_P _
MVC?^ <O_ ,<H /)\8?\ /]HW_@'+_P#'* (YCXJMHFEGU/0XHUZL]K*H'XF6
MJC&4W:*NRH0E-\L%=E)=0\77# 6,FF7*_P#/7[%*D8_X$T@S_P !!K?ZOR?Q
M9)>6[^Y?K8ZOJO)_&DH^6[^Y;?-HL7.G^,;R.,'5M-M\??2&"3#?\"W;A^!%
M'M*4/@C?S?\ EM]]P]K1I_PX7?>7^6WWW$M-(\26.XV\^AH[?>?['*7;ZL9<
MG\36=2M.I\3_ ,ON,:M>I5TF].W3Y+9%KR?&'_/]HW_@'+_\<K(Q#R?&'_/]
MHW_@'+_\<H /)\8?\_VC?^ <O_QR@ \GQA_S_:-_X!R__'* #R?&'_/]HW_@
M'+_\<H /)\8?\_VC?^ <O_QR@ \GQA_S_:-_X!R__'* #R?&'_/]HW_@'+_\
M<H /)\8?\_VC?^ <O_QR@ \GQA_S_:-_X!R__'* #R?&'_/]HW_@'+_\<H /
M)\8?\_VC?^ <O_QR@ \GQA_S_:-_X!R__'* #R?&'_/]HW_@'+_\<H /)\8?
M\_VC?^ <O_QR@ \GQA_S_:-_X!R__'* #R?&'_/]HW_@'+_\<H KW<?B15MS
M?W>F/:_:H-ZP6TB.?WJXP2Y'7':@#8U[_D7M3_Z]9?\ T$T &@_\B]IG_7K%
M_P"@B@"/Q+_R*NK_ /7G-_Z : +E]86>IV<EG?VD-W:R8WPSQAT;!R,J>#R
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ME3LNRT7_  ?G<OUSG*% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% &?K/\ QXQ_]?5O_P"CDH ->_Y%[4_^O67_ -!- !H/_(O:9_UZQ?\ H(H
MC\2_\BKJ_P#UYS?^@&@#4H * "@ H * "@ H * ,'QO_ ,B#XC_[!MQ_Z*:@
M#8M/^/.#_KFO\J )J "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@#S_ .)/Q&;PCI972(([[4=P63!WI:CCF0 Y!/0#COZ8/?@\)[:7
MOZ+\_0F4K;&IHWCVPOM'M;S4[6\TF66,,R75K(J#W$FW:1WSGIUQ653"RC)Q
M@T_1K\@4C=L-;TG5/^0?J=I=_P#7"=7_ )&L94YP^)-#NB_68Q"0H))P!WH
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MW=8OQZ<QG'YI1[>/_/N/X_YA]9CUI1_'_,/[,O1]W7;PG_:CA(_2,4>VI_\
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M 4 % !0 4 % &#XW_P"1!\1_]@VX_P#134 ;%I_QYP?]<U_E0!-0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 1W%Q!:0//<S)#"@RTDC!54>
MI)Z4TFW9 8O_  D4E_\ +H6G2WP/2YD)AM_KO(RP]T5A[UM[%1_B.WEN_P"O
M6PK]ADFCW-U&9?$&KL81R;>V)MX!_O'.]OQ8 _W:<9I.U*.OWO\ R*C"4W9:
MLY;QAK\&C6%C8^'1:)9/O$B1VZM$<;<8XVGJ>GM7M9=@?;2E+$IW5K:Z]?F?
M3Y/E,*W/]:AM:RO;OTW^\W_"^LZYJV@07+6L$TC%@9I)O+!P3_"JG^E<>.PV
M'H5W%-I=DK_BVCBS'"83#8AP4FEIHE?\6U^I9OO#CZS_ ,A.#29!Z-8B5O\
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M^)=!OB!::WI]P?2*Y1OY&IE1J1WBU\@NC35@RAE(((R".]9#%H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * ,6?Q3IB3-;V;R:C=*<&&Q3S2I
M]&8?*G_ B*V5"=KO1>?]?D*Y'GQ+J/1;;1X#_>_TB?'T&$4_BXI_NH?WOP7^
M?Y!J/B\*Z;YJSW_FZI<*<K)?/YNT^JIPBG_=44G7G:T=%Y?U<+&UM7 &!@=!
MBL1BT % !0 4 9^L_P#'C'_U]6__ *.2@ U[_D7M3_Z]9?\ T$T &@_\B]IG
M_7K%_P"@B@"/Q+_R*NK_ /7G-_Z : -2@ H * "@ H * "@ H P?&_\ R(/B
M/_L&W'_HIJ -BT_X\X/^N:_RH FH * "@ H * "@ H * "@ H * "@ H * "
M@!DLL<,9DED6-%ZLQP!^-.,7)V2*C%R=HJ[,:3Q39R.T6EQ3:K,IVD6JY13C
M^*0X4?G^%=:P<UK5:BO/?[M_P.GZG4C_ !+1]7K]V_X%"6R\6ZR<7%Y;Z/;'
M'[FV)DE]PS\?FNTU:>%I;7F_N7Z_B@Y<-#=N7IHOO=W^"+6G>#].T]7^>>1I
M.9#O*F0_[17!?_@9:IGC)/X4E^/Y[?*P?6N3^%!1^5W][O\ A8VK:RM;)-EK
M;10+Z1H%S^5<LZDZCO-MF%2K4JN]23?J3U!F% ',^,O&5GX1TX.X$U],,6]L
M#RY]3Z"M*=-S=D1.:BCQ9OM>IZA+JVL2^??3=<](Q_= [5Z]*DH(\VI4<F7?
M#_B"]\#ZD;FV5I])F;_2+;/W?]I?0_\ ZC[8UZ":NC6C6MHSW;2]4L]9TZ&_
ML)UFMY1E6'\CZ'VKRVG%V9WIIJZ+E(84 % !0 4 % !0 4 % !0 4 % %6ZT
MVPO@1=V5O<#_ *:Q*_\ ,549RC\+L!F-X+\-;BT6BVMNQ.2ULGDG/KE,<UK]
M8J]9-^NHK(3_ (1.SC_X]M0U:W]EU&9P/H'9@/RH]O+JD_D@L']A:K%_Q[^*
MM0([+/#!(!^48/ZT>U@]X+\?\PL'V7Q5#]S5=+N!_=DL71C_ ,"$I'_CM'-1
M?V6OG_P U.1^(?B+Q]H/A])M/TRS+-*JO=6CM*T8SP/+9!C<>,Y/7'7!KKPE
M+#5)VDWZ/3\;DR;2.CTOQ-J_]EVTFN>%]0M;ID!E^SA)TS[!6+CZ%>.G-<\Z
M,.9JG--?=_P!IOJ6_P#A,] 3BYO_ +"?^GZ)[;_T8%J/J]3HK^FOY#NC6M+Z
MSOH_,L[J&X3^]%(''Z5E*,HZ25AEBI * "@ H * "@ H * "@ H S+_Q#I>F
MSBWGN@UT1D6T*F68CVC4%L>^*UC2G-72T[]/O%>Q4^W:_J/%CIL>G0G_ );:
M@VY_J(D/\W4^U5RTH?$[^G^;_P @U#_A%XKOYM:OKG5#WBE;9!]/*7"L/][<
M?>CVSC\"M^?W_P"5@MW-J""&UA2&WB2*)!A410JJ/8"L6VW=C)*0!0 4 % !
M0 4 % &?K/\ QXQ_]?5O_P"CDH ->_Y%[4_^O67_ -!- !H/_(O:9_UZQ?\
MH(H C\2_\BKJ_P#UYS?^@&@#4H * "@ H * "@ H * ,'QO_ ,B#XC_[!MQ_
MZ*:@#8M/^/.#_KFO\J )J "@ H * "@ H * "@ H * ()[VTM?\ CXNH8?\
MKHX7^=:1I3G\*;-84:E3X(M^B*?_  D&E-_JKM9_^O=6ES_WR#6OU2LMXV]=
M/SL;_4<0OBC;ULOSL1S>(884W_8[LI_>>,0C_P B%::PKZR7WW_*X?5>7XZD
M5\[_ /I-S@/'/C9R;./3]12T8%_,6&]C9CTQN",<=^]>YE>#I>][1*6VZ?GW
M/>R6A@VY^UE&6VZ]>Y<\+W_BK6]$C%I<,T9=@;R9U"]>@/S,^/3"C_:K#'QP
MM"L[17I_5E^?H<>:RPU'$N-&FGHNNGW*WYG0VW@>S>5;C6KJ;5K@'($[$1+[
M!,G(]F+5YTL=4MRT_=7D>5+%UFN52LNRT7X;_,Z:**.")8HD6.-!A548 'H!
M7$VV[LYA]( H * "@ H \W\1?"^TU"6]UJ[UK4);L(T@)* # ) '' K>%9QL
MDC&5-/5GF.BNTFF1L[%FR>2<]Z]>GK$\V>DBS::8NN>+M+TF6XEA@N=RNT1P
M> 3].U8XB3BKHVH14G9GL/A/P-#X0FE-EJEY+!*/G@EVE">S# X->7.IS[H[
MXPY=CK*S+"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * #MB@#)NO"
M^@7LGF7.C63R]I/(4./HP&1^=:QK5(Z*3%9%?_A$[2+_ (\K_4[(]A%?2,H^
MB.64?E5>WD_B2?R7Z!8/[*U^W_X]?$OG>U]9))_Z+,='/2>\/N?^=PLP\_Q5
M;_?L-,O5'4Q7+PM^"LC#_P >%%J+ZM?*_P"OZ!J'_"17<'%[X;U.$#J\0CG7
M\-CEO_'11[*+^&:_%?F@N'_"9Z G%S?_ &$_]/T3VW_HP+1]7J=%?TU_(+HU
MK2^L[Z/S+.ZAN$_O12!Q^E92C*.DE88ZYNK>RA\ZZGC@BR%WR.%&2< 9/J2!
M247)V2 @U#5M.TF-7O[V&V#'""1P"Y]%'4GV%5"G*>D5<+V,[^V]2O\ C2-&
ME*'I<7Y-O']0N#(?Q4?6M/9PC\<ONU_X'XBOV#^P;V^YUG69YE/6WL\VT7Y@
MES^+X/I1[6,?@C]^O_ _ +=S3T_2[#2H##I]G#:QDY*Q(%R?4XZGW-9RG*;O
M)W':Q;J "@ H * "@ H * "@ H * ,_6?^/&/_KZM_\ T<E !KW_ "+VI_\
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MXY(U*JWS%$(92Z9!7&&7!/S!0#8H P?&_P#R(/B/_L&W'_HIJ -BT_X\X/\
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MJO7;MT*2L;58C"@ H * "@ H * "@ H * "@ H * ,_6?^/&/_KZM_\ T<E
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M)'BR\ V#C[+;\<?[E $O]AZW_P!#;>_^ MO_ /$4 ']AZW_T-M[_ . MO_\
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M'K?_ $-M[_X"V_\ \10 ?V'K?_0VWO\ X"V__P 10 ?V'K?_ $-M[_X"V_\
M\10 ?V'K?_0VWO\ X"V__P 10 ?V'K?_ $-M[_X"V_\ \10 ?V'K?_0VWO\
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ML/6_^AMO?_ 6W_\ B* #^P];_P"AMO?_  %M_P#XB@ _L/6_^AMO?_ 6W_\
MB* #^P];_P"AMO?_  %M_P#XB@ _L/6_^AMO?_ 6W_\ B* #^P];_P"AMO?_
M  %M_P#XB@ _L/6_^AMO?_ 6W_\ B* #^P];_P"AMO?_  %M_P#XB@ _L/6_
M^AMO?_ 6W_\ B* #^P];_P"AMO?_  %M_P#XB@ _L/6_^AMO?_ 6W_\ B* #
M^P];_P"AMO?_  %M_P#XB@ _L/6_^AMO?_ 6W_\ B* #^P];_P"AMO?_  %M
M_P#XB@ _L/6_^AMO?_ 6W_\ B* #^P];_P"AMO?_  %M_P#XB@ _L/6_^AMO
M?_ 6W_\ B* #^P];_P"AMO?_  %M_P#XB@ _L/6_^AMO?_ 6W_\ B* #^P];
M_P"AMO?_  %M_P#XB@ _L/6_^AMO?_ 6W_\ B* #^P];_P"AMO?_  %M_P#X
MB@"O=Z5JELMO+<^(KF[B6Z@W0O!"H;]ZO=4!]^#VH V->_Y%[4_^O67_ -!-
M !H/_(O:9_UZQ?\ H(H C\2_\BKJ_P#UYS?^@&@#4H * "@ H * "@ H * ,
M'QO_ ,B#XC_[!MQ_Z*:@#8M/^/.#_KFO\J )J "@ H * "@ H * "@ H * "
M@ H * "@ H * ,2Z\6:7:7]Q9,M_-/;,$E^S:;<3JC%0P!:-",[64XSW% $7
M_"9:7_SZZS_X)+S_ .-4 '_"9:7_ ,^NL_\ @DO/_C5 !_PF6E_\^NL_^"2\
M_P#C5 !_PF6E_P#/KK/_ ()+S_XU0 ?\)EI?_/KK/_@DO/\ XU0!%<^*]*NK
M6:W:VUH+*A0D:)>9 (Q_SRH6@'G*>"?"T:[4O_%:KZ#1KH#_ -$UT_6)HP]A
M$OZ)X>\-:)KEKJL=QXGGFMB2JRZ+=$'((_YX^]3*M*2LRHTE%W1WG_"9:7_S
MZZS_ ."2\_\ C58&H?\ "9:7_P ^NL_^"2\_^-4 '_"9:7_SZZS_ ."2\_\
MC5 !_P )EI?_ #ZZS_X)+S_XU0 ?\)EI?_/KK/\ X)+S_P"-4 '_  F6E_\
M/KK/_@DO/_C5 &CI6LV6M0S2633?N)/*E2:WDA='VJV"CJ&'RLIZ="* +] !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 9^L_P#'C'_U]6__ *.2@ U[_D7M3_Z]9?\ T$T
M&@_\B]IG_7K%_P"@B@"/Q+_R*NK_ /7G-_Z : -2@ H * "@ H * "@ H P?
M&_\ R(/B/_L&W'_HIJ -BT_X\X/^N:_RH FH * "@ H * "@ H * "@ H *
M"@ H * "@ H Y_P]_P ASQ9_V%$_]([:@#6O]2L=*M3=:C>V]G;*0#+<2K&@
M)Z#).*3:0[-B:=JNG:O;&YTR_MKV -M,EM*LB@^F5)&>15--$W3T+=(84 %
M!0 4 17%S!9VTES<S1P01*6>21@JH!U))X H\@2OL2@@C(Z4"3OJ@H&16]S;
MW<7FVT\<T>YDW1L&&Y201D=P00?<4>8=;$M !0 4 <_X>_Y#GBS_ +"B?^D=
MM0!T% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M1MRD$9!!'443CRR<>QG"7-%-D]26<_X>_P"0YXL_["B?^D=M0!T% !0 4 %
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MU5' XZ5I*3D[LE*US2J1A0 4 % !0 4 <_X>_P"0YXL_["B?^D=M0!T% !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 9^L_\>,?_ %]6_P#Z.2@ U[_D7M3_ .O67_T$T &@
M_P#(O:9_UZQ?^@B@"/Q+_P BKJ__ %YS?^@&@#4H * "@ H * "@ H * ,'Q
MO_R(/B/_ +!MQ_Z*:@#8M/\ CS@_ZYK_ "H FH * "@ H * "@ H * "@ H
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M#XC_ .P;<?\ HIJ -BT_X\X/^N:_RH FH * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * ,_6?\ CQC_ .OJW_\ 1R4 &O?\B]J?_7K+_P"@F@ T'_D7M,_Z
M]8O_ $$4 1^)?^15U?\ Z\YO_0#0!J4 % !0 4 % !0 4 % &#XW_P"1!\1_
M]@VX_P#134 ;%I_QYP?]<U_E0!-0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M_A";7_H-:]_X-9O_ (J@ _X0FU_Z#6O?^#6;_P"*H /^$)M?^@UKW_@UF_\
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M;N(4\JFTXQN(+;1& 4]%TS5DM_">E7&E36R^']OG7<DD1BGV6TD'[L*Y?EI
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M4 4]&T^0^*FU2W\.OH4#P2B[63R%:\F=XV1SY+L&*A9>7((\SC.6P =90 4
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M0NT[2NC,1Y;L%"B%>IY\SMMY .DH * /.X?"\]OJ!CCT%QJ7]K->+K1DB*)
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H S]>_P"1>U/_ *]9
M?_030 :#_P B]IG_ %ZQ?^@B@"/Q+_R*NK_]><W_ * : -2@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#/U[_D7M3_
M .O67_T$T &@_P#(O:9_UZQ?^@B@"/Q+_P BKJ__ %YS?^@&@#4H * "@ H
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MC_R1C_QH /[(\1?]#1_Y(Q_XT ']D>(O^AH_\D8_\: #^R/$7_0T?^2,?^-
M!_9'B+_H:/\ R1C_ ,: #^R/$7_0T?\ DC'_ (T ']D>(O\ H:/_ "1C_P :
M #^R/$7_ $-'_DC'_C0 ?V1XB_Z&C_R1C_QH /[(\1?]#1_Y(Q_XT ']D>(O
M^AH_\D8_\: #^R/$7_0T?^2,?^- !_9'B+_H:/\ R1C_ ,: #^R/$7_0T?\
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M\: #^R/$7_0T?^2,?^- !_9'B+_H:/\ R1C_ ,: #^R/$7_0T?\ DC'_ (T
M']D>(O\ H:/_ "1C_P : #^R/$7_ $-'_DC'_C0 ?V1XB_Z&C_R1C_QH /[(
M\1?]#1_Y(Q_XT ']D>(O^AH_\D8_\: #^R/$7_0T?^2,?^- !_9'B+_H:/\
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4MELK&WM48LD$:Q@GJ0!C^E '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g462900g24p45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g462900g24p45.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MS41:<;]?>]+1M^*Z_@:234O*R_%M?=_3Z&[I.K66N:9#J.G3&:TFR8Y-C+N
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M4#V>]VQ#9Q2F18_N_>^9N.1TYHIMQ]DWO%IOSLN5?A^;*JKFY[;-67DV[O\
M$O>(?AWJ>OW6MVKW5K%I>L7T,\[@DS)''$!A05P&+@<YZ?7%9*'N*+Z.3^;V
M^6]RW*TG)=DON;O^&WGKT.Q\*V%_I7AC3].U/[,;JTA$):VSY;!>%(! QD 9
M&, UO4GSRYNKW]3&$>1<O0V*@L* "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M_)KV_+7]1.T4Y=%S?^2FU9^.KE[^/3[W1TM[O^U?[-D$=UYB+^Y\T.&* GC
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M296W A2",'G(D3_OM?44 6U8.H92"I&01T- "T % !0 4 % !0 4 % !0 4
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MUM&US''%.5&](W+JI[@,0"1[X'TI.U]!J_4Q?$FN76CWN@PVZ1,NH:@MK*9
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M_P#6_P#+3S/], "WM]OD?Z/Y7E>7!_H\/F^1O\C]Q#^Y?S('\SYG^?\ UO\
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M:>9_I@ 6]OM\C_1_*\KRX/\ 1X?-\C?Y'[B']R_F0/YGS/\ /_K?^6GF?Z8
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MRO+@_P!'A\WR-_D?N(?W+^9 _F?,_P _^M_Y:>9_I@ 6]OM\C_1_*\KRX/\
M1X?-\C?Y'[B']R_F0/YGS/\ /_K?^6GF?Z8 %O;[?(_T?RO*\N#_ $>'S?(W
M^1^XA_<OYD#^9\S_ #_ZW_EIYG^F !;V^WR/]'\KRO+@_P!'A\WR-_D?N(?W
M+^9 _F?,_P _^M_Y:>9_I@ 6]OM\C_1_*\KRX/\ 1X?-\C?Y'[B']R_F0/YG
MS/\ /_K?^6GF?Z8 ;OA+Q%?>&;F(PPG[)F.&2VA1Y(XF80A8X0D9,L1,N[S
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M;YF5G>Y +7P[^(+^!?%=X;I@NGW5R([BTMSYL*+E@71][$[/E QNW*3\W R
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M:>9_I@ 6]OM\C_1_*\KRX/\ 1X?-\C?Y'[B']R_F0/YGS/\ /_K?^6GF?Z8
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M^9\S_/\ ZW_EIYG^F !;V^WR/]'\KRO+@_T>'S?(W^1^XA_<OYD#^9\S_/\
MZW_EIYG^F !;V^WR/]'\KRO+@_T>'S?(W^1^XA_<OYD#^9\S_/\ ZW_EIYG^
MF !;V^WR/]'\KRO+@_T>'S?(W^1^XA_<OYD#^9\S_/\ ZW_EIYG^F !;V^WR
M/]'\KRO+@_T>'S?(W^1^XA_<OYD#^9\S_/\ ZW_EIYG^F !;V^WR/]'\KRO+
M@_T>'S?(W^1^XA_<OYD#^9\S_/\ ZW_EIYG^F !;V^WR/]'\KRO+@_T>'S?(
MW^1^XA_<OYD#^9\S_/\ ZW_EIYG^F !;V^WR/]'\KRO+@_T>'S?(W^1^XA_<
MOYD#^9\S_/\ ZW_EIYG^F !;V^WR/]'\KRO+@_T>'S?(W^1^XA_<OYD#^9\S
M_/\ ZW_EIYG^F !;V^WR/]'\KRO+@_T>'S?(W^1^XA_<OYD#^9\S_/\ ZW_E
MIYG^F "6\&WR/]'\KRO+@_T>'S?(W^1^XA_<OYD#^9\S_/\ ZW_EIYG^F ',
MZ[XBM;&Q-EI[(FI(@A+P*CQ6L3)B6&&48;&X<M\V=[X8Y=YP#EKR3R_[0MO,
M\C-T&^R6S^9;_+O&0^\[MN["GYLAF.[^\ %Y)Y?]H6WF>1FZ#?9+9_,M_EWC
M(?>=VW=A3\V0S'=_> "\D\O^T+;S/(S=!OLEL_F6_P N\9#[SNV[L*?FR&8[
MO[P!M^'/$LOA'Q8NHQ2&#[/?J[V5J_F6[H-ZN ^\[L*Q53\V0Y.[^\ ?68UN
M_P!94#0+4"V;_F(7:D1$>L:<-)]?E4]0QH GMM!N(W=KK7M2NQ(C(Z,Z1KR.
MJ[%5E([$'(I-7&G9W*(^'OAH:1<Z4;2Y>QN91-)$]_<,"X;=N!+Y!W')(QD]
M<T]N5+[.WD)ZWOUW\S1@\-:;!]FR+J?[-,9XOM5[-/M<KMS^\8YP.F>F21@F
MG?5/MI]_]?=IL*VEOZT_K\NR':1X;TK09;F73K9H7N3F3=*[C@LP"AB=JY=C
MA<#D\4E[L5!;+_)+\DAO67,_ZZO[^IJT % !0 4 % !0 4 >!>-+K^T_&U_<
M 3.L4ZVBS"U+2(#Y \J,&%B\4GF?,V& \W 4APMT <[;V^WR/]'\KRO+@_T>
M'S?(W^1^XA_<OYD#^9\S_/\ ZW_EIYG^F !;V^WR/]'\KRO+@_T>'S?(W^1^
MXA_<OYD#^9\S_/\ ZW_EIYG^F !;V^WR/]'\KRO+@_T>'S?(W^1^XA_<OYD#
M^9\S_/\ ZW_EIYG^F !;V^WR/]'\KRO+@_T>'S?(W^1^XA_<OYD#^9\S_/\
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M;'S[A%* >26]OM\C_1_*\KRX/]'A\WR-_D?N(?W+^9 _F?,_S_ZW_EIYG^F
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M^9\S_/\ ZW_EIYG^F !;V^WR/]'\KRO+@_T>'S?(W^1^XA_<OYD#^9\S_/\
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MSG;G"GYLAF^;^\ )>2>7_:%MYGD9N@WV2V?S+?Y=XR'WG=MW84_-D,QW?W@
MO)/+_M"V\SR,W0;[);/YEO\ +O&0^\[MN["GYLAF.[^\ %Y)Y?\ :%MYGD9N
M@WV2V?S+?Y=XR'WG=MW84_-D,QW?W@ O)/+_ +0MO,\C-T&^R6S^9;_+O&0^
M\[MN["GYLAF.[^\ %Y)Y?]H6WF>1FZ#?9+9_,M_EWC(?>=VW=A3\V0S'=_>
M"\D\O^T+;S/(S=!OLEL_F6_R[QD/O.[;NPI^;(9CN_O #I[AK66]B23[.RW:
MN+6V?S+?*[^0^\[MN<*?FR&8[O[P!]UHP>-7&,, 1@YH =0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 >4?%I2VL:0?*(41E!-%&9)1OEB3RPGEOE'SM<X; 8#
M!W^5. >;V]OM\C_1_*\KRX/]'A\WR-_D?N(?W+^9 _F?,_S_ .M_Y:>9_I@
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MY:>9_I@ 6]OM\C_1_*\KRX/]'A\WR-_D?N(?W+^9 _F?,_S_ .M_Y:>9_I@
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M  C_ (N_M4O:_OK5+">W7AUVN2[$$C) XS\Q]\@'MM !0 4 % !0 4 % !0
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MG^?_ %O_ "T\S_3  M[?;Y'^C^5Y7EP?Z/#YOD;_ "/W$/[E_,@?S/F?Y_\
M6_\ +3S/], "WM]OD?Z/Y7E>7!_H\/F^1O\ (_<0_N7\R!_,^9_G_P!;_P M
M/,_TP +>WV^1_H_E>5Y<'^CP^;Y&_P C]Q#^Y?S('\SYG^?_ %O_ "T\S_3
M"QI=W;Z++%>S:Q;^''MX_)AO?L'VM;5VCB;R;<;/GC969C)EN6ZGS#)< &Q_
MPL#_ *KA_P"6O_\ 8T '_"P/^JX?^6O_ /8T '_"P/\ JN'_ ):__P!C0 A\
M?!@0?C>"#V/A;_[&@#GM3D\*ZQ;S07OQ2M&CGD6241^%/*,C*"%8E "2 S '
M/<^M &6/#WP[\F6#_A9KQP2,KF&+1[D(64$!B"3D@,P'ID^M &9K.B^%TANA
MH_CZT>&699?L;6%W#'P'QU#G*[L+DDX9N?4 YJ8^9;W:P2>5'-<JZ6ENQ,1
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M_P#6_P#+3S/], "WM]OD?Z/Y7E>7!_H\/F^1O\C]Q#^Y?S('\SYG^?\ UO\
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M73?%L&CZ=;V-O\4+?P^L4:[M-MM$^V16[8&Y4FVX<9R<Y;.>6<Y=@"W_ ,+
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M;_RT\S_3  M[?;Y'^C^5Y7EP?Z/#YOD;_(_<0_N7\R!_,^9_G_UO_+3S/],
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M6O\ _8T '_"P/^JX?^6O_P#8T '_  L#_JN'_EK_ /V- !_PL#_JN'_EK_\
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MY:>9_I@ 6]OM\C_1_*\KRX/]'A\WR-_D?N(?W+^9 _F?,_S_ .M_Y:>9_I@
M6]OM\C_1_*\KRX/]'A\WR-_D?N(?W+^9 _F?,_S_ .M_Y:>9_I@ 6]OM\C_1
M_*\KRX/]'A\WR-_D?N(?W+^9 _F?,_S_ .M_Y:>9_I@ 6]OM\C_1_*\KRX/]
M'A\WR-_D?N(?W+^9 _F?,_S_ .M_Y:>9_I@ 6]OM\C_1_*\KRX/]'A\WR-_D
M?N(?W+^9 _F?,_S_ .M_Y:>9_I@ 6]OM\C_1_*\KRX/]'A\WR-_D?N(?W+^9
M _F?,_S_ .M_Y:>9_I@!JZ5XBFT#2DMF\>MX5@#@)9IH_P!M@#>5&S"&3;RF
M'5LY.XOG+Y\V0 M_\+ _ZKA_Y:__ -C0 ?\ "P/^JX?^6O\ _8T '_"P/^JX
M?^6O_P#8T '_  L#_JN'_EK_ /V- !_PL#_JN'_EK_\ V- &MX=UO5_%6IC3
M]%^,3WEP%+LB^&50!1U)9@ /QH ]GC4I$B,[2,H +MC+>YQ@?E0 Z@ H * "
M@ H * "@ H * "@ H * "@".>"*YMY+>>))895*/&ZAE92,$$'J".U 'A_B_
MP*_A>^@GLXW?1W=8+>6.%9);0.\:BU"B)\QN2^YB&)WMD,S.ER <I;V^WR/]
M'\KRO+@_T>'S?(W^1^XA_<OYD#^9\S_/_K?^6GF?Z8 %O;[?(_T?RO*\N#_1
MX?-\C?Y'[B']R_F0/YGS/\_^M_Y:>9_I@ 6]OM\C_1_*\KRX/]'A\WR-_D?N
M(?W+^9 _F?,_S_ZW_EIYG^F !;V^WR/]'\KRO+@_T>'S?(W^1^XA_<OYD#^9
M\S_/_K?^6GF?Z8 6-,OK?1)8;J3Q!!X9FA3R8[D::;Q8<QQN8+?Y,-&=V\R9
M<Y;@G>99P#8_X6!_U7#_ ,M?_P"QH /^%@?]5P_\M?\ ^QH /^%@?]5P_P#+
M7_\ L: #_A8'_5</_+7_ /L: #_A8'_5</\ RU__ +&@ _X6!_U7#_RU_P#[
M&@ _X6!_U7#_ ,M?_P"QH ]"\$0>(-2^SZU+X_FUG2'!V0G1DL_-/0')&[;]
M,9]: .@\8>(_^$4\-SZO]G2X\IXTV23>4OS.%R6P< 9ST[5-_>C'N[%)73?9
M7,W1/'<6H:?=W=Y9.L<%U]G2735EU"&?Y0VY&CCR0.03MP",9JG914GY_@[7
M].Q'VFNUOQ_4OV/C70-2N((;&[EN6FB68-%:RLB(V<%V"[8_NM]XCI3:M>_3
M[MK[^C'V7?[][;>I-HWBW1=>N#;Z==222>5YR[[>2(21YQO0NH#KGNN122NK
M^GX[:?(3:3MZ_AN;5 PH * "@ H * "@ H * "@ H * "@ H * ,7Q)X;M/$
M>G^1,!'.G^JG5$+H"1N4%E8;6 VL"""I((()% '@U[H=UHM]':7=H8'@*0 V
M]N9!$&,(\F &%C)"Y<AV(8@R,#O+D78!3M[?;Y'^C^5Y7EP?Z/#YOD;_ "/W
M$/[E_,@?S/F?Y_\ 6_\ +3S/], "WM]OD?Z/Y7E>7!_H\/F^1O\ (_<0_N7\
MR!_,^9_G_P!;_P M/,_TP +>WV^1_H_E>5Y<'^CP^;Y&_P C]Q#^Y?S('\SY
MG^?_ %O_ "T\S_3  M[?;Y'^C^5Y7EP?Z/#YOD;_ "/W$/[E_,@?S/F?Y_\
M6_\ +3S/], "WM]OD?Z/Y7E>7!_H\/F^1O\ (_<0_N7\R!_,^9_G_P!;_P M
M/,_TP +>WV^1_H_E>5Y<'^CP^;Y&_P C]Q#^Y?S('\SYG^?_ %O_ "T\S_3
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MRO+@_P!'A\WR-_D?N(?W+^9 _F?,_P _^M_Y:>9_I@ 6]OM\C_1_*\KRX/\
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M_K) YW]!G@9(S5<S:L_+;1?<3RV>FVN^YV%24% !0 4 % !0 4 % !0 4 %
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MTX.:M2Y6[*RNWIIOT^_\-"7%M*[OHEKY?YH[NI*"@ H * "@ H * "@ H *
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M6@\*;8Q]790H_.@#MM"\/>*[&^$VL^.9M4@7I!'IT%N#_O$ DCZ$4 =90 4
M% !0!R>H^,9;7QQ%X9AMK$2/!'.)+R^,!DW,RE8E$;;V&W.,BBG[[:[/Y[7O
M;R"?N)/O?T]+]S17Q5I<FJ-I:R7$=\5D,:3VDT2R;/O;&90KXR/ND\<U$I/V
M<IQZ*Y5K22?5V,G2/'UDWAK2=0ULR6TU[!')))%9S&W0N=H!D"E5YX^9JV<?
M>48];?>TF1>R;>R;^Y-_Y%^V\=>';S5AID%](UR;A[49MI1'YR ED\PKLW
MG&?YBHC[RNNU_EW^77L.7N.TO+\=C5TK5;+6].CU#3IO/M)2P23:5#8)4XR
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M+>T=OZU^8)MZOS^2OHODM#3J!A0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
8% !0 4 % !0 4 % !0 4 % !0 4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g462900g30n56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g462900g30n56.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M0!5N6U30]3TUGU)KRVNYQ;R1R( 03G# CZ=* .HH * "@ H * "@ H * "@
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H>\N6'IYF!0 L.DV4+%A"'8]3(=W\Z +O3@4 % !0 4 % !0 4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g462900g35h68.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g462900g35h68.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % &=;W-]<W,NQ8%MXIC&<D[B!U/I0!H-C8<G QR<XQ4R
MMRN[L-;Z'F/A@^'=.O[K3H)?#NJVC64K7.JVZ1^8B C*W1!(?<#DL67<0?EX
MS5;TVGI:W^'LM.^[M^75O2HI+=MZ=5UW_#;33<I:>+>+1O&L.A-I\X-G&XN=
M"C\NV;Y7!544MME R3ACD%>E/3D7/\/,KW[>[?Y6W7KKK92DU4]SXN5V]=;7
M\[[?EI=T[U?"'_";Z9+IRZ1_PB!B"ZD81']C\[;)Y7FX^3/7KSG9[40TE-3V
MMI_BZV_[=[$O^''DWZ][:6O\_P!?,[_P''#'HUX+)8UTPW\YL1%_J_)+<;.V
MW=NQCC&,<4+FY(\V]G]UW;_R6P].>5MM/_25?\;W\S3UJZ\/V)M+O7I].MS%
M(3;37KHFQ\?P%NAQZ5-TI>?Z=2K-KR_JQ0E\0>&/$<T&CPZCH.KQ7)(EMFO(
MY6( W#;& V\Y X.,#GMBFH\W3;^OZ8N;E5TSI$18T5$4*JC  & !3;;=V)))
M60M(84 % !0 4 5[6QMK)[A[>((UQ*996R278@#))]@![  4+1)?UJ[@]7<L
M4 % !0!0U'_CZTS_ *^?_:;T 7Z "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H \Q^.]YJ5A\/4N-,N+FWD2]CWR6[,I";
M6ZD=LX_2@#E?@#KNH3:KK-AKFHW3W4L44MM#=R,2R@MN*AOJ.G]* />* "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H H:7_ ,OO_7R_]* +
M] $-O:PVHD$*;?,D:1N2<L3DGFA:*W];W_,.M_ZVM^A-0 4 % %6_&+?SC>R
M6D<.9)'0(<J%.0=RGCOQ@\#MD&9M13DWHD_^'^144V[)?U_6AR^A7ZW.J6VS
MQ!XEO%<$B.\T?R87&T]9/LR8]1\PR<=>E:)-731G=-71V524% !0 4 % !0
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M!0U'_CZTS_KY_P#:;T 7Z "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@#&\5>(;?PKX:O=8N1N6W3Y(QUD<\*H^I(% '/?#B
MSMM'\/"YU'4;:76]7D%Y>OYJY,DFPJ@YZ 21@#U<8^\* .N35M-DV;-0M6WX
MVXF4YSLQCGOYD>/]]?44 8/B;PWIWC2QAN+&_2#5+)A)9:A;,&:!RH8=.JD%
M21W!!]* (/!_C";4KN?P]K\*V/B6R'[Z$?<N$[2Q'NI].U '8T % !0 4 %
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M;4]/C:U=(Q<G$A92&_=OV!S69H:U !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0!Y/XLW>._%UWID:^;HWAJ%I[@!=PFO"IV
M)C:^[:.<;'YR"K9P0#F/];_TT\S_ ('OW?\ ?>[/G?\ 33=YW_+7SO\ 3P _
MUO\ TT\S_@>_=_WWNSYW_33=YW_+7SO]/ /3?AN_F:%<G?O_ -))SOW?>56S
MG>W7=NSGYMV[=+N\Z4 N>,?!T'BBUAFAG:QUFR;S+&_B^_"_H?53W% %7P=X
MON-3GGT'7X%L?$MB/WT /R3IVEC/=3^E '84 % !0 4 % !0 4 % !0 4 %
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M+)\^=V<@M][+9SOW??.=^[Y]_GS@'>4 % !0 4 % !0 4 % !0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 4-+_ .7W_KY?^E %^@ H * "@ H
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M+)\^=V<@M][+9SOW??.=^[Y]_GS@'>4 % !0 4 % !0 4 % !0 4 % !0 4
M% 'G%C_Q77Q.EU$_/H?AAF@MO[LUX1\[>^P8 ]\$4 =KXA3S/#FI1[/,WVTB
M[-F_=E3QMV/G/IL?/]UNA /$O];_ --/,_X'OW?]][L^=_TTW>=_RU\[_3P
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M]W_?>[/G?]--WG?\M?._T\ /];_TT\S_ ('OW?\ ?>[/G?\ 33=YW_+7SO\
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M '<Z3K&G:[I\=_I5Y%=VLGW9(FR/H?0^QYH O4 % !0 4 % !0 4 % !0 4
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M)]S0!?H S?$*>9X<U*/9YF^VD79LW[LJ>-NQ\Y]-CY_NMT(!XE_K?^FGF?\
M ]^[_OO=GSO^FF[SO^6OG?Z> '^M_P"FGF?\#W[O^^]V?._Z:;O._P"6OG?Z
M> >F_#=_,T*Y._?_ *23G?N^\JMG.]NN[=G/S;MVZ7=YTH!V5 !0 4 % !0
M4 <+J_P\\C4)-:\'7W]A:NW,B(N;6Y]I(^GXCGG/)H -)^(?V?48]%\8V/\
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M;4]1OF MX(&+ X^8D8"\@C)) Y!Z]* /GOP[8R/#+J=VI>]U)O,=<%@ V,*
MP9FR)!DL'9_-&0XD5+P W/\ 6_\ 33S/^![]W_?>[/G?]--WG?\ +7SO]/ -
M_0_"%OXMTNZF6X>TU2TE26QU&(Y>%R"_7+;E;<&(WG=NW9?=Y\X!U?A+QE=7
M&H/X8\40I8^);=<X'^KO$_YZ1'OTY';GW  .UH * "@ H * "@ H * "@ H
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M(>1SQGI[T ;] !0 4 % !0 4 % !0 4 % %#2_\ E]_Z^7_I0!?H * "@ H
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M+O6B3=R)U@M%^^Q_WONCUY% '<V5E;Z=8V]E:1+%;6\:QQHO15 P!0!/0 4
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M#DFX]F94Y<\%+NBE>WMI+J>GVT=S"\Z7)W1JX++^[?J.HJ"S6H * "@ H *
M"@#E_'GB:3PSX>+64?G:O>N+73X!R7F;@<>@ZGZ8[T 'AKPO'X5\$MI8;[1=
M/&\MW,1N,\S#+L>&SD\=#P!P: /*/];_ --/,_X'OW?]][L^=_TTW>=_RU\[
M_3P _P!;_P!-/,_X'OW?]][L^=_TTW>=_P M?._T\ ]#^&9WV^HR9W99/GSN
MSD%OO9;.=^[[YSOW?/O\^< [R@##\4^%=-\6Z2;'4$970[X+B,[9;>0='1NQ
MH YSPWXJU'1]8C\)>,W5=1;BQU$#$5^O_LLGJ._Y9 ._H * "@ H * "@ H
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MSO\ EKYW^G@'IOPW?S-"N3OW_P"DDYW[OO*K9SO;KNW9S\V[=NEW>=* =E0
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MMN)-WD3@'G7^M_Z:>9_P/?N_[[W9\[_IIN\[_EKYW^G@!_K?^FGF?\#W[O\
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MC=G("],-G.[;]TYW;<2;O(G /.O];_TT\S_@>_=_WWNSYW_33=YW_+7SO]/
M#_6_]-/,_P"![]W_ 'WNSYW_ $TW>=_RU\[_ $\ ]STE_,T:Q??OW0(=V[=G
MY1SG<V?KN;ZGK0!<H * ,WQ"GF>'-2CV>9OMI%V;-^[*GC;L?.?38^?[K="
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M9\[_ *:;O._Y:^=_IX ?ZW_IIYG_  /?N_[[W9\[_IIN\[_EKYW^G@'OL?\
MJU^@H \XMO\ B@/B2]F?D\/^)Y#)#_=M[W^)?8..GO@=!0!Z30 4 % !0 4
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M^ /9* "@ H X7XEKOLM/3&[,C#;C=G("],-G.[;]TYW;<2;O(G /.O\ 6_\
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M)5-OWOX%&W'S?\]<;=I_UN-A\W9>@&%_K?\ IIYG_ ]^[_OO=GSO^FF[SO\
MEKYW^G@&WX/._P 66#YWY8ONSNS\I.[.6_YZYW;C_K<[SYN^^ /9* "@ H X
M7XEKOLM/3&[,C#;C=G("],-G.[;]TYW;<2;O(G /.O\ 6_\ 33S/^![]W_?>
M[/G?]--WG?\ +7SO]/ #_6_]-/,_X'OW?]][L^=_TTW>=_RU\[_3P#W/27\S
M1K%]^_= AW;MV?E'.=S9^NYOJ>M %R@ H S?$*>9X<U*/9YF^VD79LW[LJ>-
MNQ\Y]-CY_NMT(!XE_K?^FGF?\#W[O^^]V?._Z:;O._Y:^=_IX ?ZW_IIYG_
M]^[_ +[W9\[_ *:;O._Y:^=_IX!Z;\-W\S0KD[]_^DDYW[OO*K9SO;KNW9S\
MV[=NEW>=* =E0 4 % 'BOB==WB;48]N<S,NW;G.>,8VGKYN,;3GS<;'\W;?
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MNSYW_33=YW_+7SO]/ .E\!'?XJA;._=&[YSNSQNW9RV?]9G.6_UN=Y\WS;P
M]:H * "@#SWXF#=)ID6-VX2?)UW9VI]WYLYW[?N-G?M^;?Y%P <%_K?^FGF?
M\#W[O^^]V?._Z:;O._Y:^=_IX ?ZW_IIYG_ ]^[_ +[W9\[_ *:;O._Y:^=_
MIX![['_JU^@H =0!5U'3[75M-N=/O8A+:W,9CD0]U(P: .*^'.H76F37W@;5
MY2]_HV#;2MUN+0_ZMQ].%/IQ[T =_0 4 % !0!0TO_E]_P"OE_Z4 7Z "@ H
M * "@#(UZ/2+F*"UU662/<S2PF*62)P44DE7C(8$+GH>1FIDTO>?1-_+9_F4
MKOW5U:7SW7Y#;+1=*-EI+62NMI9GS[90QPQ92-S9^9CAV/)SDY/-:23C/7=*
MWIM_E;TN9Q:E'39Z^O7\]?D;-245[]%DTZY1H1,K1,#&21OX/' )Y]@:SJJ]
M.2M?1ET])K6QPGA6WL9[^QFEN?$QN"1.+34--:.**41;/FD$" [5^49;!//)
MKH?Q-WOOKZO5^K_S,NB5K+16\D[KSM?7OW/0ZS*"@#$U'Q&=*U*"VN=(OA;3
MSQP)>J83%O? 48\S?U./N_IS1'WGR^OX)O\ )!+W8\W];V+.L:RFD+;*+2XO
M+FZE\J&WM]F]V"ECR[*H 52>2.GK2W=EZ_+^FA[*[,J/QK#<"**UT;4;B_=I
M5>R7R5EA\I@KEBT@3&67&&.<Y'>GTNM5;_->M[I_=Z"VT>G_  U_R:^\B;Q[
M9O9BZLM*U*^C2T6[G$*QAK=#NX8.ZDM\C<+N/R^XR-J*YF_=[]-D_79I[=1I
M-M1ZZZ>CMZ;Z;G4031W$$<\3;HY%#J?4$9%5*+BW%]"(R4DI+J5-1_X^M,_Z
M^?\ VF]247Z ./\ B/'YGAZW'E[_ /2E7&S=]Y67'W&Z[MN/XMVW;+N\F4 \
MP_UO_33S/^![]W_?>[/G?]--WG?\M?._T\ /];_TT\S_ ('OW?\ ?>[/G?\
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M4 % !0!XKXG7=XFU&/;G,S+MVYSGC&-IZ^;C&TY\W&Q_-VWP!E?ZW_IIYG_
M]^[_ +[W9\[_ *:;O._Y:^=_IX!TO@([_%4+9W[HW?.=V>-V[.6S_K,YRW^M
MSO/F^;> 'K5 !0 4 >>_$P;I-,BQNW"3Y.N[.U/N_-G._;]QL[]OS;_(N #@
MO];_ --/,_X'OW?]][L^=_TTW>=_RU\[_3P _P!;_P!-/,_X'OW?]][L^=_T
MTW>=_P M?._T\ ]]C_U:_04 .H * .$^(VEW=LMEXRT>/?JNADN\8_Y>+8_Z
MR,_ADCTYQS0!U^DZI::WI-IJ=C)YEK=1B2-O8^OOV- %R@ H * *&E_\OO\
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MW>=_RU\[_3P _P!;_P!-/,_X'OW?]][L^=_TTW>=_P M?._T\ ]]C_U:_04
M.H *  @$8(R* /./#&? OCBY\(2G;H^J%[S2">D;=98!]/O >GN: /1Z "@
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M;_TT\S_@>_=_WWNSYW_33=YW_+7SO]/ .E\!'?XJA;._=&[YSNSQNW9RV?\
M69SEO];G>?-\V\ /6J "@ H \]^)@W2:9%C=N$GR==V=J?=^;.=^W[C9W[?F
MW^1< '!?ZW_IIYG_  /?N_[[W9\[_IIN\[_EKYW^G@!_K?\ IIYG_ ]^[_OO
M=GSO^FF[SO\ EKYW^G@'OL?^K7Z"@!U !0!1UK?_ &%J'EAB_P!FDVA5W$G:
M<8&Q\_38W^ZW0@'S#\1=0NQI^G3)=2,Z3[HV\PMSM!R#N;/#*?O/PP;)W^==
M $W@+Q#K>J6UV+W4KJX=74)O<LQSQZ$MDD?PODOC#&0PW(![]X!F>?PT'>5I
M"92=S/NR" 0<[FSD$'.3G.=TN?-D .HH H:7_P OO_7R_P#2@"_0 4 % !0
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MO\/FW^& =V[,S-G=G.[#9SN;.<[LY.[.[?+GS9 #JJ *&E_\OO\ U\O_ $H
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M;O._Y:^=_IX!Z;\-W\S0KD[]_P#I).=^[[RJV<[VZ[MV<_-NW;I=WG2@'94
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MWGYI_P#$T 5[>QNWN+I9-0O%1) (S\@R-BD_P\\DT 6/[-E_Z"=Y^:?_ !-
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M6D$=O;Q+M2*) JH/0 < 53;>Y*26Q+2&% !0 4 % !0 4 % !0 4 % !0 4
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M%VU)PTNXW76UK?BTKAJ#:!:^ +UI[BQ@LO[2E?2$:8+&8_-4[HU)P0#N(('
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M^)<E_OCS?K=^H[7A44=O?MV^UR_I9>GD6/&MQH,FH)KD6H^&M1NELE-MI][
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M&U_^'*T2J<O\SV[.3_#\U?H=[X&FCF\. 06MC#;Q3RQQ/I\'DV\RACB1$R<
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ Z4F[:L".WN(;NWCN+:9)H9%#))&P96!Z$$=15--;AY
M$E( H * "@ H * "@ H C%Q ;EK83(9U0.T88;@I) )'7!(//L:-PV)* "@
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M(HZ7#8DH * "C8"."XANH$GMYDFA<95XV#*P]B.M >1)0 4 % !0 4 % !0
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MD,21*2X R4Z,!UP:O2Z4M-'\^R_/[O4C5)M:[?+N_39?-LZ'X?-OT*\879O
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MT[?2J=K1M_+'_P!)0E\4O\4OS9T=2,* "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@"M96%MIT4D5K%Y:22O,PW$Y
M=V+,>?4DFC9)=@>KN_ZZ%F@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H .HQ2:35F!6L+"VTO3[>QLX_*MK=!'&F
MXG:HZ#)Y-4VV[L.K??7[RS2 * "@ H * "@ H * "@ H * "@ H * "@ H *
# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g462900g42x55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g462900g42x55.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1,64&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@     !'0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4    '0!<
M %P ,0 Y #( +@ Q #8 .  N #$ -  Q "X ,0 T %P 4 !( $T 00!% $<
M4 !2 $X ,@ S       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\
M;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N
M=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT
M   0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O
M;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B
M;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P
M  ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0%@
M   *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=0
M0P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M  H  0         !.$))30/T       2 #4    ! "T    &       !.$))
M30/W       <  #_____________________________ ^@  #A"24T$"
M    $     $   )    "0      X0DE-!!X       0     .$))300:
M  ,U    !@              *    /P          0
M       !              #\    *                      !
M                 !     !        ;G5L;     (    &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG    *     !29VAT;&]N9P   /P    &<VQI
M8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$
M;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,
M15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *
M15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   "@     4F=H=&QO;F<   #\     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
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M       ! 0 X0DE-!!0       0    *.$))300,      E"     0   *
M   9   !X   +N    DF !@  ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1"  9 * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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M1KV_UF)*<?H?U@R^I]9ZEBVTMKPJ#_D^UNKK&U678&8^YP>]G],Q7_9_YO\
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MS=% D7N?Y,JM>?NKK<M1))3_ /_9.$))300A      !5     0$    / $$
M9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0
M &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      2Y-30 J
M    "  ' 1(  P    $  0   1H !0    $   !B 1L !0    $   !J 2@
M P    $  @   3$  @   !X   !R 3(  @   !0   "0AVD !     $   "D
M    T  .I@   "<0  ZF    )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD
M;W=S*0 R,#$U.C$P.C$S(# Y.C,T.C4T   #H $  P    '__P  H ( !
M  $   #\H , !     $    H          8! P #     0 &   !&@ %
M 0   1X!&P %     0   28!*  #     0 "   " 0 $     0   2X" @ $
M     0              2     $   !(     3A"24T#_0      "
M    _^$!,$U- "H    (  <!$@ #     0     !&@ %     0   &(!&P %
M     0   &H!*  #     0 "   !,0 "    '@   '(!,@ "    %    )"'
M:0 $     0   *0   #0   #P     $   /      4%D;V)E(%!H;W1O<VAO
M<"!#4S8@*%=I;F1O=W,I #(P,34Z,3 Z,3,@,#DZ,S0Z-30   .@ 0 #
M ?__  "@ @ $     0   /R@ P $     0   "@         !@$#  ,    !
M  8   $:  4    !   !'@$;  4    !   !)@$H  ,    !  (   (!  0
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M.(BI7EX&EC]XRHY$)##V;$@N=DJ(B5/W.K!H)39:X<$-#TOF$3K^+GYQ.Y.
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D(EA# U^XG4CI>AW?]N]4R[R\#-H4Y8CT$VBB4@(+.W#9A__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g462900g82f46.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g462900g82f46.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#,O=<M[
M+6-.TQHY'FOI#&K(!MC(C=QNY[B)\8STH EO=2^R3K;Q6LMU.T;2^7%M!VK@
M=6(&22 !_A0!/97D&H6-O>VL@DM[B-98W'1E89!_(T 3T % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 '2@#,T?6[?6C?"WCD06=QY
M!+@8?,:2!EP?NE9%ZXH B_X2*V66(20RI!,\D<,QV[9&C#,0!G/1'(XY"GVR
M 36NL1W4JP+;RI/OVO&V,H-H;<2"1C#+T[GZT :5 !0 4 % !0 4 % !0 4
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M _L>V_YZWG_@;-_\50 ?V/;?\];S_P #9O\ XJ@ _L>V_P">MY_X&S?_ !5
M!_8]M_SUO/\ P-F_^*H /['MO^>MY_X&S?\ Q5 !_8]M_P ];S_P-F_^*H /
M['MO^>MY_P"!LW_Q5 !_8]M_SUO/_ V;_P"*H /['MO^>MY_X&S?_%4 ']CV
MW_/6\_\  V;_ .*H /['MO\ GK>?^!LW_P 50 ?V/;?\];S_ ,#9O_BJ #^Q
M[;_GK>?^!LW_ ,50 ?V/;?\ /6\_\#9O_BJ #^Q[;_GK>?\ @;-_\50 ?V/;
M?\];S_P-F_\ BJ #^Q[;_GK>?^!LW_Q5 !_8]M_SUO/_  -F_P#BJ #^Q[;_
M )ZWG_@;-_\ %4 ']CVW_/6\_P# V;_XJ@ _L>V_YZWG_@;-_P#%4 5M*LH]
M\TK373-%<.J[[J1A@'@8+8/XT :%]:"^LIK5I9(EE7:6C(# =\9!H Q]+T?4
M=)NM:G2=+HWU[%-&LK! L8BAC8G:GWL(V .#A>F2: &Q:'=R76G)=F$VVFW4
MES"Z.2TFY)$564K@864]"<E1ZXH 1] N%M@;3R;6XDSO\ES&L?!V;=H^8)DG
M!P"23QF@#HZ "@ H * "@ H * "@ H * "@ H H:O_QZP_\ 7S#_ .C%H OT
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!GZQKFE^'[ WVK7T-G;!
MMOF2M@$^@]3P>!Z4 ><P_&W2+[XC:9H>GL)=)N4,;W3QLA\YC\F 0/E[9(_B
M]!R >K4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0!0TK[EW_ -?,G\Z +] !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MA(QY<Z?>Q['((]C0!T= !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0!0TK[EW_U\R?SH OT % !0 4 % !0 4 % !0 4 % &
M'J.H>(%NW@TG0H9DC('GW=X(4?@'Y0JNQY..0.0?K0 NC:IK%U<R6^J:1#;%
M-W[^UO!/$",?*<A6#<]-I''7M0!MT % !0!0U?\ X]8?^OF'_P!&+0!?H *
M"@ H * "@ H * "@ H * /.O$'Q?T#1O%ND:);W,%XMQ,8KR:*0%;;/"Y(XS
MN/// !H ZSQ$_B1;:%?#4.G/<,V)'OW<)&N.H"C+?F* '^'K77+6P<:_J5O?
M7;R%@;>#RDC7 ^4<DGN<GUH S[/X>^%+'59-4CT6"6_>7S3/<%IG#YSD%R<8
M[8H Z:@ H * "@ H QO$GB&T\*Z8NI7L,IM#.D<TD2@^4&./,;_9'&>IH V%
M974,K!E(R"#D$4 +0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M_P !G_PH /[6B_Y];S_P&?\ PH /[6B_Y];S_P !G_PH /[6B_Y];S_P&?\
MPH /[6B_Y];S_P !G_PH I:AXMTC2$1]2G>S5SM0SQE-Q]!GK0!7\0>(=4L]
M/5M#T&XU"\>0)LE#0I&N#\Y.#D#C@<\T 1^'-0UZ.TE?Q)MEN9'RD=E92K'$
MN/NY;EOK@4 2Z=8>'](NY[O3]!:WN;AR\LR63;W).3EL9H U/[6B_P"?6\_\
M!G_PH /[6B_Y];S_ ,!G_P * #^UHO\ GUO/_ 9_\* #^UHO^?6\_P# 9_\
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M ._&K1[1FUO >X^S/_A0 O\ :T7_ #ZWG_@,_P#A0 ?VM%_SZWG_ (#/_A0
M?VM%_P ^MY_X#/\ X4 ']K1?\^MY_P" S_X4 ']K1?\ /K>?^ S_ .% !_:T
M7_/K>?\ @,_^% !_:T7_ #ZWG_@,_P#A0 ?VM%_SZWG_ (#/_A0 ?VM%_P ^
MMY_X#/\ X4 ']K1?\^MY_P" S_X4 ']K1?\ /K>?^ S_ .% !_:T7_/K>?\
M@,_^% !_:T7_ #ZWG_@,_P#A0 ?VM%_SZWG_ (#/_A0 ?VM%_P ^MY_X#/\
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MS[. >G^#=7GUWPCIVIW-Q;7,TZ$M+:KMB<AB,J"Q(''?#>JH<J #=H * "@
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MR?E8<@]Q0!KT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M]$ /8_A5*\_A W#R^>99L_:$/[J;$:#=$O\ "G&-O&TJ1MCQY: '<4 % !0
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M_P#KYD_G0!?H * "@ H * .%U]/$@U+48HM<M+*W(:>Q9KA4<R>4JI$ZE?\
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M4 //?D=: (]:BO"D;)=1K$;B':AAR0=Z]\\\\T 6OL^I_P#00A_\!O\ [*@
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MRY_]'F\KS]GD?OX?WR>7 GE_,GR?ZK_EGY?^A@'MG@#[==>!=)FAU6TEC,1
M>&WRAPQ'RC?\J\<+A=HXV1XV* =)]GU/_H(0_P#@-_\ 94 'V?4_^@A#_P"
MW_V5 !]GU/\ Z"$/_@-_]E0 ?9]3_P"@A#_X#?\ V5 'S?;W&[R/](\WS/+G
M_P!'F\KS]GD?OX?WR>7 GE_,GR?ZK_EGY?\ H8 6]QN\C_2/-\SRY_\ 1YO*
M\_9Y'[^']\GEP)Y?S)\G^J_Y9^7_ *& %O<;O(_TCS?,\N?_ $>;RO/V>1^_
MA_?)Y<">7\R?)_JO^6?E_P"A@'NWA&/4)?!VC21ZI:2(UI$0T-IMC(VCE1D8
M7T&U<#C:O0 &U]GU/_H(0_\ @-_]E0 ?9]3_ .@A#_X#?_94 'V?4_\ H(0_
M^ W_ -E0!C:GJ?\ PC4^FVUQ>101ZC<F"-X[+$:RMEAN.[@L<_4F@#9^SZG_
M -!"'_P&_P#LJ #[/J?_ $$(?_ ;_P"RH /L^I_]!"'_ ,!O_LJ #[/J?_00
MA_\  ;_[*@ ^SZG_ -!"'_P&_P#LJ #[/J?_ $$(?_ ;_P"RH /L^I_]!"'_
M ,!O_LJ #[/J?_00A_\  ;_[*@ ^SZG_ -!"'_P&_P#LJ #[/J?_ $$(?_ ;
M_P"RH /L^I_]!"'_ ,!O_LJ #[/J?_00A_\  ;_[*@ ^SZG_ -!"'_P&_P#L
MJ #[/J?_ $$(?_ ;_P"RH /L^I_]!"'_ ,!O_LJ #[/J?_00A_\  ;_[*@ ^
MSZG_ -!"'_P&_P#LJ #[/J?_ $$(?_ ;_P"RH /L^I_]!"'_ ,!O_LJ #[/J
M?_00A_\  ;_[*@ ^SZG_ -!"'_P&_P#LJ *ND17H:<M=QM&+F3<HAP3SZ[N*
M -.[N%M+.:X>.218D+E(HR[L ,X51R3["@#!T#4HIK:[U.2WODGN9T\R)[&:
M,QYVHH =%+ #!9L8')X X *2V4][+H]B+>>$V5]<279>-E5XVCF3A\8;<TB-
M@'U[B@"18;VPS?VJ33R3EC&)HBS'" +D*!L+[5&XC"A1D9)H ZTD $DX H \
MR\2^%[B^UO4YHK;1;F6_9'MM3NKC;<:=B-5&Q=IR 5,@PR\L?J0#TF>3R+:2
M0LHV(6RYP!@=SV% 'BVM:KI6IZQ+J U/P\9)TC\QD\67$ W!%! 5!C .0#W'
M)P2: /;: "@ H Y_Q9/J\=K96^C>4D]S.8VGE@\Y8@(G8';D9RRJN<\;J (/
M NH:AJ.C7$FHL\KI<%$F:R:T\Q=B$XC;D88LN3UVD],4 =/0 4 % %#5_P#C
MUA_Z^8?_ $8M %^@ H ^?_&,GE^.=33,R[[H3^6+G;)+L,'[Z-O.7;$GE_.,
MC)B)W#R]UJ 8%O<;O(_TCS?,\N?_ $>;RO/V>1^_A_?)Y<">7\R?)_JO^6?E
M_P"A@!;W&[R/](\WS/+G_P!'F\KS]GD?OX?WR>7 GE_,GR?ZK_EGY?\ H8![
M+\)SYG@\S;EE\R8'SX^(IL1QKNB7^%/EVA>-NTC;'CRT .ZH * "@ H ^<M9
MF_XJ6^7S)3ONS-L6YVO+L>']]&WGC9%'Y?SKE?\ 5'[GE_Z( 9MO<;O(_P!(
M\WS/+G_T>;RO/V>1^_A_?)Y<">7\R?)_JO\ EGY?^A@!;W&[R/\ 2/-\SRY_
M]'F\KS]GD?OX?WR>7 GE_,GR?ZK_ )9^7_H8![O\.IO/^'^CR?:8;G,1'FP#
M$;88CY5R=J^B_+M'&R/&Q0#J* "@ H * /F"WN-WD?Z1YOF>7/\ Z/-Y7G[/
M(_?P_OD\N!/+^9/D_P!5_P L_+_T, +>XW>1_I'F^9Y<_P#H\WE>?L\C]_#^
M^3RX$\OYD^3_ %7_ "S\O_0P M[C=Y'^D>;YGES_ .CS>5Y^SR/W\/[Y/+@3
MR_F3Y/\ 5?\ +/R_]# /H/P8_F>"M$?SH9LV<7[R!-D;?*.57 VKZ#"X'&%Z
M  W* "@ H R_$6@67B;0;O2+]3Y%PN-R\,C#E64^H."* +UK$;>TAMWG>=XH
MU4R28W/@8W''<XH FH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * *&E?<N_\ KYD_G0!?H * "@ H 1E5T*, 5(P0>XH \0UJRM8M<U>PU0>
M;%]RQ6\ERR&>TB$*+'B,Q_-@ $!CWP/E H ]O(#*5(!!X(- 'D_B@VMOKNLZ
M;:ZMY<-ZR&Z6#1I[F:U/EJ,1RQ_*AV@, 02"V>] 'K/2@ H * .2\8/IU[&U
MO+J-]97.D>7?F6RA#R(&\R-0-RMDM\XP!GCT/(!:\&7<5WI,YBU74=1:.X*.
MVHPB*:)MJG85"+@8(/(S\WTH Z.@ H * *&K_P#'K#_U\P_^C%H OT % 'S_
M .,9/+\<ZFF9EWW0G\L7.V2788/WT;><NV)/+^<9&3$3N'E[K4 P+>XW>1_I
M'F^9Y<_^CS>5Y^SR/W\/[Y/+@3R_F3Y/]5_RS\O_ $, +>XW>1_I'F^9Y<_^
MCS>5Y^SR/W\/[Y/+@3R_F3Y/]5_RS\O_ $, ]E^$Y\SP>9MRR^9,#Y\?$4V(
MXUW1+_"GR[0O&W:1MCQY: '=4 % !0 4 ?.6LS?\5+?+YDIWW9FV+<[7EV/#
M^^C;SQLBC\OYURO^J/W/+_T0 S;>XW>1_I'F^9Y<_P#H\WE>?L\C]_#^^3RX
M$\OYD^3_ %7_ "S\O_0P M[C=Y'^D>;YGES_ .CS>5Y^SR/W\/[Y/+@3R_F3
MY/\ 5?\ +/R_]# /=_AU-Y_P_P!'D^TPW.8B/-@&(VPQ'RKD[5]%^7:.-D>-
MB@'44 % !0 4 ?,%O<;O(_TCS?,\N?\ T>;RO/V>1^_A_?)Y<">7\R?)_JO^
M6?E_Z& %O<;O(_TCS?,\N?\ T>;RO/V>1^_A_?)Y<">7\R?)_JO^6?E_Z& %
MO<;O(_TCS?,\N?\ T>;RO/V>1^_A_?)Y<">7\R?)_JO^6?E_Z& ?0?@Q_,\%
M:(_G0S9LXOWD";(V^4<JN!M7T&%P.,+T !N4 % !0 4 <AXDT74XO%>C^)M#
MC\ZYB(L[ZW+A1-:LV<\\90G</QH Z^@ H * "@ H * "@ H * "@ H * "@
MH * ,#6?&WAGP_<);:IK5K;W#L%$1?<XSW*C) ]SQ0!Q_P +_BE_PG&LZW87
M(6*2*4S62XP3;Y P?4@X)/?=[4 >GT % !0!0TK[EW_U\R?SH OT % !0 4
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M=F:W_<Q_*2Q))/\ K/\ MI0!OT % !0!0U?_ (]8?^OF'_T8M %^@ H ^?\
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M^7_H8![O\.IO/^'^CR?:8;G,1'FP#$;88CY5R=J^B_+M'&R/&Q0#J* "@ H
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MTH JV_@+PW!KD^M2:<MUJ4LAE\^[=IBASD! Q(4#MCI0!TM !0 4 % !0 4
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M^7_H8 6]QN\C_2/-\SRY_P#1YO*\_9Y'[^']\GEP)Y?S)\G^J_Y9^7_H8!]
M>#KF)_!>BL;JVE)LXOWD"A(V^4<JN!M7T&%P.,+T !M^?#_SU3_OH4 'GP_\
M]4_[Z% !Y\/_ #U3_OH4 4]7U2/3-%OK]2DC6MO),$WXW%5)Q^E 'B _:,O@
M(3-X8AM4EA>6.2:Y?;(!N'RXC.<LI0'INSD@9P  _:,O@(3-X8AM4EA>6.2:
MY?;(!N'RXC.<LI0'INSD@9P  _:,O@(3-X8AM4EA>6.2:Y?;(!N'RXC.<LI0
M'INSD@9P >YV&H1WNG6MT61#-$LA7=G&0#B@"QY\/_/5/^^A0 >?#_SU3_OH
M4 'GP_\ /5/^^A0!Q][\/= N-5FU2RO]0TF^GD,LTMA?-'YC$Y)*G*\_2@#=
MUZXU1=+=M!N--6]4@YORWE;>^2IR/KS0!Y=\-OB]>>)O'%[I6L&"*&Y0&R$6
M=@=!\P!(!(89;GTQWH [B^\!:!K&LR:CK5W=ZKE]\5K=W6;>'V6-<#'US0!U
MGGP_\]4_[Z% !Y\/_/5/^^A0 >?#_P ]4_[Z% !Y\/\ SU3_ +Z% '/>-O%:
M>$O"MUK"""9H,8CDD*AB3P,J&.3T'&,D9(&2 #R4?M&7P$)F\,0VJ2PO+')-
M<OMD W#Y<1G.64H#TW9R0,X  ?M&7P$)F\,0VJ2PO+')-<OMD W#Y<1G.64H
M#TW9R0,X -'P_P#'J\UCQ%HVF7/AV+3X=2E5%N);ARK N5RH"<\@J.VX<D#)
M ![5Y\/_ #U3_OH4 'GP_P#/5/\ OH4 4=)EC*W0#J2;F3 S[T :#L4C9E0N
M0"0HQD^W- &9X?U:36M.DN9;<6\D=U/;,BOO&8I6CSG Z[<].] %5O$;PR6C
MRV@%M>2RPP%7)D9T1W&5Q@!EC<CGT]> "73==.HRB%(XBZL/,:.7>@0J""#@
M9R3MQZJWI0!L21I+&T<BAD<%64C((/44 >.>)H=#T:_OO(\%^%HM/LIO(:2]
M0))*XB67$:!,,2&PHSEBI'% 'LM 'G'BVZO[;5[]=)UCQ!'>L4*6=GI*O"[;
M5 'G-$1SW8MA?PQ0!Z/^E !0 4 8'BJUU:]M;.WTN]ELD>8BYGA*"1$\M]N"
MP(^_Y8/&<$XH K^!5U5=&N!JIOBXN#Y1OY(WF*;$SN\OY0-^_&.V">30!:O-
M%U&X\76&LQ:C;1VUI#)!]G:T9G99"A?Y_, !_=KCY>.>O8 GETW46NDNHM1A
M2<"2,DVQ*F-FR@QO^\H &<X// SP 7--T^#2=*M-.M5*V]I"D,8)R0J@ <_0
M4 4]9LK1XHY7M86D:YA!8Q@DCS%'7Z4 6_[*T[_GPMO^_2_X4 ']E:=_SX6W
M_?I?\* /"/%NRV\:ZE!&LL2-<B80K<;'DV&#]]&?.79$GE_.,C)B)W#R]UJ
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MR28E_NCVH T/[*T[_GPMO^_2_P"% !_96G?\^%M_WZ7_  H /[*T[_GPMO\
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M/"1>$6ZSW,9+WD?F1S@RLOR+L.,XV \X<$[E_A /L;^RM._Y\+;_ +]+_A0
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MN>7_ *( 9MO<;O(_TCS?,\N?_1YO*\_9Y'[^']\GEP)Y?S)\G^J_Y9^7_H8
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M %7_ "S\O_0P M[C=Y'^D>;YGES_ .CS>5Y^SR/W\/[Y/+@3R_F3Y/\ 5?\
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MN<Q$>; ,1MAB/E7)VKZ+\NT<;(\;% .HH * "@ H ^8+>XW>1_I'F^9Y<_\
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M H * "@ H * "@#D=2GN$$][;S2O>0ZO;6XC5VVK&TD2LNT'!'ENS9([Y[#
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M[_T"IO\ O['_ /%4 >6WWP_\0W>KW%TJ,L,\_P!H<"Y</Y@:(H5(E!10(AE
M1NV+@I^Z^S@%2'X;>)E\KS@HSLDF\F9H_P!ZOD[3'MD'EH/*&8UP#L7!3]U]
MG "'X;>)E\KS@HSLDF\F9H_WJ^3M,>V0>6@\H9C7 .Q<%/W7V< ]&\+0ZOHO
MAFPTZ^L#-=01[9'A9$CSDG"J6.U1G  P !A5484 &O\ ;;W_ *!4W_?V/_XJ
M@"-]4N8YXX6TN8/("5'F)SCKW]Z )/MM[_T"IO\ O['_ /%4 'VV]_Z!4W_?
MV/\ ^*H \BA^&WB9?*\X*,[))O)F:/\ >KY.TQ[9!Y:#RAF-< [%P4_=?9P
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M5-_W]C_^*H C75+EKB2 :7-YD:JS#S$X!SCO_LF@"3[;>_\ 0*F_[^Q__%4
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MO^_L?_Q5 %71[FY9IT:PD16N9,N73"\_7- %C79WMM"O9DE,)2(GS!U0=V_
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M2ZBM(([B3[\JQ@.WU/4]!^5  UC:-##"UK"T<./+4H"$QTQZ4 6* "@ H *
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M;.^CM=06PFN4D8KE=B$C /!); QCIGTH ZR.1)8UDC=71AE64Y!'L: '4 %
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MDC79M6),;NJD\DJO7/S$@\4 ;E !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * ,N\\.Z5?W#7%S:!YBROO#LI!4J000>.4C/'=$/51@ KCP?H"YV::D?S*
MXV.R["NS;MP?E \N/ &!^[3^XN !4\(Z#$X:/38T*NLB[2P"E=FW: > /+CX
M''[M./E7 !HWFFV&H!1>V5O<A,[?.B5\9ZXR* *UYH-A?ZG:7MU"DOV:WEMT
MA=%:/;(T9)((ZCREQ]30!9N=,T^\P+JQMY\1M%^\B5OD889>1T(X([T *VG6
M3WBWCV<#72XQ,8P7& 0/FZ]S^9H !IUB!&!9P#RY'E3]V/E=]V]AQP3O;)ZG
M<?4T .M;.UL8S':6T5NA.2L2!03C&<#V H GH Y_5/ _AC6M1?4-3T2UN[MT
MV-)*FXD8Q_+\J **?"[P/&Q*^&;$G!'S)GJ,=_\ (H DM?AKX+LKJ.YM_#ED
MDT9RC;,[3ZC/?W[4 =(UI;--+,UO$998Q%(Y09=!DA2>X&YN/<^M $<>F6$5
MV;J.RMTN<8\U8E#] .N,] !^ H $TVQBN)+B.RMTGDR'D6)0S9ZY.,G- #[6
MSM;&,QVEM%;H3DK$@4$XQG ]@* )Z "@#"U#P9X9U6^DO=0T*QN;J7&^62$%
MFP !D]^ !^% &W'&D4:QQH$1 %55&  .@% "-%&[H[1JSQDE&(R5R,''IQ0!
M"VG63WBWCV<#72XQ,8P7& 0/FZ]S^9H 9)I.FRO(\FGVSO(P=V:%268# )XY
M."1F@"6&SM;>0O!;11.46,LB '8N2J\=AN; [9/K0! =%TIM4_M0Z9:'4, ?
M:C OFX'0;\9_6@";[!9^?Y_V2'SO-\[?Y8W>9LV;\_WMGRYZXXZ4 )#IUC;%
MS!9P1%]V[9&%SNZYP.^!F@"--(TR.%X4TZU2*2,1.BPJ R DA2,<@%F./]H^
MM $D>G6,*PK%9P(L#F2(+& (W((++QP2&89']X^M $L%O!:QF.WACACW,^V-
M0HW,2S' [DDD^I)H DH * "@ H * "@ H * "@ H * "@ H * "@ H * /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g462900snap1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g462900snap1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ .K_ .%!^%?^?_5O^_T?_P ;H'</^%!^%?\ G_U;_O\ 1_\
MQN@+A_PH/PK_ ,_^K?\ ?Z/_ .-T!</^%!^%?^?_ %;_ +_1_P#QN@+G@WB#
M3XM)\2:IIT#.T-I=RP(7(+%5<J,XQS@4#/LV@D* "@ H ^//&?\ R/7B'_L(
MW'_HQJ!GV'0(* "@ H ^//&?_(]>(?\ L(W'_HQJ!GV'0(* "@ H ^//&?\
HR/7B'_L(W'_HQJ!GV'0(* "@ H ^//&?_(]>(?\ L(W'_HQJ!G__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
